ERBB receptors and cancer: the complexity of targeted

Nature Reviews Cancer

5, 341-354

DOI: 10.1038/nrc1609

Citation Report

#	Article	IF	Citations
2	Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: Relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on the tyrosine kinase activity of HER2. International Journal of Oncology, 1992, 34, 43.	1.4	17
3	Autocrine loop for IGF-I receptor signaling in SLUG-mediated epithelial-mesenchymal transition. International Journal of Oncology, 1992, 34, 329.	1.4	13
4	EGFR kinase possesses a broad specificity for ErbB phosphorylation sites, and ligand increases catalytic-centre activity without affecting substrate binding affinity. Biochemical Journal, 2005, 392, 417-423.	1.7	29
6	Genetic analysis of the kinome and phosphatome in cancer. Cellular and Molecular Life Sciences, 2005, 62, 2092-2099.	2.4	52
7	Strategies and methodologies for identifying molecular targets in sarcomas and other tumors. Current Treatment Options in Oncology, 2005, 6, 487-497.	1.3	5
8	Inhibition of EGFR Signaling: All Mutations Are Not Created Equal. PLoS Medicine, 2005, 2, e377.	3.9	38
9	Mammalian Target of Rapamycin, a Molecular Target in Squamous Cell Carcinomas of the Head and Neck. Cancer Research, 2005, 65, 9953-9961.	0.4	212
10	Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelialâ€“mesenchymal transition. Journal of Cell Biology, 2005, 171, 1023-1034.	2.3	539
11	Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients. Clinical Cancer Research, 2005, 11, 8686-8698.	3.2	485
12	Development of Ewing's Sarcoma from Primary Bone Marrowâ€“Derived Mesenchymal Progenitor Cells. Cancer Research, 2005, 65, 11459-11468.	0.4	326
13	Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14344-14349.	3.3	139
14	Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2. Clinical Cancer Research, 2005, 11, 6382-6389.	3.2	181
15	Mechanism of Action of (â˜)-Epigallocatechin-3-Gallate: Auto-oxidationâ€“Dependent Inactivation of Epidermal Growth Factor Receptor and Direct Effects on Growth Inhibition in Human Esophageal Cancer KYSE 150 Cells. Cancer Research, 2005, 65, 8049-8056.	0.4	262
16	Construction of a Novel Constitutively Active Chimeric EGFR to Identify New Targets for Therapy. Neoplasia, 2005, 7, 1065-1072.	2.3	13
17	The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: whatâ€™s genetics got to do with it?. Expert Opinion on Therapeutic Targets, 2005, 9, 1009-1030.	1.5	47
18	Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17987-17992.	3.3	224
19	Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Research, 2005, 7, R1028-35.	2.2	134
20	Mouse models of breast cancer metastasis. Breast Cancer Research, 2006, 8, 212.	2.2	252

#	Article	IF	Citations
21	Constitutive Activation of Neuregulin/ERBB3 Signaling Pathway in Clear Cell Sarcoma of Soft Tissue. Neoplasia, 2006, 8, 613-622.	2.3	26
22	Epidermal Growth Factor Receptor Biology in Head and Neck Cancer. Journal of Clinical Oncology, 2006, 24, 2666-2672.	0.8	600
23	Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics. Advances in Cancer Research, 2006, 96, 213-268.	1.9	141
24	Potential use of humanized antibodies in the treatment of breast cancer. Expert Review of Anticancer Therapy, 2006, 6, 1065-1074.	1.1	17
25	Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opinion on Therapeutic Patents, 2006, 16, 147-164.	2.4	3
26	Protease-Activated Receptor-2 Activation in Gastric Cancer Cells Promotes Epidermal Growth Factor Receptor Trans-Activation and Proliferation. American Journal of Pathology, 2006, 169, 268-278.	1.9	71
27	The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy: Fig. 1.. Clinical Cancer Research, 2006, 12, 5268-5272.	3.2	776
28	Antiproliferative effects of EGFR tyrosine kinase inhibition and radiation-induced genotoxic injury are attenuated by adhesion to fibronectin. Radiotherapy and Oncology, 2006, 80, 178-184.	0.3	39
29	Tyrosine Kinase Inhibitors. 19. 6-Alkynamides of 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d]pyrimidines as Irreversible Inhibitors of the erbB Family of Tyrosine Kinase Receptors. Journal of Medicinal Chemistry, 2006, 49, 1475-1485.	2.9	80
30	Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine, 2006, 354, 567-578.	13.9	4,705
31	Tumor Endothelial Cells Express Epidermal Growth Factor Receptor (EGFR) but not ErbB3 and Are Responsive to EGF and to EGFR Kinase Inhibitors. Cancer Research, 2006, 66, 2173-2180.	0.4	200
32	Activation of ErbB2 by 2-methyl-1,4-naphthoquinone (menadione) in human keratinocytes: Role of EGFR and protein tyrosine phosphatases. FEBS Letters, 2006, 580, 1859-1864.	1.3	32
33	BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochemical and Biophysical Research Communications, 2006, 348, 406-412.	1.0	74
34	Chemical genetic approaches to the development of cancer therapeutics. Current Opinion in Genetics and Development, 2006, 16, 85-91.	1.5	3
35	Palmitoylation of the EGFR Ligand Spitz by Rasp Increases Spitz Activity by Restricting Its Diffusion. Developmental Cell, 2006, 10, 167-176.	3.1	105
36	Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?. Trends in Molecular Medicine, 2006, 12, 122-129.	3.5	100
37	Deconstructing the molecular portrait of basal-like breast cancer. Trends in Molecular Medicine, 2006, 12, 537-544.	3.5	132
38	The IGF-1 network in lung carcinoma therapeutics. Trends in Molecular Medicine, 2006, 12, 595-602.	3.5	30

#	Article	IF	Citations
39	Epidermal growth factor receptor pathway inhibitors. Update on Cancer Therapeutics, 2006, 1, 299-310.	0.9	6
40	The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2Î² and agonist-independent coupling with downstream signalling events. Biochemical Journal, 2006, 396, 79-88.	1.7	16
41	Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy. Current Signal Transduction Therapy, 2006, 1, 337-351.	0.3	1
42	Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anti-Cancer Drugs, 2006, 17, 783-795.	0.7	51
43	Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. Topics in Medicinal Chemistry, 2006, , 83-132.	0.4	1
44	EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. Journal of Pathology, 2006, 209, 445-453.	2.1	230
45	The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Dermatology, 2006, 155, 852-854.	1.4	79
46	Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Science, 2006, 97, 341-347.	1.7	117
47	Signalling in cancer. Nature, 2006, 441, 423-423.	13.7	12
48	The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nature Biotechnology, 2006, 24, 985-995.	9.4	124
49	Par6â€“aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nature Cell Biology, 2006, 8, 1235-1245.	4.6	226
50	ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli. Nature Medicine, 2006, 12, 961-966.	15.2	139
51	Quantitative multiplexed profiling of cellular signaling networks using phosphotyrosine-specific DNA-tagged SH2 domains. Nature Methods, 2006, 3, 737-744.	9.0	31
52	Monitoring regulated protein-protein interactions using split TEV. Nature Methods, 2006, 3, 985-993.	9.0	236
53	Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews Cancer, 2006, 6, 803-812.	12.8	667
54	Protein therapeutics: new applications for pharmacogenetics. Nature Reviews Drug Discovery, 2006, 5, 507-521.	21.5	76
55	Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Modern Pathology, 2006, 19, 1213-1220.	2.9	71
56	Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene, 2006, 25, 7180-7191.	2.6	86

#	Article	IF	Citations
57	Inhibitors of epidermal growth factor receptor tyrosine kinase: Optimisation of potency and in vivo pharmacokinetics. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4908-4912.	1.0	31
58	The ErbB2 Signaling Network as a Target for Breast Cancer Therapy. Journal of Mammary Gland Biology and Neoplasia, 2006, 11, 13-25.	1.0	65
59	The mTOR Pathway in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2006, 11, 53-61.	1.0	42
60	Exploiting Our Knowledge of NF-Î²B Signaling for the Treatment of Mammary Cancer. Journal of Mammary Gland Biology and Neoplasia, 2006, 11, 63-73.	1.0	40
61	Probing the Microenvironment of Mammary Tumors Using Multiphoton Microscopy. Journal of Mammary Gland Biology and Neoplasia, 2006, 11, 151-163.	1.0	118
63	Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 441-452.	3.3	38
64	Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment. Cancer Immunology, Immunotherapy, 2006, 55, 1091-1099.	2.0	17
65	Cell signalling: growth factors and tyrosine kinase receptors. Clinical and Translational Oncology, 2006, 8, 77-82.	1.2	122
66	Novel therapies in colon cancer. Current Colorectal Cancer Reports, 2006, 2, 116-119.	1.0	4
67	Extracellular generation of hydrogen peroxide is responsible for activation of EGF receptor by ultraviolet A radiation. Free Radical Biology and Medicine, 2006, 41, 1478-1487.	1.3	25
68	Is Cyclin D1-CDK4 kinase a bona fide cancer target?. Cancer Cell, 2006, 9, 2-4.	7.7	96
69	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell, 2006, 9, 485-495.	7.7	427
70	Targeting ADAMS and ERBBs in lung cancer. Cancer Cell, 2006, 10, 7-11.	7.7	36
71	A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell, 2006, 10, 515-527.	7.7	2,729
72	Ligand-independent and EGF receptor-supported transactivation: Lessons from Î²2-adrenergic receptor signalling. Cellular Signalling, 2006, 18, 1633-1646.	1.7	57
73	Epidermal growth factor receptor and DNA double strand break repair: The cell's self-defence. Cellular Signalling, 2006, 18, 1537-1548.	1.7	50
74	Osteopontin: role in cell signaling and cancer progression. Trends in Cell Biology, 2006, 16, 79-87.	3.6	653
75	Emerging roles of pseudokinases. Trends in Cell Biology, 2006, 16, 443-452.	3.6	475

#	Article	IF	Citations
76	Induced endoplasmic reticulum (ER) stress and binding of over-expressed ER specific chaperone GRP78/BiP with dimerized epidermal growth factor receptor in mammalian cells exposed to low concentration of N-methyl-Nâ€²-nitro-N-nitrosoguanidine. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2006, 596, 12-21.	0.4	20
77	Concomitant chemo-radio-immunotherapy has a lethal therapeutic effect on tongue carcinomas independent of the clinical stage and histological characteristics of the tumor. Oral Oncology, 2006, 42, 873-879.	0.8	2
78	Molecular Predictive Factors in Patients Receiving Trastuzumab-Based Chemotherapy for Metastatic Disease. Clinical Breast Cancer, 2006, 7, 254-261.	1.1	28
79	Targeted nanoparticles for detecting and treating cancer. Drug Development Research, 2006, 67, 70-93.	1.4	202
80	Gene targeting ofErbB3 using a Cre-mediated unidirectional DNA inversion strategy. Genesis, 2006, 44, 477-486.	0.8	35
81	Cell cycle control in breast cancer cells. Journal of Cellular Biochemistry, 2006, 97, 261-274.	1.2	184
82	Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. International Journal of Cancer, 2006, 119, 441-454.	2.3	26
83	Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. International Journal of Cancer, 2006, 119, 2557-2566.	2.3	113
84	Cell system perturbation for time-resolved quantification of tyrosine phosphorylation in complex samples. , 2006, 2006, 51-2.		0
85	Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Molecular Systems Biology, 2006, 2, 54.	3.2	217
86	Past, present and future of gene expression-tailored therapy for lung cancer. Personalized Medicine, 2006, 3, 165-175.	0.8	3
87	EGFR Targeted Therapy: View from Biological Standpoint. Cell Cycle, 2006, 5, 2072-2076.	1.3	32
88	Gefitinib accumulation in glioblastoma tissue. Cancer Biology and Therapy, 2006, 5, 483-484.	1.5	23
89	Correlation of ErbB2 Gene Status, mRNA and Protein Expression. Oncology Research and Treatment, 2006, 29, 246-247.	0.8	2
90	Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling. Cancer Research, 2006, 66, 11389-11398.	0.4	112
91	Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Molecular Cancer Therapeutics, 2006, 5, 1029-1040.	1.9	27
92	Her2-Targeted Therapies in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 4377s-4383s.	3.2	63
93	Epidermal Growth Factor Receptor as a Therapeutic Target in Human Thyroid Carcinoma: Mutational and Functional Analysis. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3662-3666.	1.8	57

#	Article	IF	Citations
94	Molecular Diagnosis of Chronic Liver Disease and Hepatocellular Carcinoma: The Potential of Gene Expression Profiling. Seminars in Liver Disease, 2006, 26, 373-384.	1.8	48
95	Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain. Expert Opinion on Investigational Drugs, 2006, 15, 669-690.	1.9	19
96	Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5090-5095.	3.3	147
97	Dynamics of biological systems: role of systems biology in medical research. Expert Review of Molecular Diagnostics, 2006, 6, 891-902.	1.5	48
98	Molecular imaging in oncology. Annals of Oncology, 2006, 17, x287-x292.	0.6	5
99	Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain. PLoS Medicine, 2006, 3, e485.	3.9	298
100	The Multifaceted Roles of Osteopontin in Cell Signaling, Tumor Progression and Angiogenesis. Current Molecular Medicine, 2006, 6, 819-830.	0.6	126
101	EGFR in colorectal cancer: more than a simple receptor. Annals of Oncology, 2006, 17, 962-967.	0.6	42
102	EGFR expression in colon cancer: a break in the clouds. Annals of Oncology, 2006, 17, 1850-1851.	0.6	3
103	Antitumor Activity of Epidermal Growth Factor Receptorâ€"Related Protein Is Mediated by Inactivation of ErbB Receptors and Nuclear Factor-ÎºB in Pancreatic Cancer. Cancer Research, 2006, 66, 1025-1032.	0.4	49
104	Selective Modulation of Hedgehog/GLI Target Gene Expression by Epidermal Growth Factor Signaling in Human Keratinocytes. Molecular and Cellular Biology, 2006, 26, 6283-6298.	1.1	215
105	Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Molecular Cancer Therapeutics, 2006, 5, 1197-1208.	1.9	93
106	Essential Role for Rac in Heregulin Î²1 Mitogenic Signaling: a Mechanism That Involves Epidermal Growth Factor Receptor and Is Independent of ErbB4. Molecular and Cellular Biology, 2006, 26, 831-842.	1.1	82
107	p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer. Clinical Cancer Research, 2006, 12, 424-431.	3.2	190
108	A Herpes Simplex Virus Recombinant That Exhibits a Single-Chain Antibody to HER2/neu Enters Cells through the Mammary Tumor Receptor, Independently of the gD Receptors. Journal of Virology, 2006, 80, 5531-5539.	1.5	49
109	Derepression of the Her-2 uORF is mediated by a novel post-transcriptional control mechanism in cancer cells. Genes and Development, 2006, 20, 939-953.	2.7	49
110	Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma. Clinical Cancer Research, 2006, 12, 1680-1685.	3.2	151
111	Heregulin-Dependent Delay in Mitotic Progression Requires HER4 and BRCA1. Molecular and Cellular Biology, 2006, 26, 6412-6424.	1.1	41

#	Article	IF	Citations
112	Molecular Diagnostics as a Tool to Personalize Treatment in Adult Glioma Patients. Technology in Cancer Research and Treatment, 2006, 5, 215-229.	0.8	19
113	Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines. Journal of Clinical Oncology, 2006, 24, 4914-4921.	0.8	504
114	A Novel Mechanism for Integrin-Mediated Ras Activation in Breast Carcinoma Cells: The Î±6Î²4 Integrin Regulates ErbB2 Translation and Transactivates Epidermal Growth Factor Receptor/ErbB2 Signaling. Cancer Research, 2006, 66, 2732-2739.	0.4	69
115	Lung cancer genetics and pharmacogenomics. Cytogenetic and Genome Research, 2006, 115, 298-302.	0.6	2
116	Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Human Reproduction Update, 2006, 13, 121-141.	5.2	434
117	Suppression of the Ligand-mediated Down-regulation of Epidermal Growth Factor Receptor by Ymer, a Novel Tyrosine-phosphorylated and Ubiquitinated Protein. Journal of Biological Chemistry, 2006, 281, 24612-24622.	1.6	33
118	Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor. Molecular Pharmacology, 2006, 70, 1534-1541.	1.0	74
119	Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7817-7822.	3.3	248
120	Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells. Clinical Cancer Research, 2006, 12, 4103-4111.	3.2	231
121	Expression and Nuclear Localization of ErbB3 in Prostate Cancer. Clinical Cancer Research, 2006, 12, 2730-2737.	3.2	114
122	A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19063-19068.	3.3	82
123	CFBP Is a Novel Tyrosine-phosphorylated Protein That Might Function as a Regulator of CIN85/CD2AP. Journal of Biological Chemistry, 2006, 281, 28919-28931.	1.6	26
124	Technology Insight: pharmacoproteomics for cancerâ€"promises of patient-tailored medicine using protein microarrays. Nature Clinical Practice Oncology, 2006, 3, 256-268.	4.3	119
125	p130Cas as a New Regulator of Mammary Epithelial Cell Proliferation, Survival, and HER2-Neu Oncogeneâ€"Dependent Breast Tumorigenesis. Cancer Research, 2006, 66, 4672-4680.	0.4	123
126	CELL ADHESION-MEDIATED RADIATION RESISTANCE: THE ROLE OF INTEGRINS AND INTEGRIN PROXIMAL PROTEIN. , 2006, , 141-162.		1
127	Tumor-Associated Antigens and Biomarkers in Cancer and Immune Therapy. International Reviews of Immunology, 2007, 26, 223-247.	1.5	23
128	Pharmacological inhibition of EGFR tyrosine kinase affects ILK-mediated cellular radiosensitization in vitro. International Journal of Radiation Biology, 2007, 83, 793-802.	1.0	29
129	Tumor Growth Inhibition with Cetuximab and Chemotherapy in Nonâ€"Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor. Clinical Cancer Research, 2007, 13, 1540-1551.	3.2	102

#	Article	IF	Citations
130	In vivo selection for metastasis promoting genes in the mouse. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6696-6701.	3.3	75
131	Targeting HER2 in Prostate Cancer: Where to Next?. Journal of Clinical Oncology, 2007, 25, 241-243.	0.8	47
132	The Asn418-Linked N-Glycan of ErbB3 Plays a Crucial Role in Preventing Spontaneous Heterodimerization and Tumor Promotion. Cancer Research, 2007, 67, 1935-1942.	0.4	51
133	Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. Journal of the National Cancer Institute, 2007, 99, 628-638.	3.0	769
134	Pharmacology and Signaling Properties of Epidermal Growth Factor Receptor Isoforms Studied by Bioluminescence Resonance Energy Transfer. Molecular Pharmacology, 2007, 71, 508-518.	1.0	24
135	PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. British Journal of Cancer, 2007, 96, 801-807.	2.9	75
136	Emerging therapies for colorectal cancer. Expert Opinion on Investigational Drugs, 2007, 16, 867-876.	1.9	4
137	Current Concepts for the Combined Treatment Modality of Ionizing Radiation with Anticancer Agents. Current Pharmaceutical Design, 2007, 13, 519-535.	0.9	25
138	Why Do Cancer Cells Become â€œAddictedâ€•to Oncogenic Epidermal Growth Factor Receptor?. PLoS Medicine, 2007, 4, e321.	3.9	5
139	PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors. Clinical Cancer Research, 2007, 13, 378-381.	3.2	114
141	Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology, 2007, 25, 257-262.	0.8	127
142	Neuregulin Expression Modulates Clinical Response to Trastuzumab in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2007, 25, 2656-2663.	0.8	53
143	Mig-6, Signal Transduction, Stress Response and Cancer. Cell Cycle, 2007, 6, 507-513.	1.3	90
144	Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Molecular Cancer Therapeutics, 2007, 6, 93-100.	1.9	56
145	Ebp1-mediated inhibition of cell growth requires serine 363 phosphorylation. International Journal of Oncology, 2007, 31, 851.	1.4	3
146	Genomics and Signaling Pathways in Hepatocellular Carcinoma. Seminars in Liver Disease, 2007, 27, 055-076.	1.8	491
147	The HER4 Cytoplasmic Domain, But Not Its C Terminus, Inhibits Mammary Cell Proliferation. Molecular Endocrinology, 2007, 21, 1861-1876.	3.7	33
148	Emerging drugs for targeted therapy of bladder cancer. Expert Opinion on Emerging Drugs, 2007, 12, 435-448.	1.0	7

#	Article	IF	Citations
149	Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Oncology, 2007, 3, 277-283.	1.1	32
150	Aberrant kinase signaling: lessons from head and neck cancer. Future Oncology, 2007, 3, 353-361.	1.1	4
151	Recent advances in the design and discovery of small-molecule therapeutics targeting HER2/neu. Expert Opinion on Therapeutic Patents, 2007, 17, 83-102.	2.4	10
152	Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opinion on Biological Therapy, 2007, 7, 257-268.	1.4	96
153	Oncogene and tumor-suppressor gene products as serum biomarkers in occupational-derived lung cancer. Expert Review of Molecular Diagnostics, 2007, 7, 555-568.	1.5	10
155	Targeting Human Epidermal Growth Factor Receptor 2: It Is Time to Kill Kinase Death Human Epidermal Growth Factor Receptor 3. Journal of Clinical Oncology, 2007, 25, 2496-2498.	0.8	6
156	Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Nonâ€“Small Cell Lung Cancer Cells Bearing EGFR Gene Mutation and Amplification. Cancer Research, 2007, 67, 2046-2053.	0.4	166
157	Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. Molecular Cancer Therapeutics, 2007, 6, 773-781.	1.9	26
158	Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21WAF1/CIP1 expression with rapamycin. Molecular Cancer Therapeutics, 2007, 6, 2127-2138.	1.9	63
159	Biology of Interactions: Antiepidermal Growth Factor Receptor Agents. Journal of Clinical Oncology, 2007, 25, 4057-4065.	0.8	209
160	CETUXIMAB (ERBITUXÂ®), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER. , 2007, , 43-67.		0
161	HER4 D-Box Sequences Regulate Mitotic Progression and Degradation of the Nuclear HER4 Cleavage Product s80HER4. Cancer Research, 2007, 67, 6582-6590.	0.4	13
162	Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer. Clinical Cancer Research, 2007, 13, 6579-6584.	3.2	144
163	Protein-Tyrosine Phosphatase 1B Is Required for HER2/Neuâ€“Induced Breast Cancer. Cancer Research, 2007, 67, 2420-2424.	0.4	200
164	The Biology of Metastasis to a Sanctuary Site. Clinical Cancer Research, 2007, 13, 1656-1662.	3.2	138
165	HKI-272 in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 4593s-4596s.	3.2	47
166	Viable Mice with Compound Mutations in the Wnt/Dvl Pathway Antagonists nkd1 and nkd2. Molecular and Cellular Biology, 2007, 27, 4454-4464.	1.1	37
167	Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications. Clinical Cancer Research, 2007, 13, 7289-7295.	3.2	23

#	Article	IF	Citations
168	Erlotinib Directly Inhibits HER2 Kinase Activation and Downstream Signaling Events in Intact Cells Lacking Epidermal Growth Factor Receptor Expression. Cancer Research, 2007, 67, 1228-1238.	0.4	76
170	Degradation of HER2 by Cbl-Based Chimeric Ubiquitin Ligases. Cancer Research, 2007, 67, 8716-8724.	0.4	33
171	The Î±6Î²4 Integrin Can Regulate ErbB-3 Expression: Implications for Î±6Î²4 Signaling and Function. Cancer Research, 2007, 67, 1645-1652.	0.4	54
172	Human Epidermal Growth Factor Receptor 2 Regulates Angiopoietin-2 Expression in Breast Cancer via AKT and Mitogen-Activated Protein Kinase Pathways. Cancer Research, 2007, 67, 1487-1493.	0.4	40
173	Distinct ErbB-2â€“Coupled Signaling Pathways Promote Mammary Tumors with Unique Pathologic and Transcriptional Profiles. Cancer Research, 2007, 67, 7579-7588.	0.4	23
174	Breast Cancer Expressing the Activated HER2/neu Is Sensitive to Gefitinib In vitro and In vivo and Acquires Resistance through a Novel Point Mutation in the HER2/neu. Cancer Research, 2007, 67, 6825-6843.	0.4	42
175	Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer. Clinical Cancer Research, 2007, 13, 1892-1902.	3.2	130
176	In vivo Therapeutic Synergism of Antiâ€“Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas. Clinical Cancer Research, 2007, 13, 3356-3362.	3.2	75
177	Smoking and Lung Cancer: Future Research Directions. International Journal of Toxicology, 2007, 26, 353-364.	0.6	21
178	Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Annals of Oncology, 2007, 18, 421-430.	0.6	40
179	Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Molecular Systems Biology, 2007, 3, 151.	3.2	128
180	Brain Metastases of Breast Cancer. Breast Disease, 2007, 26, 139-147.	0.4	75
181	Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood, 2007, 110, 2674-2684.	0.6	53
182	The role of taxanes and targeted therapies in locally advanced head and neck cancer. Current Opinion in Oncology, 2007, 19, 195-201.	1.1	17
183	Translational approaches for the prevention of estrogen receptor-negative breast cancer. European Journal of Cancer Prevention, 2007, 16, 203-215.	0.6	15
184	Insights Into the Pathophysiology and Management of Dermatologic Toxicities to EGFR-Targeted Therapies in Colorectal Cancer. Cancer Nursing, 2007, 30, S17-S26.	0.7	26
185	Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). European Journal of Cancer, 2007, 43, 481-489.	1.3	142
186	Molecular targeted therapies in breast cancer: Where are we now?. International Journal of Biochemistry and Cell Biology, 2007, 39, 1375-1387.	1.2	32

#	Article	IF	Citations
187	Rational bases for the development of EGFR inhibitors for cancer treatment. International Journal of Biochemistry and Cell Biology, 2007, 39, 1416-1431.	1.2	115
188	Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Letters, 2007, 248, 219-228.	3.2	153
189	Epidermal growth factor receptor inhibitors: A new era of drug reactions in a new era of cancer therapy. Journal of the American Academy of Dermatology, 2007, 56, 514-517.	0.6	17
190	Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Human Pathology, 2007, 38, 1184-1191.	1.1	54
191	Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy. Radiotherapy and Oncology, 2007, 82, 10-17.	0.3	46
192	Rule-Based Modelling of Cellular Signalling. Lecture Notes in Computer Science, 2007, , 17-41.	1.0	153
193	EGF Prevents the Neuroendocrine Differentiation of LNCaP Cells Induced By Serum Deprivation: The Modulator Role of P13K/Akt. Neoplasia, 2007, 9, 614-624.	2.3	42
194	Apoptosis, Senescence, and Cancer. , 2007, , .		8
195	Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer. Breast Cancer Research, 2007, 9, 112.	2.2	20
196	Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?. Breast Cancer Research, 2007, 9, 111.	2.2	19
197	Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Research, 2007, 9, R63.	2.2	182
198	HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Research, 2007, 9, .	2.2	51
199	Involvement of alpha6beta4 integrin in the mechanisms that regulate breast cancer progression. Breast Cancer Research, 2007, 9, 203.	2.2	44
201	Cdc42: an effector and regulator of ErbB1 as a strategic target in breast cancer therapy. Expert Review of Anticancer Therapy, 2007, 7, 147-157.	1.1	14
202	Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells. Expert Review of Endocrinology and Metabolism, 2007, 2, 689-704.	1.2	7
203	Her-2 Overexpression Increases the Metastatic Outgrowth of Breast Cancer Cells in the Brain. Cancer Research, 2007, 67, 4190-4198.	0.4	299
204	Epidermal Growth Factor Receptor Inhibitorâ€“Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management. Oncologist, 2007, 12, 610-621.	1.9	318
205	Chapter 25 Systems Biology and Kinase Signaling. Annual Reports in Medicinal Chemistry, 2007, , 393-627.	0.5	2

#	Article	IF	Citations
206	Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies. Science, 2007, 318, 287-290.	6.0	849
207	Flipped Out:â€‰ Structure-Guided Design of Selective Pyrazolylpyrrole ERK Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 1280-1287.	2.9	108
208	FDA Drug Approval Summary: Panitumumab (Vectibixâ„¢). Oncologist, 2007, 12, 577-583.	1.9	184
210	Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain. Molecular Cancer, 2007, 6, 56.	7.9	22
211	Highlights from: Annual Meeting of the American Society of Clinical Oncology Chicago, Illinois; June 1â€“5, 2007. Clinical Colorectal Cancer, 2007, 6, 556-560.	1.0	0
212	HB-EGF, Transactivation, and Cardiac Hypertrophy. International Journal of Gerontology, 2007, 1, 2-9.	0.7	5
213	A Dimerization Hierarchy in the Transmembrane Domains of the HER Receptor Family. Biochemistry, 2007, 46, 2010-2019.	1.2	67
214	Tyrosine Kinases as Targets for Anti-Inflammatory Therapy. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2007, 6, 47-60.	1.1	3
215	Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutantâ€“dependent lung carcinomas. Journal of Clinical Investigation, 2007, 117, 346-352.	3.9	44
217	EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR ONCOLOGY: DISCOVERY AND DEVELOPMENT OF ERLOTINIB. , 2007, , 155-178.		0
219	Whole genome tiling path array CGH analysis of segmental copy number alterations in cervical cancer cell lines. International Journal of Cancer, 2007, 120, 436-443.	2.3	34
220	Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. International Journal of Cancer, 2008, 122, 1722-1729.	2.3	15
221	Targeting cell signaling pathways for drug discovery: An old lock needs a new key. Journal of Cellular Biochemistry, 2007, 102, 580-592.	1.2	127
222	Inverse In Silico Screening for Identification of Kinase Inhibitor Targets. Chemistry and Biology, 2007, 14, 1207-1214.	6.2	80
223	The Hypoxic Tumour Microenvironment, Patient Selection and Hypoxia-modifying Treatments. Clinical Oncology, 2007, 19, 385-396.	0.6	68
224	Marked Dependence on Growth State of Backup Pathways of NHEJ. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1462-1470.	0.4	49
225	Inhibition of the epidermal growth factor receptor enhances castration-induced prostate involution and reduces testosterone-stimulated prostate growth in adult rats. Prostate, 2007, 67, 573-581.	1.2	16
226	HPV16 E6-mediated stabilization of ErbB2 in neoplastic transformation of human cervical keratinocytes. Oncogene, 2007, 26, 2988-2996.	2.6	49

#	Article	IF	Citations
227	Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 2007, 26, 3291-3310.	2.6	2,421
228	Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. Oncogene, 2007, 26, 6905-6914.	2.6	63
229	ErbB-2 via PYK2 upregulates the adhesive ability of androgen receptor-positive human prostate cancer cells. Oncogene, 2007, 26, 7552-7559.	2.6	24
230	A module of negative feedback regulators defines growth factor signaling. Nature Genetics, 2007, 39, 503-512.	9.4	506
231	Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer, 2007, 7, 169-181.	12.8	2,741
232	Modulation of Porcine Wound Repair with a Transfected ErbB3 Gene and Relevant EGF-Like Ligands. Journal of Investigative Dermatology, 2007, 127, 1030-1041.	0.3	20
233	A monkey wrench in the kinase machine. Nature Structural and Molecular Biology, 2007, 14, 1120-1121.	3.6	0
234	Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Modern Pathology, 2007, 20, 120-129.	2.9	171
235	Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Modern Pathology, 2007, 20, 192-198.	2.9	60
236	Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature, 2007, 450, 741-744.	13.7	311
237	The epidermal growth factor receptor: from development to tumorigenesis. Differentiation, 2007, 75, 770-787.	1.0	289
238	KIT and RAS signalling pathways in testicular germ cell tumours: new data and a review of the literature. Journal of Developmental and Physical Disabilities, 2007, 30, 337-349.	3.6	101
239	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science, 2007, 98, 1817-1824.	1.7	554
240	Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: Immunohistochemistry and chromogenic in situ hybridization. Pathology International, 2008, 58, 17-25.	0.6	41
241	Epidermal Growth Factor Receptor Inhibitors plus Chemotherapy in Nonâ€“Small-Cell Lung Cancer: Biologic Rationale for Combination Strategies. Clinical Lung Cancer, 2007, 8, S61-S67.	1.1	24
242	Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptinâ„¢) in HER2-overexpressing breast cancer cells. BMC Cancer, 2007, 7, 80.	1.1	154
243	Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity. Cancer Cell, 2007, 11, 217-227.	7.7	933
244	A Case of Mistaken Identity? Nonductal Origins of Pancreatic â€œDuctalâ€•Cancers. Cancer Cell, 2007, 11, 211-213.	7.7	45

#	Article	IF	Citations
245	The EGF Receptor Hokey-Cokey. Cancer Cell, 2007, 11, 209-211.	7.7	6
246	A Brake Becomes an Accelerator: PTP1Bâ€"A New Therapeutic Target for Breast Cancer. Cancer Cell, 2007, 11, 214-216.	7.7	86
247	The EGF receptor family: spearheading a merger of signaling and therapeutics. Current Opinion in Cell Biology, 2007, 19, 124-134.	2.6	356
248	Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discovery Today, 2007, 12, 34-42.	3.2	947
249	Specificity, selection and significance of gene amplifications in cancer. Seminars in Cancer Biology, 2007, 17, 42-55.	4.3	58
250	Mechanisms of HER2-Induced Endothelial Cell Retraction. Annals of Surgical Oncology, 2007, 14, 2971-2978.	0.7	9
251	Long-term immunity elicited by antibodyâ€"cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies. Cancer Immunology, Immunotherapy, 2007, 56, 1507-1512.	2.0	8
252	Role of heregulin in human cancer. Cellular and Molecular Life Sciences, 2007, 64, 2358-2377.	2.4	80
253	Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Research and Treatment, 2007, 106, 319-331.	1.1	18
254	Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. International Journal of Clinical Oncology, 2007, 12, 99-110.	1.0	36
256	An update into the pathophysiological role of HER2 in cancer: therapeutic implications. Clinical and Translational Oncology, 2007, 9, 543-544.	1.2	1
257	Mechanisms of resistance to EGFR inhibitors. Targeted Oncology, 2007, 2, 31-37.	1.7	10
258	Targeted therapies in head and neck cancer. Targeted Oncology, 2007, 2, 73-88.	1.7	15
259	Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report. Targeted Oncology, 2007, 2, 253-257.	1.7	0
260	Targeting PTPs with small molecule inhibitors in cancer treatment. Cancer and Metastasis Reviews, 2008, 27, 263-272.	2.7	119
261	The Role of ErbB3 and its Binding Partners in Breast Cancer Progression and Resistance to Hormone and Tyrosine Kinase Directed Therapies. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 225-233.	1.0	64
262	Role of ErbB4 in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 259-268.	1.0	121
263	ErbB4/HER4: Role in Mammary Gland Development, Differentiation and Growth Inhibition. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 235-246.	1.0	85

#	Article	IF	Citations
264	ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 215-223.	1.0	122
265	Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 485-498.	1.0	131
266	The epidermal growth factor receptor family: Biology driving targeted therapeutics. Cellular and Molecular Life Sciences, 2008, 65, 1566-1584.	2.4	593
267	Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemotherapy and Pharmacology, 2008, 62, 605-620.	1.1	30
268	A Mathematical Model for the Effects of HER2 Overexpression on Cell Proliferation in Breast Cancer. Bulletin of Mathematical Biology, 2008, 70, 1707-1729.	0.9	21
269	Molekulardiagnostik von Mutationen des epidermalen Wachstumsfaktor-Rezeptors und Aktivierung nachgeschalteter Signalwege in nichtkleinzelligen Lungenkarzinomen. Onkopipeline, 2008, 1, 101-108.	0.0	0
270	An update on the biology of cancer stem cells in breast cancer. Clinical and Translational Oncology, 2008, 10, 786-793.	1.2	16
271	Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochemistry and Cell Biology, 2008, 129, 563-578.	0.8	166
272	Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. Cancer Cell International, 2008, 8, 1.	1.8	23
273	Quantitative phosphoproteomics â€“ an emerging key technology in signalâ€transduction research. Proteomics, 2008, 8, 4416-4432.	1.3	57
274	Characterisation of tumoral markers correlated with ErbB2 (HER2/Neu) overexpression and metastasis in breast cancer. Proteomics - Clinical Applications, 2008, 2, 1313-1326.	0.8	11
275	Câ€erbBâ€2 expression and prognostic significance in osteosarcoma. Pediatric Blood and Cancer, 2008, 51, 222-227.	0.8	16
276	Herceptinâ€“Platinum(II) Binding Complexes: Novel Cancer-Cell-Specific Agents. ChemMedChem, 2008, 3, 954-962.	1.6	12
277	Allene as an Alternative Functional Group for Drug Design: Effect of Cï£¿C Multiple Bonds Conjugated with Quinazolines on the Inhibition of EGFR Tyrosine Kinase. ChemMedChem, 2008, 3, 1094-1103.	1.6	19
278	Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer, 2008, 113, 1453-1461.	2.0	92
279	Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib. International Journal of Cancer, 2008, 123, 2939-2949.	2.3	36
280	Quercetinâ€induced ubiquitination and downâ€regulation of Herâ€2/neu. Journal of Cellular Biochemistry, 2008, 105, 585-595.	1.2	65
281	Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head and Neck, 2008, 30, 667-674.	0.9	50

#	Article	IF	Citations
282	Antagonism of the human epidermal growth factor receptor family controls disease severity in murine collagenâ€induced arthritis. Arthritis and Rheumatism, 2008, 58, 3071-3080.	6.7	8
283	Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. Bioorganic and Medicinal Chemistry, 2008, 16, 3482-3488.	1.4	88
284	Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 959-962.	1.0	69
285	Augmentation of Radiation Response by Panitumumab in Models of Upper Aerodigestive Tract Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 534-542.	0.4	41
286	Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3178-3182.	1.0	78
287	Enhanced phosphorylation of the epidermal growth factor receptor at the site of tyrosine 992 in esophageal carcinomas. Apmis, 2008, 116, 1097-1106.	0.9	8
288	Structural basis for EGFR ligand sequestration by Argos. Nature, 2008, 453, 1271-1275.	13.7	48
289	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 2008, 27, 4702-4711.	2.6	1,272
290	A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. British Journal of Cancer, 2008, 98, 80-85.	2.9	217
291	Phosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cells. British Journal of Cancer, 2008, 98, 1132-1140.	2.9	21
292	Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs. British Journal of Cancer, 2008, 99, 473-480.	2.9	22
293	Deregulation of MUC4 in gastric adenocarcinoma: potential pathobiological implication in poorly differentiated non-signet ring cell type gastric cancer. British Journal of Cancer, 2008, 99, 949-956.	2.9	35
294	Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. British Journal of Cancer, 2008, 99, 1415-1425.	2.9	115
295	Getting invasive with GEP100 and Arf6. Nature Cell Biology, 2008, 10, 16-18.	4.6	8
296	GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. Nature Cell Biology, 2008, 10, 85-92.	4.6	194
297	The ADAMs: signalling scissors in the tumour microenvironment. Nature Reviews Cancer, 2008, 8, 932-941.	12.8	450
298	Membraneâ€anchored growth factors, the epidermal growth factor family: Beyond receptor ligands. Cancer Science, 2008, 99, 214-220.	1.7	195
299	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Proliferation, 2008, 41, 59-85.	2.4	160

#	Article	IF	Citations
300	Signals and Systems: Towards a Systems Biology of Signal Transduction. Proceedings of the IEEE, 2008, 96, 1386-1397.	16.4	13
301	Update on novel therapeutic agents for cervical cancer. Gynecologic Oncology, 2008, 110, S72-S76.	0.6	59
302	Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer, 2008, 8, 10.	1.1	45
303	A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents. BMC Cancer, 2008, 8, 119.	1.1	2
304	The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population. BMC Cancer, 2008, 8, 359.	1.1	25
305	tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO). BMC Cancer, 2008, 8, 377.	1.1	108
306	FoxO tumor suppressors and BCRâ€“ABL-induced leukemia: A matter of evasion of apoptosis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1785, 63-84.	3.3	51
307	A Molecular View of Anti-ErbB Monoclonal Antibody Therapy. Cancer Cell, 2008, 13, 291-293.	7.7	28
308	RanBP2: A Tumor Suppressor with a New Twist on TopoII, SUMO, and Centromeres. Cancer Cell, 2008, 13, 293-295.	7.7	17
309	Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis. Journal of Cellular and Molecular Medicine, 2008, 12, 1527-1534.	1.6	91
310	Targeted Molecular Imaging in Oncology: Focus on Radiation Therapy. Seminars in Radiation Oncology, 2008, 18, 136-148.	1.0	27
311	Recent progress in tumor pH targeting nanotechnology. Journal of Controlled Release, 2008, 132, 164-170.	4.8	784
312	Mechanism of Activation and Inhibition of the HER4/ErbB4 Kinase. Structure, 2008, 16, 460-467.	1.6	159
313	Proteomic Profiling of Tyrosine Kinases as Pharmacological Endpoints for Targeted Cancer Therapy. , 2008, , 59-77.		0
314	Herceptin. Handbook of Experimental Pharmacology, 2008, , 183-219.	0.9	57
315	Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. Lung Cancer, 2008, 62, 193-201.	0.9	46
316	Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer, 2008, 62, 316-320.	0.9	97
317	Discovery of Novel Small-Molecule Inhibitors of Human Epidermal Growth Factor Receptor-2: Combined Ligand and Target-Based Approach. Journal of Medicinal Chemistry, 2008, 51, 3367-3377.	2.9	119

#	Article	IF	Citations
318	EGFR family: Structure physiology signalling and therapeutic targets^{â€}. Growth Factors, 2008, 26, 263-274.	0.5	223
319	The Cancer Preventive Potential of Tea Polyphenol EGCG in HER2-Positive Breast Cancer. ACS Symposium Series, 2008, , 335-344.	0.5	0
320	Clinical Approaches to Minimize Rash Associated With EGFR Inhibitors. Oncology Nursing Forum, 2008, 35, 103-111.	0.5	20
321	Molecular targets and biological modifiers in gastric cancer. Seminars in Diagnostic Pathology, 2008, 25, 274-287.	1.0	30
322	Structure-Based View of Epidermal Growth Factor Receptor Regulation. Annual Review of Biophysics, 2008, 37, 353-373.	4.5	306
323	Signalling by the EGF receptor in human cancers: accentuate the positive, eliminate the negative. , 2008, , 224-244.		1
324	EGFR Signaling Networks in Cancer Therapy. , 2008, , .		11
325	Chapter 4 Adhesion Proteins Meet Receptors. Advances in Cancer Research, 2008, 101, 63-92.	1.9	62
326	Cell polarity and cancer â€“ cell and tissue polarity as a non-canonical tumor suppressor. Journal of Cell Science, 2008, 121, 1141-1150.	1.2	242
328	Comparative expression analysis of four breast cancer subtypes versus matched normal tissue from the same patients. Journal of Steroid Biochemistry and Molecular Biology, 2008, 109, 207-211.	1.2	3
329	Efficient Selection of DARPins with Sub-nanomolar Affinities using SRP Phage Display. Journal of Molecular Biology, 2008, 382, 1211-1227.	2.0	236
330	Phosphoproteomics: Unraveling the Signaling Web. Molecular Cell, 2008, 31, 777-781.	4.5	50
331	Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvascular Research, 2008, 76, 15-22.	1.1	51
332	Molecular Imaging in Oncology. , 2008, , 675-691.		1
333	EGFR Antagonists in Cancer Treatment. New England Journal of Medicine, 2008, 358, 1160-1174.	13.9	1,869
334	A new era of cancer therapy: Cancer cell targeted therapies are coming of age. International Journal of Biochemistry and Cell Biology, 2008, 40, 1-8.	1.2	13
335	Genetic and epigenetic alterations in breast cancer: What are the perspectives for clinical practice?. International Journal of Biochemistry and Cell Biology, 2008, 40, 565-575.	1.2	23
336	Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1. Cancer Letters, 2008, 265, 298-306.	3.2	33

#	Article	IF	Citations
337	Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 718-725.	2.0	97
338	Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochemical and Biophysical Research Communications, 2008, 365, 555-561.	1.0	113
339	Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. Lung Cancer, 2008, 60, S10-S18.	0.9	21
340	Cancer Genetics in the Clinic. , 2008, , 259-279.		0
341	Modification of the Primary Tumor Microenvironment by Transforming Growth Factor Î±-Epidermal Growth Factor Receptor Signaling Promotes Metastasis in an Orthotopic Colon Cancer Model. American Journal of Pathology, 2008, 173, 205-216.	1.9	48
342	Antiangiogenic Drugs: Current Knowledge and New Approaches to Cancer Therapy. Journal of Pharmaceutical Sciences, 2008, 97, 4129-4154.	1.6	24
343	Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncology, The, 2008, 9, 962-972.	5.1	709
344	Translational Research in Gastric Malignancy. Surgical Oncology Clinics of North America, 2008, 17, 323-340.	0.6	9
345	Comparison of Expression Profiles of Metastatic versus Primary Mammary Tumors in MMTV-Wnt-1 and MMTV-Neu Transgenic Mice. Neoplasia, 2008, 10, 118-124.	2.3	18
346	EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Review of Molecular Diagnostics, 2008, 8, 417-434.	1.5	86
347	Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 1626-1634.	0.8	3,032
348	EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opinion on Investigational Drugs, 2008, 17, 1517-1531.	1.9	44
349	Isomerization of a Single Aspartyl Residue of Anti-Epidermal Growth Factor Receptor Immunoglobulin Î³2 Antibody Highlights the Role Avidity Plays in Antibody Activity. Biochemistry, 2008, 47, 2518-2530.	1.2	108
350	Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nature Clinical Practice Oncology, 2008, 5, 521-530.	4.3	107
351	Functional and Structural Stability of the Epidermal Growth Factor Receptor in Detergent Micelles and Phospholipid Nanodiscs. Biochemistry, 2008, 47, 10314-10323.	1.2	89
352	Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy. Journal of Dental Research, 2008, 87, 14-32.	2.5	405
353	EGFR, p16, HPV Titer, Bcl-xL and p53, Sex, and Smoking As Indicators of Response to Therapy and Survival in Oropharyngeal Cancer. Journal of Clinical Oncology, 2008, 26, 3128-3137.	0.8	559
354	Insulin-like Growth Factor-1 Receptor and ErbB Kinase Inhibitor Combinations Block Proliferation and Induce Apoptosis through Cyclin D1 Reduction and Bax Activation. Journal of Biological Chemistry, 2008, 283, 23721-23730.	1.6	22

#	Article	IF	Citations
355	Histone Deacetylase Inhibition and Blockade of the Glycolytic Pathway Synergistically Induce Glioblastoma Cell Death. Clinical Cancer Research, 2008, 14, 3132-3140.	3.2	54
356	t10,c12-Conjugated linoleic acid stimulates mammary tumor progression in Her2/ErbB2 mice through activation of both proliferative and survival pathways. Carcinogenesis, 2008, 29, 1013-1021.	1.3	21
357	Myopic acts in the endocytic pathway to enhance signaling by theDrosophilaEGF receptor. Development (Cambridge), 2008, 135, 1913-1922.	1.2	51
358	ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocrine-Related Cancer, 2008, 15, 985-1002.	1.6	76
359	MUC4 Mucin Interacts with and Stabilizes the HER2 Oncoprotein in Human Pancreatic Cancer Cells. Cancer Research, 2008, 68, 2065-2070.	0.4	148
360	A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer. Clinical Cancer Research, 2008, 14, 4484-4490.	3.2	70
361	Neuregulins and Cancer. Clinical Cancer Research, 2008, 14, 3237-3241.	3.2	95
362	DNA Vaccines Targeting Tumor Antigens to B7 Molecules on Antigen-Presenting Cells Induce Protective Antitumor Immunity and Delay Onset of HER-2/Neu-Driven Mammary Carcinoma. Clinical Cancer Research, 2008, 14, 6933-6943.	3.2	23
363	Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma. Molecular Cancer Therapeutics, 2008, 7, 3006-3017.	1.9	19
364	Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells. Carcinogenesis, 2008, 29, 299-306.	1.3	37
365	Pharmacology and Pharmacotherapy. , 2008, , 65-203.		1
366	High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer. Clinical Cancer Research, 2008, 14, 7843-7849.	3.2	123
367	Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Molecular Cancer Therapeutics, 2008, 7, 38-47.	1.9	62
368	Differential sensitivity of A549 non small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors. Cancer Biology and Therapy, 2008, 7, 557-568.	1.5	26
369	ErbB4 targeting approaches for prostate cancer treatment. Cancer Biology and Therapy, 2008, 7, 1095-1097.	1.5	2
370	Killing cancer cells by targeting the EGF receptor. Cancer Biology and Therapy, 2008, 7, 243-244.	1.5	1
371	The EGFR-GEP100-Arf6 pathway in breast cancer. Cell Adhesion and Migration, 2008, 2, 71-73.	1.1	15
372	Targeting Growth Factors in Lung Cancer. Chest, 2008, 133, 1209-1216.	0.4	39

#	Article	IF	Citations
373	Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer. Breast Care, 2008, 3, 7-12.	0.8	1
374	Overexpression, Refolding, Purification of Erbin PDZ Domain fromEscherichia coliand Preparation of its Polyclonal Antibody. Preparative Biochemistry and Biotechnology, 2008, 38, 282-293.	1.0	4
375	Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent. Cancer Research, 2008, 68, 1970-1978.	0.4	332
376	EGF receptor variant III as a target antigen for tumor immunotherapy. Expert Review of Vaccines, 2008, 7, 977-985.	2.0	70
377	Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. British Journal of Cancer, 2008, 98, 923-930.	2.9	131
378	Combinatorial patterns of somatic gene mutations in cancer. FASEB Journal, 2008, 22, 2605-2622.	0.2	235
379	Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers. Clinical Cancer Research, 2008, 14, 6963-6973.	3.2	112
380	Ectodomain cleavage of the EGF ligands HBâ€EGF, neuregulin1â€Î², and TGFâ€Îµ is specifically triggered by different stimuli and involves different PKC isoenzymes. FASEB Journal, 2008, 22, 4281-4295.	0.2	27
381	Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4162-4167.	3.3	90
382	Caspase Cleavage of HER-2 Releases a Bad-like Cell Death Effector. Journal of Biological Chemistry, 2008, 283, 18269-18282.	1.6	36
383	Mutational Activation of ErbB2 Reveals a New Protein Kinase Autoinhibition Mechanism. Journal of Biological Chemistry, 2008, 283, 1588-1596.	1.6	35
384	Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptorâ€“Activating Mutations. Cancer Research, 2008, 68, 9479-9487.	0.4	574
385	Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16254-16259.	3.3	45
386	Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 12463-12468.	3.3	104
387	Synergistic Growth Inhibition by 9-cis-Retinoic Acid Plus Trastuzumab in Human Hepatocellular Carcinoma Cells. Clinical Cancer Research, 2008, 14, 2806-2812.	3.2	32
388	A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy. Cancer Research, 2008, 68, 5878-5887.	0.4	559
389	Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging. Clinical Cancer Research, 2008, 14, 3840-3849.	3.2	164
390	Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Annals of Oncology, 2008, 19, 1860-1869.	0.6	57

#	Article	IF	Citations
391	ADAM10 as a Target for Anti-Cancer Therapy. Current Pharmaceutical Biotechnology, 2008, 9, 2-8.	0.9	82
392	EGFR-targeting agents in oncology. Expert Opinion on Therapeutic Patents, 2008, 18, 889-901.	2.4	23
393	Epidermal growth factor receptor-targeted therapy. British Journal of Radiology, 2008, 81, S36-S44.	1.0	27
394	Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer. Molecular and Cellular Proteomics, 2008, 7, 1902-1924.	2.5	103
395	Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (TykerbÂ®) in human breast carcinoma cells. Annals of Oncology, 2008, 19, 1097-1109.	0.6	39
396	The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer. Current Genomics, 2008, 9, 252-262.	0.7	20
397	Construction of a Fully Retargeted Herpes Simplex Virus 1 Recombinant Capable of Entering Cells Solely via Human Epidermal Growth Factor Receptor 2. Journal of Virology, 2008, 82, 10153-10161.	1.5	102
398	Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Molecular Cancer Therapeutics, 2008, 7, 1880-1889.	1.9	204
399	HER3 Is a Determinant for Poor Prognosis in Melanoma. Clinical Cancer Research, 2008, 14, 5188-5197.	3.2	142
400	Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain. Journal of the National Cancer Institute, 2008, 100, 1092-1103.	3.0	251
401	The EGFR-STAT3 Oncogenic Pathway Up-regulates the Eme1 Endonuclease to Reduce DNA Damage after Topoisomerase I Inhibition. Cancer Research, 2008, 68, 815-825.	0.4	55
402	ADAM-17 predicts adverse outcome in patients with breast cancer. Annals of Oncology, 2008, 19, 1075-1081.	0.6	75
403	Structure, evolution, and biology of the MUC4 mucin. FASEB Journal, 2008, 22, 966-981.	0.2	223
404	Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors. Molecular Pharmacology, 2008, 73, 338-348.	1.0	37
405	CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4. Journal of Immunology, 2008, 180, 8135-8145.	0.4	19
406	Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Antiâ€“Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. Clinical Cancer Research, 2008, 14, 5069-5080.	3.2	139
407	Noninvasive Imaging and Quantification of Epidermal Growth Factor Receptor Kinase Activation In vivo. Cancer Research, 2008, 68, 4990-4997.	0.4	30
408	Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors. Oncologist, 2008, 13, 978-992.	1.9	48

#	Article	IF	Citations
409	Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2008, 14, 6730-6734.	3.2	102
410	ErbB Antagonists Patenting: “Playing Chess with Cancer”. Recent Patents on Biotechnology, 2008, 2, 181-187.	0.4	8
411	The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nature Clinical Practice Oncology, 2008, 5, 531-542.	4.3	153
412	Phosphoinositide 3-Kinase p110Î² Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development. Science Signaling, 2008, 1, ra3.	1.6	219
413	Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops. Cancer Prevention Research, 2008, 1, 156-160.	0.7	80
414	Memo Is Homologous to Nonheme Iron Dioxygenases and Binds an ErbB2-derived Phosphopeptide in Its Vestigial Active Site. Journal of Biological Chemistry, 2008, 283, 2734-2740.	1.6	25
415	Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation. Molecular Pharmacology, 2008, 74, 807-822.	1.0	54
416	Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Molecular Cancer Therapeutics, 2008, 7, 599-606.	1.9	67
417	Targeting important pathways in head and neck cancer: from the bench to the clinic. Expert Review of Anticancer Therapy, 2008, 8, 1819-1835.	1.1	2
418	Mutations of epidermal growth factor receptor in colon cancer indicate susceptibility or resistance to gefitinib. Oncology Reports, 0, , .	1.2	4
419	Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck. Oncology Reports, 0, , .	1.2	7
420	In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncology Reports, 2008, 19, 853-7.	1.2	35
421	Imaging of HER-2 Overexpression in Tumors for Guiding Therapy. Current Pharmaceutical Design, 2008, 14, 2999-3019.	0.9	108
422	Expression of EGFR in Gastric Stromal Tumors. Applied Immunohistochemistry and Molecular Morphology, 2008, 16, 310-315.	0.6	3
423	Radionuclide carriers for targeting of cancer. International Journal of Nanomedicine, 2008, 3, 181.	3.3	88
424	Targeting Receptor Tyrosine Kinases for Chemoprevention by Green Tea Catechin, EGCG. International Journal of Molecular Sciences, 2008, 9, 1034-1049.	1.8	91
425	PET and SPECT Imaging of Tumor Biology: New Approaches Towards Oncology Drug Discovery and Development. Current Computer-Aided Drug Design, 2008, 4, 46-53.	0.8	39
426	ERK/p44p42 Mitogen-Activated Protein Kinase Mediates EGF-Stimulated Proliferation of Conjunctival Goblet Cells in Culture. , 2008, 49, 3351.		24

#	Article	IF	Citations
427	Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling. PLoS ONE, 2008, 3, e3065.	1.1	248
428	Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World Journal of Gastroenterology, 2008, 14, 7033.	1.4	91
429	Tyrphostin ErbB2 Inhibitors AG825 and AG879 Have Non-specific Suppressive Effects on gp130/ STAT3 Signaling. Korean Journal of Physiology and Pharmacology, 2008, 12, 281.	0.6	4
430	Anti-HER2 Treatment and Breast Cancer: State of the Art, Recent Patents, and New Strategies. Recent Patents on Anti-Cancer Drug Discovery, 2009, 4, 9-18.	0.8	17
433	Trastuzumab Resistance: Role for Notch Signaling. Scientific World Journal, The, 2009, 9, 1438-1448.	0.8	15
434	Expression of the Epidermal Growth Factor Receptor Family in Correlation to the Estrogen Receptor Î± Expression in Peritoneal and Ovarian Endometriosis. Journal of Endometriosis, 2009, 1, 122-130.	1.0	0
435	Update in Antiepidermal Growth Factor Receptor Therapy in the Management of Metastatic Colorectal Cancer. Journal of Oncology, 2009, 2009, 1-6.	0.6	6
436	Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. Journal of Oncology, 2009, 2009, 1-14.	0.6	99
437	Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept. Journal of Oncology, 2009, 2009, 1-8.	0.6	36
438	Update on Anti-EGFR Targeted Therapy. Journal of Oncology, 2009, 2009, 1-2.	0.6	2
439	Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target. PLoS ONE, 2009, 4, e5565.	1.1	99
440	Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2. PLoS ONE, 2009, 4, e5933.	1.1	91
441	Epidermal Growth Factor Receptor Signaling Synergizes with Hedgehog/GLI in Oncogenic Transformation via Activation of the MEK/ERK/JUN Pathway. Cancer Research, 2009, 69, 1284-1292.	0.4	189
442	HER1-ECD vaccination dispenses with emulsification to elicit HER1-specific anti-proliferative effects. Hum Vaccin, 2009, 5, 158-165.	2.4	6
443	Heat Shock Protein 90 Inhibitors: New Mode of Therapy to Overcome Endocrine Resistance. Cancer Research, 2009, 69, 8670-8677.	0.4	31
444	^{V600E} BRAF is associated with disabled feedback inhibition of RAFâ€“MEK signaling and elevated transcriptional output of the pathway. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4519-4524.	3.3	535
445	Targeting Signal Transducer and Activator of Transcription Signaling Pathway in Leukemias. Journal of Clinical Oncology, 2009, 27, 4422-4432.	0.8	123
446	A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis. Molecular and Cellular Biology, 2009, 29, 3319-3331.	1.1	150

#	Article	IF	Citations
447	Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs, 2009, 1, 41-48.	2.6	195
448	Somatic Mutations of ErbB4. Journal of Biological Chemistry, 2009, 284, 5582-5591.	1.6	55
449	GAREM, a Novel Adaptor Protein for Growth Factor Receptor-bound Protein 2, Contributes to Cellular Transformation through the Activation of Extracellular Signal-regulated Kinase Signaling. Journal of Biological Chemistry, 2009, 284, 20206-20214.	1.6	44
450	Combined Treatment of Î³-Tocotrienol with Statins Induce Mammary Tumor Cell Cycle Arrest in G1. Experimental Biology and Medicine, 2009, 234, 639-650.	1.1	43
451	Biomarkers of response to therapy in oesophago-gastric cancer. Gut, 2009, 58, 127-143.	6.1	74
452	Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC. Oncologist, 2009, 14, 399-411.	1.9	86
453	Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3294-3299.	3.3	161
454	Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion on Therapeutic Targets, 2009, 13, 339-362.	1.5	77
455	ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes and Development, 2009, 23, 1882-1894.	2.7	264
456	Nuclear Translocation of the Epidermal Growth Factor Receptor Family Membrane Tyrosine Kinase Receptors. Clinical Cancer Research, 2009, 15, 6484-6489.	3.2	157
458	Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor Xenografts. Cancer Research, 2009, 69, 873-878.	0.4	164
459	HER-2 as a Target for Breast Cancer Therapy. Clinical Cancer Research, 2009, 15, 1848-1852.	3.2	36
460	PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer. Clinical Cancer Research, 2009, 15, 3184-3188.	3.2	296
461	Expression of Epidermal Growth Factor Receptor or ErbB3 Facilitates Geldanamycin-Induced Down-Regulation of ErbB2. Molecular Cancer Research, 2009, 7, 275-284.	1.5	16
462	Tyrosine Phosphorylation of Grb2: Role in Prolactin/Epidermal Growth Factor Cross Talk in Mammary Epithelial Cell Growth and Differentiation. Molecular and Cellular Biology, 2009, 29, 2505-2520.	1.1	28
463	Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo. Neuro-Oncology, 2009, 11, 250-259.	0.6	23
464	Systemic Therapies in Hepatocellular Carcinoma. Digestive Diseases, 2009, 27, 175-188.	0.8	58
465	Targeting Epidermal Growth Factor Receptor 1 Signaling in Human Thyroid-Stimulating Hormoneâ€“Independent Thyroid Carcinoma FRO Cells Results in a More Chemosensitive and Less Angiogenic Phenotype. Thyroid, 2009, 19, 629-637.	2.4	11

#	Article	IF	Citations
466	EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?. Journal of Thoracic Oncology, 2009, 4, 1-4.	0.5	167
467	Resistance to Trastuzumab in Breast Cancer. Clinical Cancer Research, 2009, 15, 7479-7491.	3.2	397
468	Targeting ERBB Receptors to Inhibit Metastasis: Old Hopes and New Certainties. Current Cancer Drug Targets, 2009, 9, 1-18.	0.8	6
469	Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?. Current Cancer Drug Targets, 2009, 9, 252-272.	0.8	44
470	Theme: Oncology - Molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates. Biomarkers in Medicine, 2009, 3, 139-151.	0.6	4
471	A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies. Clinical Cancer Research, 2009, 15, 6702-6708.	3.2	81
472	Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel. Current Pharmaceutical Design, 2009, 15, 207-242.	0.9	10
473	Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer. Current Cancer Drug Targets, 2009, 9, 148-162.	0.8	53
474	Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. Nature Reviews Clinical Oncology, 2009, 6, 287-294.	12.5	21
475	Metalloproteinases and osteoblast EGFR signaling in osteolytic bone metastasis of breast cancer. Cell Cycle, 2009, 8, 3804-3805.	1.3	4
476	Oncolytic herpes virus retargeted to HER-2. Cell Cycle, 2009, 8, 2859-2860.	1.3	3
477	Oncogenic EGFR Signaling Networks in Glioma. Science Signaling, 2009, 2, re6.	1.6	299
478	Roles of MKK1/2-ERK1/2 and Phosphoinositide 3-Kinaseâ€“AKT Signaling Pathways in Erlotinib-Induced Rad51 Suppression and Cytotoxicity in Human Nonâ€“Small Cell Lung Cancer Cells. Molecular Cancer Research, 2009, 7, 1378-1389.	1.5	48
479	Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity. Molecular Cancer Research, 2009, 7, 1563-1571.	1.5	38
480	Integrin signal masks growth-promotion activity of HB-EGF in monolayer cell cultures. Journal of Cell Science, 2009, 122, 4277-4286.	1.2	32
481	EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma. Future Oncology, 2009, 5, 323-338.	1.1	30
482	Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9039-9044.	3.3	83
483	Targeted therapy in biliary tract cancer: 2009 update. Future Oncology, 2009, 5, 1675-1684.	1.1	8

#	Article	IF	Citations
484	Memo is a cofilin-interacting protein that influences PLCÎ³1 and cofilin activities, and is essential for maintaining directionality during ErbB2-induced tumor-cell migration. Journal of Cell Science, 2009, 122, 787-797.	1.2	32
485	Functional Genomic Analysis Identified Epidermal Growth Factor Receptor Activation as the Most Common Genetic Event in Oral Squamous Cell Carcinoma. Cancer Research, 2009, 69, 2568-2576.	0.4	143
486	A Novel Proximity Assay for the Detection of Proteins and Protein Complexes: Quantitation of HER1 and HER2 Total Protein Expression and Homodimerization in Formalin-fixed, Paraffin-Embedded Cell Lines and Breast Cancer Tissue. Diagnostic Molecular Pathology, 2009, 18, 11-21.	2.1	88
487	CCAAT/enhancer-binding protein Î²: its role in breast cancer and associations with receptor tyrosine kinases. Expert Reviews in Molecular Medicine, 2009, 11, e12.	1.6	147
488	Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor. Molecular Cancer Therapeutics, 2009, 8, 1526-1535.	1.9	31
489	Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma. Clinical Cancer Research, 2009, 15, 3697-3704.	3.2	69
490	The E3 Ubiquitin Ligase WWP1 Selectively Targets HER4 and Its Proteolytically Derived Signaling Isoforms for Degradation. Molecular and Cellular Biology, 2009, 29, 892-906.	1.1	49
491	Expert Consensus on the Management of Erlotinib-Associated Cutaneous Toxicity in the U.K.. Oncologist, 2009, 14, 840-847.	1.9	37
492	Applying the molecular biology and epigenetics of head and neck cancer in everyday clinical practice. Oral Oncology, 2009, 45, 440-446.	0.8	69
493	Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment. Trends in Biotechnology, 2009, 27, 350-358.	4.9	83
494	ErbBs in lung cancer. Experimental Cell Research, 2009, 315, 557-571.	1.2	61
495	The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology. Experimental Cell Research, 2009, 315, 602-610.	1.2	127
496	ErbB receptors in the biology and pathology of the aerodigestive tract. Experimental Cell Research, 2009, 315, 572-582.	1.2	59
497	Interaction of antibodies with ErbB receptor extracellular regions. Experimental Cell Research, 2009, 315, 659-670.	1.2	81
498	The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Experimental and Molecular Pathology, 2009, 87, 1-11.	0.9	90
499	DLG1/SAP97 modulates transforming growth factor Î± bioavailability. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 264-272.	1.9	15
500	Metastasis mechanisms. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1796, 293-308.	3.3	277
501	Functional genomics and proteomics approaches to study the ERBB network in cancer. FEBS Letters, 2009, 583, 1766-1771.	1.3	4

#	Article	IF	Citations
502	Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941. Cancer Cell, 2009, 15, 429-440.	7.7	725
503	Inflamed Snail Speeds Metastasis. Cancer Cell, 2009, 15, 355-357.	7.7	15
504	PI3K Inhibition Overcomes Trastuzumab Resistance: Blockade of ErbB2/ErbB3 Is Not Always Enough. Cancer Cell, 2009, 15, 353-355.	7.7	35
505	ErbB receptors and signaling pathways in cancer. Current Opinion in Cell Biology, 2009, 21, 177-184.	2.6	832
506	Optimal targeting of the mTORC1 kinase in human cancer. Current Opinion in Cell Biology, 2009, 21, 219-229.	2.6	75
507	EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. Cellular Signalling, 2009, 21, 892-898.	1.7	82
508	Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology, 2009, 625, 6-22.	1.7	22
509	Differential erbB signaling in astrocytes from the cerebral cortex and the hypothalamus of the human brain. Glia, 2009, 57, 362-379.	2.5	50
510	HER3 is required for the maintenance of neuregulinâ€dependent and â€independent attributes of malignant progression in prostate cancer cells. International Journal of Cancer, 2009, 125, 2565-2575.	2.3	41
511	Novel chemotherapy approaches for cervical cancer. Cancer, 2009, 115, 3166-3180.	2.0	73
512	Delphinidin inhibits a broad spectrum of receptor tyrosine kinases of the ErbB and VEGFR family. Molecular Nutrition and Food Research, 2009, 53, 1075-1083.	1.5	30
514	Timing is everything: using fluidics to understand the role of temporal dynamics in cellular systems. Microfluidics and Nanofluidics, 2009, 6, 717-729.	1.0	32
515	ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. International Journal of Colorectal Disease, 2009, 24, 1059-1068.	1.0	40
516	Affibody-mediated retention of the epidermal growth factor receptor in the secretory compartments leads to inhibition of phosphorylation in the kinase domain. New Biotechnology, 2009, 25, 417-423.	2.4	3
517	Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Research and Treatment, 2009, 114, 263-75.	1.1	129
518	The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Research and Treatment, 2009, 116, 225-237.	1.1	80
519	An improved model to study tumor cell autonomous metastasis programs using MTLn3 cells and the Rag2â^'/â^' Î³câ^'/â^' mouse. Clinical and Experimental Metastasis, 2009, 26, 673-684.	1.7	25
520	Stemming Resistance to HER-2 Targeted Therapy. Journal of Mammary Gland Biology and Neoplasia, 2009, 14, 55-66.	1.0	57

#	Article	IF	Citations
521	Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. Clinical and Translational Oncology, 2009, 11, 737-747.	1.2	9
522	Recent advances of novel targeted therapy for squamous cell carcinoma of the head and neck. Oncology Reviews, 2009, 3, 149-160.	0.8	1
523	Investigational agents in the management of non-small cell lung cancer. Current Oncology Reports, 2009, 11, 275-284.	1.8	5
524	Skin toxicities associated with epidermal growth factor receptor inhibitors. Targeted Oncology, 2009, 4, 107-119.	1.7	240
525	HER2+ breast cancer: How to evaluate?. Advances in Therapy, 2009, 26, 1-8.	1.3	22
526	Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2009, 65, 107-112.	1.1	20
527	Tid1 functions as a tumour suppressor in head and neck squamous cell carcinoma. Journal of Pathology, 2009, 219, 347-355.	2.1	47
528	Tracing pathway activities with kinase inhibitors and reverse phase protein arrays. Proteomics - Clinical Applications, 2009, 3, 412-422.	0.8	50
529	Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma. Neuropathology and Applied Neurobiology, 2009, 35, 208-213.	1.8	29
530	Realâ€time quantitative polymerase chain reaction (qPCR) analysis with fluorescence resonance energy transfer (FRET) probes reveals differential expression of the four ERBB4 juxtamembrane region variants between medulloblastoma and pilocytic astrocytoma. Neuropathology and Applied Neurobiology, 2009, 35, 353-366.	1.8	18
531	Involvement of CD44v6 in InlBâ€dependent Listeria invasion. Molecular Microbiology, 2009, 72, 1196-1207.	1.2	22
532	Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor Î³. Cell Research, 2009, 19, 720-732.	5.7	23
533	ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor. Nature, 2009, 461, 287-291.	13.7	69
534	Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer, 2009, 9, 463-475.	12.8	993
535	Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nature Reviews Cancer, 2009, 9, 785-797.	12.8	824
536	Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene, 2009, 28, 1309-1319.	2.6	54
537	Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway. Oncogene, 2009, 28, 2756-2765.	2.6	26
538	The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility. Oncogene, 2009, 28, 2839-2848.	2.6	38

#	Article	IF	Citations
539	Physical and functional interaction between polyoma virus middle T antigen and insulin and IGF-I receptors is required for oncogene activation and tumour initiation. Oncogene, 2009, 28, 3477-3486.	2.6	19
540	Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. British Journal of Cancer, 2009, 100, 145-152.	2.9	39
541	The EGFRâ€GEP100â€Arf6â€AMAP1 Signaling Pathway Specific to Breast Cancer Invasion and Metastasis^{â€}. Traffic, 2009, 10, 982-993.	1.3	102
542	Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck. Oral Diseases, 2009, 15, 121-132.	1.5	33
543	Design, Synthesis, and Docking Studies of Peptidomimetics Based on HER2â€“Herceptin Binding Site with Potential Antiproliferative Activity Against Breast Cancer Cell lines. Chemical Biology and Drug Design, 2009, 74, 246-257.	1.5	43
544	High frequency of common DNA copy number abnormalities detected by bacterial artificial chromosome array comparative genomic hybridization in 24 breast cancer cell lines. Human Cell, 2009, 22, 1-10.	1.2	15
545	New drugs for the treatment of hepatocellular carcinoma. Liver International, 2009, 29, 148-158.	1.9	22
546	Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathology Research and Practice, 2009, 205, 858-862.	1.0	285
547	Evolution of clinical trials in head and neck cancer. Critical Reviews in Oncology/Hematology, 2009, 71, 29-42.	2.0	19
548	Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives. European Journal of Medicinal Chemistry, 2009, 44, 3046-3055.	2.6	116
549	Allosteric inhibitors of Akt1 and Akt2: Discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 834-836.	1.0	54
550	Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1718-1721.	1.0	20
551	Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5037-5042.	1.0	7
552	Beyond structure, to survival: activation of Stat3 by cadherin engagement. Biochemistry and Cell Biology, 2009, 87, 835-843.	0.9	36
553	Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptorâ€“PI3K Axis. Science Signaling, 2009, 2, ra31.	1.6	337
554	Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies. Journal of Medicinal Chemistry, 2009, 52, 1493-1509.	2.9	152
555	In Vitro Enzymatic Characterization of Near Full Length EGFR in Activated and Inhibited States. Biochemistry, 2009, 48, 6624-6632.	1.2	47
556	Suppression of the Kinase Activity of Receptor Tyrosine Kinases by Anthocyanin-Rich Mixtures Extracted from Bilberries and Grapes. Journal of Agricultural and Food Chemistry, 2009, 57, 3094-3101.	2.4	31

#	Article	IF	Citations
557	Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treatment Reviews, 2009, 35, 262-271.	3.4	184
558	Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions. Cancer Treatment Reviews, 2009, 35, 685-691.	3.4	52
559	Targeted therapies in the treatment of advanced/metastatic NSCLC. European Journal of Cancer, 2009, 45, 2473-2487.	1.3	68
560	Contemporary pre-clinical development of anticancer agents â€“ What are the optimal preclinical models?. European Journal of Cancer, 2009, 45, 2768-2781.	1.3	74
561	EGFR-Nrf2 pathway plays a role in cancer cell's chemoresistance. Bioscience Hypotheses, 2009, 2, 261-263.	0.2	4
562	Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction. Cell, 2009, 136, 823-837.	13.5	1,576
563	Quantification of ErbB3 receptor density on human breast cancer cells, using a stable radio-labeled mutant of NRG1beta. Biochemical and Biophysical Research Communications, 2009, 378, 285-289.	1.0	4
564	Blockade of constitutively activated ERK signaling enhances cytotoxicity of microtubule-destabilizing agents in tumor cells. Biochemical and Biophysical Research Communications, 2009, 378, 650-655.	1.0	16
565	Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues. Research in Veterinary Science, 2009, 87, 432-437.	0.9	63
566	Enhancement of antitumor immune response by targeted interleukin-12 electrogene transfer through antiHER2 single-chain antibody in a murine bladder tumor model. Vaccine, 2009, 27, 5383-5392.	1.7	11
567	Ectodomain orientation, conformational plasticity and oligomerization of ErbB1 receptors investigated by molecular dynamics. Journal of Structural Biology, 2009, 167, 117-128.	1.3	42
568	HER-2 amplification is highly homogenous in gastric cancer. Human Pathology, 2009, 40, 769-777.	1.1	194
569	The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. Microvascular Research, 2009, 78, 278-285.	1.1	37
570	Cervical cancer therapy: current, future and anti-angiogensis targeted treatment. Expert Review of Anticancer Therapy, 2009, 9, 895-903.	1.1	38
571	RNA interference as an anticancer therapy: a patent perspective. Expert Opinion on Therapeutic Patents, 2009, 19, 475-491.	2.4	24
572	EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments. Journal of Dermatological Science, 2009, 56, 148-153.	1.0	59
573	Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas. Lung Cancer, 2009, 65, 25-33.	0.9	47
574	Engineered affinity proteins for tumourâ€targeting applications. Biotechnology and Applied Biochemistry, 2009, 53, 1-29.	1.4	65

#	Article	IF	Citations
575	Recent advances of novel targeted therapy in non-small cell lung cancer. Journal of Hematology and Oncology, 2009, 2, 2.	6.9	69
576	Discovery of A Novel Her-1/Her-2 Dual Tyrosine Kinase Inhibitor for the Treatment of Her-1 Selective Inhibitor-Resistant Non-small Cell Lung Cancer. Journal of Medicinal Chemistry, 2009, 52, 6880-6888.	2.9	36
577	Targeting the EGF receptor ectodomain in the context of cancer. Expert Opinion on Therapeutic Targets, 2009, 13, 1347-1361.	1.5	1
578	The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment. Expert Opinion on Therapeutic Targets, 2009, 13, 689-700.	1.5	34
579	A pan-HER approach for cancer therapy: background, current status and future development. Expert Opinion on Biological Therapy, 2009, 9, 97-110.	1.4	42
580	Evaluation of HER2 in breast cancer: reality and expectations. Expert Opinion on Medical Diagnostics, 2009, 3, 607-620.	1.6	15
581	Chapter 3 Acquisition of Membrane Polarity in Epithelial Tube Formation. International Review of Cell and Molecular Biology, 2009, 274, 129-182.	1.6	19
583	Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations. Journal of Experimental and Clinical Cancer Research, 2009, 28, 65.	3.5	49
584	Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells. Journal of Experimental and Clinical Cancer Research, 2009, 28, 28.	3.5	127
585	Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2overexpression in breast cancer cell lines. Breast Cancer Research, 2009, 11, R83.	2.2	25
586	Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Research, 2009, 11, R11.	2.2	70
587	Salivary Biomarkers for the Detection of Malignant Tumors That are Remote from the Oral Cavity. Clinics in Laboratory Medicine, 2009, 29, 71-85.	0.7	81
588	Targeting Transduction Pathways for Research and Medical Intervention. , 2009, , 735-761.		0
589	Signalling Pathways Operated by Receptor Protein Tyrosine Kinases. , 2009, , 315-374.		0
590	Quantitative Prediction of Fold Resistance for Inhibitors of EGFR. Biochemistry, 2009, 48, 8435-8448.	1.2	64
591	Androgen Receptor Controls EGFR and ERBB2 Gene Expression at Different Levels in Prostate Cancer Cell Lines. Cancer Research, 2009, 69, 2941-2949.	0.4	62
592	Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells. Journal of Receptor and Signal Transduction Research, 2009, 29, 182-194.	1.3	17
593	The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment. Radiotherapy and Oncology, 2009, 92, 399-404.	0.3	23

#	Article	IF	Citations
594	Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells. Radiotherapy and Oncology, 2009, 92, 393-398.	0.3	36
595	EGFR Signaling and Drug Discovery. Oncology, 2009, 77, 400-410.	0.9	387
596	Discovery and Preclinical Evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic Acid, (3S)-3-Morpholinylmethyl Ester (BMS-599626), a Selective and Orally Efficacious Inhibitor of Human Epidermal Growth Factor Receptor 1 and 2 Kinases. Journal of Medicinal Chemistry, 2009, 52, 6527-6530.	2.9	28
597	Targeting of HER2-Expressing Tumors with a Site-Specifically ^{99m}Tc-Labeled Recombinant Affibody Molecule, Z_{HER2:2395}, with C-Terminally Engineered Cysteine. Journal of Nuclear Medicine, 2009, 50, 781-789.	2.8	97
598	Sensitive Detection of KRAS Mutations in Archived Formalin-Fixed Paraffin-Embedded Tissue Using Mutant-Enriched PCR and Reverse-Hybridization. Journal of Molecular Diagnostics, 2009, 11, 508-513.	1.2	37
599	Application of Laser Microdissection and Reverse-Phase Protein Microarrays to the Molecular Profiling of Cancer Signal Pathway Networks in the Tissue Microenvironment. Clinics in Laboratory Medicine, 2009, 29, 1-13.	0.7	30
600	Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 492-498.	0.6	24
601	A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. International Journal of Oncology, 2009, 36, .	1.4	1
602	EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort. Journal of Thoracic Oncology, 2009, 4, 318-325.	0.5	52
604	The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. International Journal of Oncology, 2009, 34, 797-803.	1.4	20
605	Epidermal growth factor receptor inhibitors in oncology. Current Opinion in Oncology, 2010, 22, 573-578.	1.1	46
606	Radionuclide Molecular Imaging Using Affibody Molecules. Current Pharmaceutical Biotechnology, 2010, 11, 581-589.	0.9	52
607	Molecular Targeted Therapy of Biliary Tract Cancer â€“ Results of the First Clinical Studies. Current Drug Targets, 2010, 11, 834-850.	1.0	36
608	The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies. Genes and Cancer, 2010, 1, 1200-1210.	0.6	88
609	EGFR(S) Inhibitors in the Treatment of Gastro-Intestinal Cancers: Whats New?. Current Drug Targets, 2010, 11, 682-698.	1.0	12
610	Allosteric AKT inhibitors as a targeted cancer therapy. Cancer Biology and Therapy, 2010, 9, 504-506.	1.5	9
611	Cancer Therapy-Associated Cardiotoxicity and Signaling in the Myocardium. Journal of Cardiovascular Pharmacology, 2010, 56, 141-146.	0.8	31
612	The ErbB Receptors and Their Ligands in PKD, an Overview. Current Signal Transduction Therapy, 2010, 5, 170-180.	0.3	0

#	Article	IF	Citations
613	ErbB Targeted Drugs and Angiogenesis. Current Vascular Pharmacology, 2010, 8, 421-431.	0.8	11
615	Critical involvement of RQCD1 in the EGFR-Akt pathway in mammary carcinogenesis. International Journal of Oncology, 2010, 37, 1085-93.	1.4	23
616	EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. Oncology Reports, 2010, 25, .	1.2	8
617	Deregulation of p27 and Cyclin D1/D3 Control Over Mitosis Is Associated with Unfavorable Prognosis in Non-small Cell Lung Cancer, as Determined in 405 Operated Patients. Journal of Thoracic Oncology, 2010, 5, 1325-1336.	0.5	41
618	Quantitative Analysis of HER2 Receptor Expression In Vivo by Near-Infrared Optical Imaging. Molecular Imaging, 2010, 9, 7290.2010.00018.	0.7	29
620	Posttranscriptional regulation of cancer traits by HuR. Wiley Interdisciplinary Reviews RNA, 2010, 1, 214-229.	3.2	361
621	Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Advanced Drug Delivery Reviews, 2010, 62, 346-361.	6.6	376
622	Personalized Medicine in Nonâ€“Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptorâ€“Targeted Therapy?. Journal of Clinical Oncology, 2010, 28, 4769-4777.	0.8	243
625	A new immunomodulatory protein from Ganoderma microsporum inhibits epidermal growth factor mediated migration and invasion in A549 lung cancer cells. Process Biochemistry, 2010, 45, 1537-1542.	1.8	90
626	PIKing the right isoform: the emergent role of the p110Î² subunit in breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 235-243.	1.4	37
627	Metaplastic breast carcinoma: a rare entity. Gynecological Surgery, 2010, 7, 289-293.	0.9	0
628	A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Supportive Care in Cancer, 2010, 18, 509-522.	1.0	142
629	EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Targeted Oncology, 2010, 5, 245-255.	1.7	56
630	In Silico Identification of Significant Detrimental Missense Mutations of EGFR and Their Effect with 4-Anilinoquinazoline-Based Drugs. Applied Biochemistry and Biotechnology, 2010, 160, 1723-1733.	1.4	12
631	Transactivation of ErbB-2 induced by tumor necrosis factor Î± promotes NF-ÎºB activation and breast cancer cell proliferation. Breast Cancer Research and Treatment, 2010, 122, 111-124.	1.1	35
632	Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy. Breast Cancer Research and Treatment, 2010, 124, 1-11.	1.1	22
633	Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer and Metastasis Reviews, 2010, 29, 37-48.	2.7	81
634	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer and Metastasis Reviews, 2010, 29, 49-60.	2.7	191

#	Article	IF	Citations
635	Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents. , 2010, 128, 82-90.		10
636	A Review of Epidermal Growth Factor Receptor/HER2 Inhibitors in the Treatment of Patients With Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2010, 11, 8-12.	1.1	22
637	Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer, 2010, 10, 189.	1.1	70
638	From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. Journal of Hematology and Oncology, 2010, 3, 8.	6.9	206
639	Molecularly targeted therapy in hepatocellular carcinoma. Biochemical Pharmacology, 2010, 80, 550-560.	2.0	110
640	Targeting inflammatory pathways for tumor radiosensitization. Biochemical Pharmacology, 2010, 80, 1904-1914.	2.0	129
641	Unfavorable Drug Interactions in Targeted Breast Cancer Therapy. Cancer Cell, 2010, 18, 401-402.	7.7	6
642	Effective Suppression of Vascular Network Formation by Combination of Antibodies Blocking VEGFR Ligand Binding and Receptor Dimerization. Cancer Cell, 2010, 18, 630-640.	7.7	119
643	Mechanisms of resistance to HER family targeting antibodies. Experimental Cell Research, 2010, 316, 1083-1100.	1.2	136
644	NBCn1 and NHE1 expression and activity in Î”NErbB2 receptor-expressing MCF-7 breast cancer cells: Contributions to pHi regulation and chemotherapy resistance. Experimental Cell Research, 2010, 316, 2538-2553.	1.2	111
645	Oncologistâ€™s/haematologistâ€™s view on the roles of pathologists for molecular targeted cancer therapy. Journal of Cellular and Molecular Medicine, 2010, 14, 805-817.	1.6	3
646	Insulinâ€like growth factorâ€1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus. International Journal of Cancer, 2010, 127, 1931-1940.	2.3	25
647	Early response to ErbB2 overâ€expression in polarized Cacoâ€2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling. Journal of Cellular Biochemistry, 2010, 111, 643-652.	1.2	5
648	Unnatural Polyketide Analogues Selectively Target the HER Signaling Pathway in Human Breast Cancer Cells. ChemBioChem, 2010, 11, 573-580.	1.3	10
649	Mechanistic and signaling analysis of Muc4â€“ErbB2 signaling module: New insights into the mechanism of ligandâ€independent ErbB2 activity. Journal of Cellular Physiology, 2010, 224, 649-657.	2.0	20
650	Deciphering signaling pathways in clinical tissues for personalized medicine using protein microarrays. Journal of Cellular Physiology, 2010, 225, 364-370.	2.0	26
651	Promising tumorâ€associated antigens for future prostate cancer therapy. Medicinal Research Reviews, 2010, 30, 67-101.	5.0	25
652	Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors. Journal of Molecular Graphics and Modelling, 2010, 28, 472-477.	1.3	9

#	Article	IF	Citations
653	Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity. Bioorganic and Medicinal Chemistry, 2010, 18, 3812-3822.	1.4	51
654	Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6067-6071.	1.0	24
655	A Phase I/II Trial of Gefitinib Given Concurrently With Radiotherapy in Patients With Nonmetastatic Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, 42-49.	0.4	20
656	Andrographolide regulates epidermal growth factor receptor and transferrin receptor trafficking in epidermoid carcinoma (Aâ€431) cells. British Journal of Pharmacology, 2010, 159, 1497-1510.	2.7	33
657	Targeting the Dimerization of Epidermal Growth Factor Receptors with Smallâ€Molecule Inhibitors. Chemical Biology and Drug Design, 2010, 76, 1-9.	1.5	33
658	Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS Journal, 2010, 277, 301-308.	2.2	456
659	Homogeneous EGFR amplification defines a subset of aggressive Barrettâ€™s adenocarcinomas with poor prognosis. Histopathology, 2010, 57, 418-426.	1.6	30
660	Copine-III interacts with ErbB2 and promotes tumor cell migration. Oncogene, 2010, 29, 1598-1610.	2.6	52
661	Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene, 2010, 29, 3997-4006.	2.6	199
662	Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene, 2010, 29, 4517-4527.	2.6	33
663	FRS2Î², a potential prognostic gene for non-small cell lung cancer, encodes a feedback inhibitor of EGF receptor family members by ERK binding. Oncogene, 2010, 29, 3087-3099.	2.6	13
664	Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene, 2010, 29, 2893-2904.	2.6	334
665	Epidermal growth factor signalling and bone metastasis. British Journal of Cancer, 2010, 102, 457-461.	2.9	103
666	Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. British Journal of Cancer, 2010, 103, 1284-1291.	2.9	111
667	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer, 2010, 10, 760-774.	12.8	943
668	Epidermal Growth Factor Receptor Targeted Therapy in Stages III and IV Head and Neck Cancer. Current Oncology, 2010, 17, 37-48.	0.9	88
669	Glutaminase: A Hot Spot For Regulation Of Cancer Cell Metabolism?. Oncotarget, 2010, 1, 734-740.	0.8	139
670	Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients. Recent Patents on Anti-Cancer Drug Discovery, 2010, 5, 29-57.	0.8	136

#	Article	IF	Citations
671	Downregulation of Epidermal Growth Factor Receptor Expression Contributes to<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î±</mml:mi></mml:math>-TEA's Proapoptotic Effects in Human Ovarian Cancer Cell Lines. Journal of Oncology, 2010, 2010, 1-11.	0.6	16
672	A proximity ligation assay using transiently transfected, epitope-tagged proteins: application for in situ detection of dimerized receptor tyrosine kinases. BioTechniques, 2010, 48, 145-152.	0.8	41
673	Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clinical Medicine Insights: Oncology, 2010, 4, CMO.S4773.	0.6	109
674	Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-Trastuzumab. PLoS ONE, 2010, 5, e8859.	1.1	121
676	Electrolyte and protein imbalance following anti-EGFR therapy in cancer patients: A comparative study. Experimental and Therapeutic Medicine, 2010, 1, 307-311.	0.8	20
677	EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget, 2010, 1, 497-514.	0.8	159
678	Cancer-Associated Fibroblasts Derived from EGFR-TKIâ€“Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs. Molecular Cancer Research, 2010, 8, 809-820.	1.5	65
679	A Bispecific Enediyne-Energized Fusion Protein Containing Ligand-Based and Antibody-Based Oligopeptides against Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Shows Potent Antitumor Activity. Clinical Cancer Research, 2010, 16, 2085-2094.	3.2	44
680	Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer. Clinical Cancer Research, 2010, 16, 3349-3355.	3.2	108
681	Structural Evidence for Loose Linkage between Ligand Binding and Kinase Activation in the Epidermal Growth Factor Receptor. Molecular and Cellular Biology, 2010, 30, 5432-5443.	1.1	179
682	Disruption of Laminin-Integrin-CD151-Focal Adhesion Kinase Axis Sensitizes Breast Cancer Cells to ErbB2 Antagonists. Cancer Research, 2010, 70, 2256-2263.	0.4	124
683	Preparation, Biological Evaluation, and Pharmacokinetics of the Human Anti-HER1 Monoclonal Antibody Panitumumab Labeled with 86Y for Quantitative PET of Carcinoma. Journal of Nuclear Medicine, 2010, 51, 942-950.	2.8	54
684	EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. Expert Opinion on Emerging Drugs, 2010, 15, 185-201.	1.0	32
685	Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2â€“Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clinical Cancer Research, 2010, 16, 2688-2695.	3.2	137
686	p130Cas is an essential transducer element in ErbB2 transformation. FASEB Journal, 2010, 24, 3796-3808.	0.2	49
687	Roles for Growth Factors in Cancer Progression. Physiology, 2010, 25, 85-101.	1.6	342
688	Frequent Deregulations in the Hedgehog Signaling Network and Cross-Talks with the Epidermal Growth Factor Receptor Pathway Involved in Cancer Progression and Targeted Therapies. Pharmacological Reviews, 2010, 62, 497-524.	7.1	105
689	Phase I Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study. Journal of Clinical Oncology, 2010, 28, 4221-4227.	0.8	71

#	Article	IF	Citations
690	Protein-tyrosine Phosphatase PTPN9 Negatively Regulates ErbB2 and Epidermal Growth Factor Receptor Signaling in Breast Cancer Cells. Journal of Biological Chemistry, 2010, 285, 14861-14870.	1.6	70
691	Fatty Acid-binding Protein 5 and PPARÎ²/Î´ Are Critical Mediators of Epidermal Growth Factor Receptor-induced Carcinoma Cell Growth. Journal of Biological Chemistry, 2010, 285, 19106-19115.	1.6	85
692	Blockade of the Extracellular Signal-Regulated Kinase Pathway Enhances the Therapeutic Efficacy of Microtubule-Destabilizing Agents in Human Tumor Xenograft Models. Clinical Cancer Research, 2010, 16, 1170-1178.	3.2	15
693	VRK2 Inhibits Mitogen-Activated Protein Kinase Signaling and Inversely Correlates with ErbB2 in Human Breast Cancer. Molecular and Cellular Biology, 2010, 30, 4687-4697.	1.1	37
694	Dietary olive oil and corn oil differentially affect experimental breast cancer through distinct modulation of the p21Ras signaling and the proliferation-apoptosis balance. Carcinogenesis, 2010, 31, 871-879.	1.3	32
695	The Prolyl Isomerase Pin1 Enhances HER-2 Expression and Cellular Transformation via Its Interaction with Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase 1. Molecular Cancer Therapeutics, 2010, 9, 606-616.	1.9	30
696	Role of Survivin in EGFR Inhibitorâ€“Induced Apoptosis in Nonâ€“Small Cell Lung Cancers Positive for EGFR Mutations. Cancer Research, 2010, 70, 10402-10410.	0.4	78
697	Activation by Tyrosine Phosphorylation as a Prerequisite for Protein Kinase CÎ¶ to Mediate Epidermal Growth Factor Receptor Signaling to ERK. Molecular Cancer Research, 2010, 8, 783-797.	1.5	10
698	Applications of Molecular Imaging. Progress in Molecular Biology and Translational Science, 2010, 95, 237-298.	0.9	22
699	Mammary Gland Growth Factors: Roles in Normal Development and in Cancer. Cold Spring Harbor Perspectives in Biology, 2010, 2, a003186-a003186.	2.3	87
700	Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy. Cancer Research, 2010, 70, 299-308.	0.4	182
701	Downregulation of Notch Pathway by a Î³-Secretase Inhibitor Attenuates AKT/Mammalian Target of Rapamycin Signaling and Glucose Uptake in an ERBB2 Transgenic Breast Cancer Model. Cancer Research, 2010, 70, 2476-2484.	0.4	81
702	Effective Therapeutic Targeting of the Overexpressed HER-2 Receptor in a Highly Metastatic Orthotopic Model of Esophageal Carcinoma. Molecular Cancer Therapeutics, 2010, 9, 2037-2045.	1.9	33
703	Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 1351-1357.	0.8	410
704	Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin ligase activators Ndfip1 and Ndfip2. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11429-11434.	3.3	65
705	Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients. Clinical Cancer Research, 2010, 16, 1245-1255.	3.2	46
706	Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Annals of Oncology, 2010, 21, 98-103.	0.6	67
707	Clinical, pathological and molecular determinants in squamous cell carcinoma of the oral cavity. Future Oncology, 2010, 6, 837-850.	1.1	48

#	Article	IF	Citations
708	Itâ€™s all in for the HER family in tumorigenesis. Expert Review of Vaccines, 2010, 9, 29-34.	2.0	2
709	The Constitutive Activity of Epidermal Growth Factor Receptor vIII Leads to Activation and Differential Trafficking of Wild-type Epidermal Growth Factor Receptor and erbB2. Journal of Histochemistry and Cytochemistry, 2010, 58, 529-541.	1.3	8
710	Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin. Chemotherapy, 2010, 56, 268-274.	0.8	5
711	Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent mechanism. Journal of Cell Biology, 2010, 190, 461-477.	2.3	121
712	Docosahexaenoic acid alters epidermal growth factor receptor-related signaling by disrupting its lipid raft association. Carcinogenesis, 2010, 31, 1523-1530.	1.3	96
713	Understanding resistance to EGFR inhibitorsâ€”impact on future treatment strategies. Nature Reviews Clinical Oncology, 2010, 7, 493-507.	12.5	593
714	Therapeutic targeting of EGFR in malignant gliomas. Expert Opinion on Therapeutic Targets, 2010, 14, 303-316.	1.5	23
715	The Vulnerability of the Heart As a Pluricellular Paracrine Organ. Circulation Research, 2010, 106, 35-46.	2.0	177
716	Critical Roles of DMP1 in Human Epidermal Growth Factor Receptor 2/neu-Arf-p53 Signaling and Breast Cancer Development. Cancer Research, 2010, 70, 9084-9094.	0.4	37
717	Effect of Multikinase Inhibitors on Caspase-Independent Cell Death and DNA Damage in HER2-Overexpressing Breast Cancer Cells. Journal of the National Cancer Institute, 2010, 102, 1432-1446.	3.0	43
718	New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile. Modern Pathology, 2010, 23, 856-865.	2.9	88
719	Advances and perspectives in the molecular diagnosis of head and neck cancer. Expert Opinion on Medical Diagnostics, 2010, 4, 53-65.	1.6	59
720	pH-(low)-insertion-peptide (pHLIP) translocation of membrane impermeable phalloidin toxin inhibits cancer cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20246-20250.	3.3	129
721	Potential for Targeting the Fibroblast Growth Factor Receptors in Breast Cancer. Cancer Research, 2010, 70, 5199-5202.	0.4	54
722	Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis. Cancer Research, 2010, 70, 4151-4162.	0.4	162
723	Pleiotropic Effects of p300-mediated Acetylation on p68 and p72 RNA Helicase. Journal of Biological Chemistry, 2010, 285, 30443-30452.	1.6	55
724	Potential role of PI3K inhibitors in the treatment of breast cancer. Future Oncology, 2010, 6, 1251-1263.	1.1	8
725	Potential of ErbB4 antibodies for cancer therapy. Future Oncology, 2010, 6, 37-53.	1.1	31

#	Article	IF	Citations
726	Human Prostatic Acid Phosphatase, an Authentic Tyrosine Phosphatase, Dephosphorylates ErbB-2 and Regulates Prostate Cancer Cell Growth. Journal of Biological Chemistry, 2010, 285, 23598-23606.	1.6	45
727	P2Y2 Nucleotide Receptors Mediate Metalloprotease-dependent Phosphorylation of Epidermal Growth Factor Receptor and ErbB3 in Human Salivary Gland Cells. Journal of Biological Chemistry, 2010, 285, 7545-7555.	1.6	45
728	Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3728-3733.	3.3	53
729	Current therapies and novel targets in treatment of breast cancer. Systematic Reviews in Pharmacy (discontinued), 2010, 1, 40.	0.6	5
730	An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biology and Therapy, 2010, 9, 493-503.	1.5	61
731	Tumor initiating cells: Development and critical characterization of a model derived from the A431 carcinoma cell line forming spheres in suspension. Cell Cycle, 2010, 9, 1194-1206.	1.3	75
732	Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene. Breast Care, 2010, 5, 3-7.	0.8	19
733	Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2010, 5, 142-151.	0.8	3
734	Epidermal Growth Factor Receptor Expression Identifies Functionally and Molecularly Distinct Tumor-Initiating Cells in Human Glioblastoma Multiforme and Is Required for Gliomagenesis. Cancer Research, 2010, 70, 7500-7513.	0.4	198
735	MYC and Breast Cancer. Genes and Cancer, 2010, 1, 629-640.	0.6	275
736	Effects of an EGFR-binding affibody molecule on intracellular signaling pathways. International Journal of Oncology, 2010, 36, 967-72.	1.4	14
738	Safety profile of new anticancer drugs. Expert Opinion on Drug Safety, 2010, 9, 301-317.	1.0	21
739	Sustained Activity of the EGF Receptor Is an Absolute Requisite for LH-Induced Oocyte Maturation and Cumulus Expansion. Molecular Endocrinology, 2010, 24, 402-411.	3.7	86
740	Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies. Current Cancer Drug Targets, 2010, 10, 799-812.	0.8	28
741	EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Modern Pathology, 2010, 23, 644-653.	2.9	103
742	The Epidermal Growth Factor Variant III Peptide Vaccine for Treatment of Malignant Gliomas. Neurosurgery Clinics of North America, 2010, 21, 87-93.	0.8	31
743	Targeted Therapies for Solid Tumors. BioDrugs, 2010, 24, 303-316.	2.2	18
744	Dual Inhibitor AEE78 Reduces Tumor Growth in Preclinical Models of Medulloblastoma. Translational Oncology, 2010, 3, 326-335.	1.7	16

#	Article	IF	Citations
745	Molecular Testing in Colorectal Carcinoma. Surgical Pathology Clinics, 2010, 3, 429-445.	0.7	1
746	Stem Cells in Normal Development and Cancer. Progress in Molecular Biology and Translational Science, 2010, 95, 113-158.	0.9	57
747	Tyrosine kinase inhibitors to treat liver cancer. Expert Opinion on Emerging Drugs, 2010, 15, 13-26.	1.0	20
748	Self-Association of Models of Transmembrane Domains of ErbB Receptors in a Lipid Bilayer. Biophysical Journal, 2010, 99, 3657-3665.	0.2	41
749	HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches. Pharmacological Research, 2010, 62, 150-165.	3.1	63
750	PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer, 2010, 69, 279-283.	0.9	161
751	Tripleâ€negative breast cancer: Present challenges and new perspectives. Molecular Oncology, 2010, 4, 209-229.	2.1	252
752	Reverse phase protein microarrays advance to use in clinical trials. Molecular Oncology, 2010, 4, 461-481.	2.1	126
753	Targeted therapy in non-small-cell lung cancerâ€"is it becoming a reality?. Nature Reviews Clinical Oncology, 2010, 7, 401-414.	12.5	231
754	Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Molecular Cancer, 2010, 9, 196.	7.9	156
755	ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis. Molecular Cancer, 2010, 9, 235.	7.9	10
756	Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis. Molecular Cancer, 2010, 9, 288.	7.9	51
757	Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab. Clinical Pharmacokinetics, 2010, 49, 729-740.	1.6	63
758	CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer, 2010, 10, 489-491.	1.1	128
759	Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry, 2010, 53, 2000-2009.	2.9	229
760	Direct Activation of TACE-Mediated Ectodomain Shedding by p38 MAP Kinase Regulates EGF Receptor-Dependent Cell Proliferation. Molecular Cell, 2010, 37, 551-566.	4.5	223
761	Identification of the Rac-GEF P-Rex1 as an Essential Mediator of ErbB Signaling in Breast Cancer. Molecular Cell, 2010, 40, 877-892.	4.5	194
762	ErbB receptor signaling in astrocytes: A mediator of neuron-glia communication in the mature central nervous system. Neurochemistry International, 2010, 57, 344-358.	1.9	25

#	Article	IF	Citations
763	Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. Journal of Steroid Biochemistry and Molecular Biology, 2010, 121, 408-412.	1.2	36
764	Growth factors and corneal epithelial wound healing. Brain Research Bulletin, 2010, 81, 229-235.	1.4	169
765	Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer. Cancer Treatment Reviews, 2010, 36, 410-415.	3.4	27
766	The long road to colorectal cancer therapy: Searching for the right signals. Drug Resistance Updates, 2010, 13, 44-56.	6.5	25
767	Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues. European Journal of Cancer, 2010, 46, 47-55.	1.3	59
768	Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. European Journal of Cancer, 2010, 46, 2010-2019.	1.3	71
769	Blockade of the ERK or PI3Kâ€“Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. Biochemical and Biophysical Research Communications, 2010, 391, 1610-1615.	1.0	42
770	Novel monoclonal antibodies recognizing the active conformation of epidermal growth factor receptor. Biochemical and Biophysical Research Communications, 2010, 394, 685-690.	1.0	8
771	Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell, 2010, 141, 52-67.	13.5	4,103
772	The Ins and Outs of EGFR Asymmetry. Cell, 2010, 142, 513-515.	13.5	9
773	Usage of signaling in neurodegeneration and regeneration of peripheral nerves by leprosy bacteria. Progress in Neurobiology, 2010, 91, 102-107.	2.8	47
774	Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine. Nuclear Medicine and Biology, 2010, 37, 539-546.	0.3	29
775	EGFR signaling in breast cancer: Bad to the bone. Seminars in Cell and Developmental Biology, 2010, 21, 951-960.	2.3	129
776	E3 ubiquitin ligases in ErbB receptor quantity control. Seminars in Cell and Developmental Biology, 2010, 21, 936-943.	2.3	39
777	Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treatment Reviews, 2010, 36, S80-S86.	3.4	159
778	PTP1B Suppresses Prolactin Activation of Stat5 in Breast Cancer Cells. American Journal of Pathology, 2010, 177, 2971-2983.	1.9	49
779	Matriptase Is Involved in ErbB-2-Induced Prostate Cancer Cell Invasion. American Journal of Pathology, 2010, 177, 3145-3158.	1.9	34
781	Cytotoxic copper(ii) salicylaldehyde semicarbazone complexes: Mode of action and proteomic analysis. Metallomics, 2010, 2, 694.	1.0	29

#	Article	IF	Citations
782	Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Research, 2010, 12, R27.	2.2	68
784	Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2010, 28, 3965-3972.	0.8	332
785	A Conformationally Constrained Peptidomimetic Binds to the Extracellular Region of HER2 Protein. Journal of Biomolecular Structure and Dynamics, 2010, 28, 289-308.	2.0	43
786	Targeting of HER2-Expressing Tumors Using ¹¹¹In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold. Journal of Nuclear Medicine, 2010, 51, 1131-1138.	2.8	81
787	Pertuzumab for the treatment of ovarian cancer. Expert Opinion on Biological Therapy, 2010, 10, 1113-1120.	1.4	26
788	Clinical Implications for Girdin Protein Expression in Breast Cancer. Cancer Investigation, 2011, 29, 405-410.	0.6	30
789	Suppression of Epidermal Growth Factor Receptor (EGFR) Expression by Small Hairpin RNA Inhibits the Growth of Human Nonsmall Cell Lung Cancers Bearing Wild-type and Mutant EGFR. Cancer Investigation, 2011, 29, 701-708.	0.6	3
790	Primary Tumor Xenografts of Human Lung Adeno and Squamous Cell Carcinoma Express Distinct Proteomic Signatures. Journal of Proteome Research, 2011, 10, 161-174.	1.8	27
791	Molecular Evidence for Differences in Endometrium in Severe Versus Mild Endometriosis. Reproductive Sciences, 2011, 18, 229-251.	1.1	130
792	Anti-DLL4 Inhibits Growth and Reduces Tumor-Initiating Cell Frequency in Colorectal Tumors with Oncogenic KRAS Mutations. Cancer Research, 2011, 71, 1520-1525.	0.4	113
793	Mechanistic insights into the activation of oncogenic forms of EGF receptor. Nature Structural and Molecular Biology, 2011, 18, 1388-1393.	3.6	81
794	Mechanisms of Resistance to HER2 Target Therapy. Journal of the National Cancer Institute Monographs, 2011, 2011, 95-98.	0.9	28
795	Ror1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis. Cancer Research, 2011, 71, 3132-3141.	0.4	119
796	EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target. British Journal of Cancer, 2011, 105, 420-427.	2.9	62
797	Real-Time Measurements of Protein Dynamics Using Fluorescence Activation-Coupled Protein Labeling Method. Journal of the American Chemical Society, 2011, 133, 6745-6751.	6.6	122
799	Structureâ€“activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines. MedChemComm, 2011, 2, 752.	3.5	18
800	Reduction-Sensitive Liposomes from a Multifunctional Lipid Conjugate and Natural Phospholipids: Reduction and Release Kinetics and Cellular Uptake. Langmuir, 2011, 27, 10820-10829.	1.6	63
801	Growth Suppression of HER2-Overexpressing Breast Cancer Cells by Berberine via Modulation of the HER2/PI3K/Akt Signaling Pathway. Journal of Agricultural and Food Chemistry, 2011, 59, 8216-8224.	2.4	72

#	Article	IF	Citations
802	A Molecularly Annotated Platform of Patient-Derived Xenografts (â€œXenopatientsâ€) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. Cancer Discovery, 2011, 1, 508-523.	7.7	818
803	Chapter 5. Kinase Mutations and Resistance in Cancer. RSC Drug Discovery Series, 2011, , 126-160.	0.2	1
804	Carbon nanotubes and pleural damage: Perspectives of nanosafety in the light of asbestos experience. Biointerphases, 2011, 6, P1-P17.	0.6	46
805	Platinum resistance in breast and ovarian cancer cell lines. Journal of Experimental and Clinical Cancer Research, 2011, 30, 91.	3.5	97
806	Orthotopic Models of Esophageal Carcinoma and Their Use in Drug Discovery. Current Protocols in Pharmacology, 2011, 54, Unit14.20.	4.0	5
808	Could precision-engineered peptide epitopes/vaccines be the key to a cancer cure?. Future Oncology, 2011, 7, 807-810.	1.1	4
809	Targeted Therapies. , 2011, , .		4
810	The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncology, 2011, 7, 519-541.	1.1	47
811	Targeted protein-omic methods are bridging the gap between proteomic and hypothesis-driven protein analysis approaches. Expert Review of Proteomics, 2011, 8, 565-575.	1.3	22
812	New targeted therapies for gastric cancer. Expert Opinion on Investigational Drugs, 2011, 20, 595-604.	1.9	20
813	Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?. Cancer Treatment Reviews, 2011, 37, 533-542.	3.4	31
814	Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treatment Reviews, 2011, 37, 456-64.	3.4	69
815	Magnolol down-regulates HER2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells. Cancer Letters, 2011, 311, 11-19.	3.2	39
816	Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: A systematic review. Drug Resistance Updates, 2011, 14, 177-190.	6.5	50
817	A novel hybrid peptide targeting EGFR-expressing cancers. European Journal of Cancer, 2011, 47, 773-783.	1.3	69
818	Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance. European Journal of Cancer, 2011, 47, 1231-1243.	1.3	127
819	Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-Î¹B. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1591-1600.	1.8	36
820	Activation of H-Ras and Rac1 correlates with epidermal growth factor-induced invasion in Hs578T and MDA-MB-231 breast carcinoma cells. Biochemical and Biophysical Research Communications, 2011, 406, 25-29.	1.0	19

#	Article	IF	Citations
821	Novel irreversible EGFR tyrosine kinase inhibitor 324674 sensitizes human colon carcinoma HT29 and SW480 cells to apoptosis by blocking the EGFR pathway. Biochemical and Biophysical Research Communications, 2011, 411, 751-756.	1.0	7
822	Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance. Clinical Cancer Research, 2011, 17, 5935-5944.	3.2	87
823	Asialoglycoprotein Receptor Promotes Cancer Metastasis by Activating the EGFRâ€“ERK Pathway. Cancer Research, 2011, 71, 6419-6427.	0.4	26
824	P-Rex1, a Guanine Exchange Factor that Is Overexpressed in Breast Cancer, Is a Convergence Node for ErbB and CXCR4 Signaling. Molecular Cell, 2011, 41, 5-7.	4.5	7
825	EGF receptor activation by GPCRs: An universal pathway reveals different versions. Molecular and Cellular Endocrinology, 2011, 331, 222-231.	1.6	129
826	HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Review of Anticancer Therapy, 2011, 11, 263-275.	1.1	368
827	Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferation. Genes and Development, 2011, 25, 1716-1733.	2.7	162
828	GrapheneâEncapsulated NanoparticleâBased Biosensor for the Selective Detection of Cancer Biomarkers. Advanced Materials, 2011, 23, 2221-2225.	11.1	260
829	Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4. Breast Cancer Research, 2011, 13, 106.	2.2	22
830	A Mathematical Model for the Effects of HER2 Over-Expression on Cell Cycle Progression in Breast Cancer. Bulletin of Mathematical Biology, 2011, 73, 2865-2887.	0.9	6
831	Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy. Frontiers in Bioscience - Landmark, 2011, 16, 1714.	3.0	8
832	Epidermal Growth Factor Receptor Mutations in Colorectal Cancer Patients. Journal of the Korean Society of Coloproctology, 2011, 27, 127.	0.9	16
833	ErbB2/HER2: Its Contribution to Basic Cancer Biology and the Development of Molecular Targeted Therapy. , 2011, , .		2
835	Metastasis-Promoting Genes. , 0, , 55-63.		1
836	Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells. Oncology Letters, 2011, 2, 91-94.	0.8	11
837	EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives. Frontiers in Bioscience - Landmark, 2011, 16, 1811.	3.0	15
838	Trastuzumab-Resistance and Breast Cancer. , 2011, , .		3
839	Impact of KRAS Mutations on Management of Colorectal Carcinoma. Pathology Research International, 2011, 2011, 1-11.	1.4	18

#	Article	IF	Citations
840	Role of α6β4 Integrin in Cell Motility, Invasion and Metastasis of Mammary Tumors. Current Protein and Peptide Science, 2011, 12, 23-29.	0.7	21
841	Targeted therapies in cancer - challenges and chances offered by newly developed techniques for protein analysis in clinical tissues. Journal of Cancer, 2011, 2, 26-35.	1.2	21
842	Breast Tumor Angiogenesis and Tumor-Associated Macrophages: Histopathologist's Perspective. Pathology Research International, 2011, 2011, 1-13.	1.4	18
843	Receptor-Tyrosine-Kinase-Targeted Therapies for Head and Neck Cancer. Journal of Signal Transduction, 2011, 2011, 1-11.	2.0	21
844	EGFR Signaling in Colorectal Carcinoma. Pathology Research International, 2011, 2011, 1-6.	1.4	118
845	Gliotransmission by Prostaglandin E2: A Prerequisite for GnRH Neuronal Function?. Frontiers in Endocrinology, 2011, 2, 91.	1.5	28
846	Chemopreventive Activity of Vitamin E in Breast Cancer: A Focus on Î³- and Î´-Tocopherol. Nutrients, 2011, 3, 962-986.	1.7	71
847	Designing Nanoconjugates to Effectively Target Pancreatic Cancer Cells In Vitro and In Vivo. PLoS ONE, 2011, 6, e20347.	1.1	60
848	Molecular Biology and Genetics of Lung Cancer. Medical Radiology, 2011, , 3-15.	0.0	2
849	Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Current Opinion in Oncology, 2011, 23, 566-577.	1.1	67
850	Epigenetic Multiple Modulators. Current Topics in Medicinal Chemistry, 2011, 11, 2749-2787.	1.0	11
851	Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy. Current Opinion in Obstetrics and Gynecology, 2011, 23, 24-30.	0.9	30
852	Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells. International Journal of Oncology, 2011, 39, 1501-9.	1.4	21
853	Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America. Journal of Thoracic Oncology, 2011, 6, 1955-1959.	0.5	113
854	Targeting the Extracellular Signal-Regulated Kinase Pathway in Cancer Therapy. Biological and Pharmaceutical Bulletin, 2011, 34, 1781-1784.	0.6	54
855	Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line. International Journal of Oncology, 2011, 40, 1677-82.	1.4	20
856	Mechanisms of resistance to antiâ€human epidermal growth factor receptor 2 agents in breast cancer. Cancer Science, 2011, 102, 1-8.	1.7	102
857	Selection and analysis of antiâ€cancer antibodies for cancer therapy obtained from antibody phage library. Cancer Science, 2011, 102, 175-181.	1.7	17

#	Article	IF	Citations
858	Towards therapeutic antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein. Cancer Science, 2011, 102, 25-35.	1.7	20
859	The inâ€ƒvitro and inâ€ƒvivo antiâ€tumor effect of KOâ€202125, a sauristolactam derivative, as a novel epidermal growth factor receptor inhibitor in human breast cancer. Cancer Science, 2011, 102, 597-604.	1.7	3
860	Gene status of head and neck squamous cell carcinoma cell lines and cetuximabâ€mediated biological activities. Cancer Science, 2011, 102, 1717-1723.	1.7	15
861	Î³-Tocotrienol inhibits HGF-dependent mitogenesis and Met activation in highly malignant mammary tumour cells. Cell Proliferation, 2011, 44, 516-526.	2.4	30
862	Novel molecular therapies in hepatocellular carcinoma. Liver International, 2011, 31, 151-160.	1.9	38
863	Crosstalk between ArgÂ1175 methylation and TyrÂ1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nature Cell Biology, 2011, 13, 174-181.	4.6	192
864	The molecular biology of head and neck cancer. Nature Reviews Cancer, 2011, 11, 9-22.	12.8	2,151
865	Harnessing synthetic lethal interactions in anticancer drug discovery. Nature Reviews Drug Discovery, 2011, 10, 351-364.	21.5	236
866	P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer. Oncogene, 2011, 30, 1059-1071.	2.6	92
867	Expression of NRG1 and its receptors in human bladder cancer. British Journal of Cancer, 2011, 104, 1135-1143.	2.9	19
868	Barrett's esophagus: treatments of adenocarcinomas II. Annals of the New York Academy of Sciences, 2011, 1232, 265-291.	1.8	1
869	Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway. Toxicology and Applied Pharmacology, 2011, 251, 130-136.	1.3	52
870	Analysis of cancer signaling networks by systems biology to develop therapies. Seminars in Cancer Biology, 2011, 21, 200-206.	4.3	28
871	The impact of EGFR stimulation and inhibition on BPDE induced DNA fragmentation in oral/oropharyngeal mucosa in vitro. Oral Oncology, 2011, 47, 1141-1147.	0.8	4
872	Positron Emission Tomography Imaging of Cancer Biology: Current Status and Future Prospects. Seminars in Oncology, 2011, 38, 70-86.	0.8	98
873	Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecologic Oncology, 2011, 122, 116-120.	0.6	62
874	Efficient Blockade of Akt signaling is a determinant factor to overcome resistance to Matuzumab. Molecular Cancer, 2011, 10, 151.	7.9	7
875	The challenge of developing robust drugs to overcome resistance. Drug Discovery Today, 2011, 16, 755-61.	3.2	21

#	Article	IF	Citations
876	p130Cas promotes invasiveness of three-dimensional ErbB2-transformed mammary acinar structures by enhanced activation of mTOR/p70S6K and Rac1. European Journal of Cell Biology, 2011, 90, 237-248.	1.6	29
877	Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway. Free Radical Biology and Medicine, 2011, 51, 1164-1174.	1.3	89
878	Calmodulin binds HER2 and modulates HER2 signaling. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 1074-1082.	1.9	12
879	The multiple roles of amphiregulin in human cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1816, 119-131.	3.3	148
880	Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells. Biochemical Pharmacology, 2011, 81, 1263-1270.	2.0	51
881	Implication of nuclear EGFR in the development of resistance to anticancer therapies. BioMedicine		

#	Article	IF	Citations
896	Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. Journal of Translational Medicine, 2011, 9, 126.	1.8	59
897	ATP synthase ecto-Î±-subunit: a novel therapeutic target for breast cancer. Journal of Translational Medicine, 2011, 9, 211.	1.8	33
898	Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity. BMC Systems Biology, 2011, 5, 29.	3.0	8
899	Conformational regulation of the EGFR kinase core by the juxtamembrane and Câ€terminal tail: A molecular dynamics study. Proteins: Structure, Function and Bioinformatics, 2011, 79, 99-114.	1.5	26
900	Leptin signaling and apoptotic effects in human prostate cancer cell lines. Prostate, 2011, 71, 929-945.	1.2	23
901	Rethinking herpes simplex virus: the way to oncolytic agents. Reviews in Medical Virology, 2011, 21, 213-226.	3.9	63
902	Establishment of A431 cell membrane chromatographyâ€RPLC method for screening target components from Radix Caulophylli. Journal of Separation Science, 2011, 34, 508-513.	1.3	26
903	Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Molecular Nutrition and Food Research, 2011, 55, 832-843.	1.5	105
904	Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells. Molecular Carcinogenesis, 2011, 50, 901-912.	1.3	22
905	ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells. Journal of Cellular Physiology, 2011, 226, 375-384.	2.0	28
906	Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells. Journal of Cellular Physiology, 2011, 226, 1741-1749.	2.0	100
907	EpCAMâ€•and EGFRâ€targeted selective gene therapy for biliary cancers using Z33â€fiberâ€•modified adenovirus. International Journal of Cancer, 2011, 129, 1244-1253.	2.3	24
908	Stem cell property epithelialâ€toâ€•mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbituxâ„¢) efficacy in KRAS wildâ€type tumor cells. Journal of Cellular Biochemistry, 2011, 112, 10-29.	1.2	41
909	Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 781-785.	1.0	23
910	Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Critical Reviews in Oncology/Hematology, 2011, 79, 224-250.	2.0	38
911	The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer. Clinical Cancer Research, 2011, 17, 3619-3630.	3.2	46
912	Docking and Molecular Dynamics Study on the Inhibitory Activity of Novel Inhibitors on Epidermal Growth Factor Receptor (EGFR). Medicinal Chemistry, 2011, 7, 24-31.	0.7	71
913	Bone Metastatic Disease: Taking Aim at New Therapeutic Targets. Current Medicinal Chemistry, 2011, 18, 3093-3115.	1.2	23

#	Article	IF	Citations
914	Activation of the Signal Transducer and Activator of Transcription 3 Pathway Up-Regulates Estrogen Receptor-Î² Expression in Lung Adenocarcinoma Cells. Molecular Endocrinology, 2011, 25, 1145-1158.	3.7	16
915	Development of targeted therapy for squamous cell carcinomas of the head and neck. Expert Review of Anticancer Therapy, 2011, 11, 373-386.	1.1	9
916	Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion. Mini-Reviews in Medicinal Chemistry, 2011, 11, 1019-1030.	1.1	37
917	Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2011, 11, 131-149.	0.5	63
918	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biology and Therapy, 2011, 11, 777-792.	1.5	209
919	Nucleic Acid Aptamers Against Protein Kinases. Current Medicinal Chemistry, 2011, 18, 4152-4158.	1.2	9
920	Evolving Molecular Mechanism-Based Strategies for Control of Hepatocellular Carcinoma. Current Medicinal Chemistry, 2011, 18, 4375-4388.	1.2	7
921	Optics clustered to output unique solutions: A multi-laser facility for combined single molecule and ensemble microscopy. Review of Scientific Instruments, 2011, 82, 093705.	0.6	10
922	EGFR Mutant Lung Cancer. Current Topics in Microbiology and Immunology, 2011, 355, 59-81.	0.7	8
923	The Effects of Artesunate on the Expression of EGFR and ABCG2 in A549 Human Lung Cancer Cells and a Xenograft Model. Molecules, 2011, 16, 10556-10569.	1.7	52
924	Pharmacologie et pharmacothÃ©rapie. , 2011, , 65-209.		0
925	Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies. International Immunology, 2011, 23, 391-403.	1.8	8
926	The Membrane-proximal Intracellular Domain of the Epidermal Growth Factor Receptor Underlies Negative Cooperativity in Ligand Binding. Journal of Biological Chemistry, 2011, 286, 45146-45155.	1.6	21
927	hVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer. Clinical Cancer Research, 2011, 17, 7816-7827.	3.2	37
929	Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocrine-Related Cancer, 2011, 18, 257-264.	1.6	15
930	Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer. Chemotherapy Research and Practice, 2011, 2011, 1-12.	1.6	15
931	Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer. International Journal of Breast Cancer, 2011, 2011, 1-11.	0.6	82
932	Distinctive Mechanism for Sustained TGF-Î² Signaling and Growth Inhibition: MEK1 Activation-Dependent Stabilization of Type II TGF-Î² Receptors. Molecular Cancer Research, 2011, 9, 78-89.	1.5	7

#	Article	IF	Citations
933	On the Road to Combinations of Targeted Therapies: PPM1H Phosphatase as a Suppressor of Trastuzumab Resistance: Table 1.. Cancer Discovery, 2011, 1, 285-286.	7.7	4
934	Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects. Oncologist, 2011, 16, 1006-1020.	1.9	13
935	Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer. Oncologist, 2011, 16, 1535-1546.	1.9	50
936	Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies. Molecular Endocrinology, 2011, 25, 199-211.	3.7	138
937	Non-Small Cell Lung Cancer in Never-Smokers: A New Disease Entity?. Onkologie, 2011, 34, 202-207.	1.1	3
938	Emerging antibody combinations in oncology. MAbs, 2011, 3, 338-351.	2.6	27
939	Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate. Cancer Biology and Therapy, 2011, 11, 368-370.	1.5	2
940	RINQ: Reference-based Indexing for Network Queries. Bioinformatics, 2011, 27, i149-i158.	1.8	9
941	Combination Treatment with HER-2 and VEGF Peptide Mimics Induces Potent Anti-tumor and Anti-angiogenic Responses in Vitro and in Vivo. Journal of Biological Chemistry, 2011, 286, 13626-13637.	1.6	45
942	IQGAP1 Protein Binds Human Epidermal Growth Factor Receptor 2 (HER2) and Modulates Trastuzumab Resistance. Journal of Biological Chemistry, 2011, 286, 29734-29747.	1.6	37
943	Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome. Journal of Clinical Oncology, 2011, 29, 3030-3036.	0.8	217
944	ErbB2 Stabilizes Epidermal Growth Factor Receptor (EGFR) Expression via Erk and Sprouty2 in Extracellular Matrix-detached Cells. Journal of Biological Chemistry, 2011, 286, 79-90.	1.6	44
945	Integrated Quantitative Analysis of the Phosphoproteome and Transcriptome in Tamoxifen-resistant Breast Cancer. Journal of Biological Chemistry, 2011, 286, 818-829.	1.6	42
946	Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells. Journal of Biological Chemistry, 2011, 286, 20558-20568.	1.6	154
947	Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. British Journal of Cancer, 2011, 105, 1-8.	2.9	52
948	EGFRâ€“PI3Kâ€“AKTâ€“mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opinion on Therapeutic Targets, 2011, 15, 63-74.	1.5	134
949	Time-resolved Fluorescence Resonance Energy Transfer (TR-FRET) to Analyze the Disruption of EGFR/HER2 Dimers. Journal of Biological Chemistry, 2011, 286, 11337-11345.	1.6	54
951	The Crosstalk of PTGS2 and EGF Signaling Pathways in Colorectal Cancer. Cancers, 2011, 3, 3894-3908.	1.7	43

#	Article	IF	Citations
952	Using In-Vivo Fluorescence Imaging in Personalized Cancer Diagnostics and Therapy, an Image and Treat Paradigm. Technology in Cancer Research and Treatment, 2011, 10, 549-560.	0.8	31
953	Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Engineering, Design and Selection, 2011, 24, 385-396.	1.0	62
954	Sputum-Based Molecular Biomarkers for the Early Detection of Lung Cancer: Limitations and Promise. Cancers, 2011, 3, 2975-2989.	1.7	12
955	Epithelial Protein-Tyrosine Phosphatase 1B Contributes to the Induction of Mammary Tumors by HER2/Neu but Is Not Essential for Tumor Maintenance. Molecular Cancer Research, 2011, 9, 1377-1384.	1.5	38
956	EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway. Carcinogenesis, 2012, 33, 1169-1177.	1.3	20
957	Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Medicinal Chemistry, 2012, 4, 107-119.	1.1	28
958	The Q43L mutant of neuregulin 2Î² is a pan-ErbB receptor antagonist. Biochemical Journal, 2012, 443, 133-144.	1.7	7
959	Triptolide Transcriptionally Represses HER2 in Ovarian Cancer Cells by Targeting NF-Î°B. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-10.	0.5	12
960	Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease. Biochemical Society Transactions, 2012, 40, 1058-1062.	1.6	32
961	Single Molecule Fluorescence Detection and Tracking in Mammalian Cells: The State-of-the-Art and Future Perspectives. International Journal of Molecular Sciences, 2012, 13, 14742-14765.	1.8	25
962	Galectin-3 Regulates Intracellular Trafficking of EGFR through Alix and Promotes Keratinocyte Migration. Journal of Investigative Dermatology, 2012, 132, 2828-2837.	0.3	89
963	Frank-ter Haar Syndrome Protein Tks4 Regulates Epidermal Growth Factor-dependent Cell Migration. Journal of Biological Chemistry, 2012, 287, 31321-31329.	1.6	28
964	Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biology and Therapy, 2012, 13, 1325-1338.	1.5	26
965	Prevention of ER-negative breast cancer. European Journal of Cancer Prevention, 2012, 21, 171-181.	0.6	10
966	Inference of modules associated to eQTLs. Nucleic Acids Research, 2012, 40, e98-e98.	6.5	12
967	Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Panâ€“Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3337-3344.	0.8	247
968	SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo. Molecular Cancer Therapeutics, 2012, 11, 952-962.	1.9	21
969	Uncoupling of PI3K from ErbB3 Impairs Mammary Gland Development but Does Not Impact on ErbB2-Induced Mammary Tumorigenesis. Cancer Research, 2012, 72, 3080-3090.	0.4	23

#	Article	IF	Citations
970	ErbB receptor tyrosine kinase/NF-Î²B signaling controls mammosphere formation in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6584-6589.	3.3	97
971	EGFRgene copy number increase in vulvar carcinomas is linked with poor clinical outcome. Journal of Clinical Pathology, 2012, 65, 133-139.	1.0	30
972	Growth and metastasis suppression of glioma xenografts expressing exon 4â€deletion variant of epidermal growth factor receptor by monoclonal antibody CH12â€mediated receptor degradation. FASEB Journal, 2012, 26, 73-80.	0.2	13
973	Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Modern Pathology, 2012, 25, 1566-1573.	2.9	46
974	Lapatinib and Obatoclax Kill Breast Cancer Cells through Reactive Oxygen Species-Dependent Endoplasmic Reticulum Stress. Molecular Pharmacology, 2012, 82, 1217-1229.	1.0	37
975	Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer. Current Medicinal Chemistry, 2012, 19, 3689-3700.	1.2	11
976	Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy. Current Molecular Medicine, 2012, 12, 788-803.	0.6	5
977	Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance. Current Cancer Drug Targets, 2012, 12, 197-209.	0.8	196
978	Targeting the Human Epidermal Growth Factor Receptor 2 Pathway in Breast Cancer. Hospital Practice (1995), 2012, 40, 7-15.	0.5	10
979	Cancer Treatment with Gene Therapy and Radiation Therapy. Advances in Cancer Research, 2012, 115, 221-263.	1.9	64
980	Food Increased the Bioavailability of BMSâ€690514, an Orally Active EGFR/HER2/VEGF Receptor Kinase Inhibitor, in Healthy Subjects. Journal of Clinical Pharmacology, 2012, 52, 1350-1356.	1.0	5
981	Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3417-3420.	0.8	61
982	Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. British Journal of Cancer, 2012, 106, 666-672.	2.9	33
983	A functional comparison between the HER2high/HER3 and the HER2low/HER3 dimers on heregulin-Î²1-induced MMP-1 and MMP-9 expression in breast cancer cells. Experimental and Molecular Medicine, 2012, 44, 473.	3.2	20
984	Mechanics of EGF Receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 137-142.	3.3	65
985	Protein Inhibitor of Activated STAT3 (PIAS3) Protein Promotes SUMOylation and Nuclear Sequestration of the Intracellular Domain of ErbB4 Protein. Journal of Biological Chemistry, 2012, 287, 23216-23226.	1.6	35
986	Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 21058-21063.	3.3	34
987	Migfilin Protein Promotes Migration and Invasion in Human Glioma through Epidermal Growth Factor Receptor-mediated Phospholipase C-Î³ and STAT3 Protein Signaling Pathways. Journal of Biological Chemistry, 2012, 287, 32394-32405.	1.6	30

#	Article	IF	Citations
988	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2736-2741.	3.3	95
989	Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Nonâ€“Small Cell Lung Cancer with T790M Resistance Mutation. Molecular Cancer Therapeutics, 2012, 11, 2254-2264.	1.9	179
990	The reninâ€“angiotensin system in the breast and breast cancer. Endocrine-Related Cancer, 2012, 19, R1-R19.	1.6	51
991	Advances in Targeting HER3 as an Anticancer Therapy. Chemotherapy Research and Practice, 2012, 2012, 1-9.	1.6	36
992	Nucleic Acids in Human Glioma Treatment: Innovative Approaches and Recent Results. Journal of Signal Transduction, 2012, 2012, 1-11.	2.0	22
993	Suppressor of Cytokine Signaling 3 Inhibits Breast Tumor Kinase Activation of STAT3. Journal of Biological Chemistry, 2012, 287, 20904-20912.	1.6	26
994	Obatoclax and Lapatinib Interact to Induce Toxic Autophagy through NOXA. Molecular Pharmacology, 2012, 81, 527-540.	1.0	53
995	Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. Protein Engineering, Design and Selection, 2012, 25, 551-560.	1.0	40
996	Membrane microdomain-associated uroplakin IIIa contributes to Src-dependent mechanisms of anti-apoptotic proliferation in human bladder carcinoma cells. Biology Open, 2012, 1, 1024-1034.	0.6	5
997	Polymorphisms to Predict Outcome to the Tyrosine Kinase Inhibitors Gefitinib, Erlotinib, Sorafenib and Sunitinib. Current Topics in Medicinal Chemistry, 2012, 12, 1649-1659.	1.0	25
998	Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells. Oncology Reports, 2012, 28, 15-20.	1.2	11
999	Review: The JAK/STAT Protein Activation â€“ Role in Cancer Development and Targeted Therapy. Current Signal Transduction Therapy, 2012, 7, 187-201.	0.3	17
1000	Monoclonal Antibody Therapy of Pancreatic Cancer With Cetuximab. Journal of Immunotherapy, 2012, 35, 367-373.	1.2	28
1001	The Molecular Basis of Herpesviruses as Oncolytic Agents. Current Pharmaceutical Biotechnology, 2012, 13, 1795-1803.	0.9	4
1002	Genomics and Cancer Drug Resistance. Current Pharmaceutical Biotechnology, 2012, 13, 651-673.	0.9	39
1003	Cancer Chemoprevention with Green Tea Catechins: From Bench to Bed. Current Drug Targets, 2012, 13, 1842-1857.	1.0	56
1004	EGFR Mutation-specific Antibodies in Pulmonary Adenocarcinoma. Applied Immunohistochemistry & Molecular Morphology, 2012, 20, 356-362.	2.0	14
1005	Upregulated Expression of ADAM17 Is a Prognostic Marker for Patients With Gastric Cancer. Annals of Surgery, 2012, 256, 1014-1022.	2.1	58

#	Article	IF	Citations
1006	Treatment of nonsmall cell lung cancer. Current Opinion in Oncology, 2012, 24, 123-129.	1.1	25
1007	EGFR-dependent phosphorylation of leucine-rich repeat kinase LRRK1 is important for proper endosomal trafficking of EGFR. Molecular Biology of the Cell, 2012, 23, 1294-1306.	0.9	31
1008	Protein Expression Signatures for Inhibition of Epidermal Growth Factor Receptor-mediated Signaling. Molecular and Cellular Proteomics, 2012, 11, M111.015222.	2.5	18
1009	Heparin-binding epidermal growth factor-like growth factor is a potent regulator of invasion activity in oral squamous cell carcinoma. Oncology Reports, 2012, 27, 954-958.	1.2	17
1011	First- and second-line treatment of non-small-cell lung cancer patients withEGFRmutation-positive tumors. Lung Cancer Management, 2012, 1, 201-217.	1.5	0
1012	Investigating extracellular in situ EGFR structure and conformational changes using FRET microscopy. Biochemical Society Transactions, 2012, 40, 189-194.	1.6	8
1013	Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. International Journal of Oncology, 2012, 41, 1128-1138.	1.4	50
1014	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, The, 2012, 379, 633-640.	6.3	1,165
1015	Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5870-5875.	1.0	35
1016	Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping. Clinical Cancer Research, 2012, 18, 6426-6435.	3.2	110
1017	Winning the Arms Race by Improving Drug Discovery against Mutating Targets. ACS Chemical Biology, 2012, 7, 278-288.	1.6	14
1018	Midkine and Chemoresistance in Cancers. , 2012, , 225-236.		1
1019	Pathological significance of epidermal growth factor receptor expression and amplification in human gliomas. Histopathology, 2012, 61, 726-736.	1.6	10
1020	Lapatinib and Obatoclax Kill Tumor Cells through Blockade of ERBB1/3/4 and through Inhibition of BCL-xL and MCL-1. Molecular Pharmacology, 2012, 81, 748-758.	1.0	22
1021	Targeted delivery via avidin fusion protein: Intracellular fate of biotinylated doxorubicin derivative and cellular uptake kinetics and biodistribution of biotinylated liposomes. European Journal of Pharmaceutical Sciences, 2012, 47, 848-856.	1.9	19
1022	Mechanisms for Kinase-mediated Dimerization of the Epidermal Growth Factor Receptor. Journal of Biological Chemistry, 2012, 287, 38244-38253.	1.6	70
1023	Alterations of the extracellular matrix of lung during zinc deficiency. British Journal of Nutrition, 2012, 108, 62-70.	1.2	12
1024	Antibody-Linked Spherical Nucleic Acids for Cellular Targeting. Journal of the American Chemical Society, 2012, 134, 16488-16491.	6.6	126

#	Article	IF	Citations
1025	Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells. Cell Death and Disease, 2012, 3, e440-e440.	2.7	10
1026	Up-regulation of Pro-apoptotic Protein Bim and Down-regulation of Anti-apoptotic Protein Mcl-1 Cooperatively Mediate Enhanced Tumor Cell Death Induced by the Combination of ERK Kinase (MEK) Inhibitor and Microtubule Inhibitor. Journal of Biological Chemistry, 2012, 287, 10289-10300.	1.6	22
1027	Differential Sensitivity of Glioma- versus Lung Cancerâ€“Specific EGFR Mutations to EGFR Kinase Inhibitors. Cancer Discovery, 2012, 2, 458-471.	7.7	304
1028	Molecular markers for cancer prognosis and treatment: Have we struck gold?. Cancer Letters, 2012, 327, 142-152.	3.2	33
1029	EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity. Future Oncology, 2012, 8, 1015-1029.	1.1	21
1030	Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion. Breast Cancer Research, 2012, 14, R131.	2.2	45
1031	Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo. Breast Cancer Research, 2012, 14, R132.	2.2	31
1032	Pathology: Commonly Monitored Glioblastoma Markers: EFGR, EGFRvIII, PTEN, and MGMT. Neurosurgery Clinics of North America, 2012, 23, 237-246.	0.8	24
1033	Molecular docking and 3D QSAR studies of substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as insulin-like growth factor-1 receptor (IGF1R) inhibitors. Medicinal Chemistry Research, 2012, 21, 3301-3311.	1.1	4
1034	Animal models for IgE-meditated cancer immunotherapy. Cancer Immunology, Immunotherapy, 2012, 61, 1535-1546.	2.0	18
1035	IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells. Cancer Immunology, Immunotherapy, 2012, 61, 1473-1484.	2.0	4
1036	Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells. Cancer Immunology, Immunotherapy, 2012, 61, 1905-1916.	2.0	22
1037	Recombinant IgE antibody engineering to target EGFR. Cancer Immunology, Immunotherapy, 2012, 61, 1565-1573.	2.0	23
1038	Expression of EGFR Under Tumor Hypoxia: Identification of a Subpopulation of Tumor Cells Responsible for Aggressiveness and Treatment Resistance. International Journal of Radiation Oncology Biology Physics, 2012, 84, 807-814.	0.4	24
1039	Cetuximab in combination with anti-human IgG antibodies efficiently down-regulates the EGF receptor by macropinocytosis. Experimental Cell Research, 2012, 318, 2578-2591.	1.2	37
1040	HER2 as a therapeutic target in the gastric cancer: is it sufficient?. Indian Journal of Gastroenterology, 2012, 31, 103-105.	0.7	1
1041	Breast Cancer Therapies and Cardiomyopathy. Medical Clinics of North America, 2012, 96, 1001-1019.	1.1	13
1042	Capillary electrophoretic genotyping of epidermal growth factor receptor for pharmacogenomic assay of lung cancer therapy. Journal of Chromatography A, 2012, 1256, 276-279.	1.8	7

#	Article	IF	Citations
1043	New Tracers PET in Head and Neck Squamous Cell Carcinoma. PET Clinics, 2012, 7, 431-441.	1.5	2
1044	Targeting the mTOR-DEPTOR Pathway by CRL E3 Ubiquitin Ligases: Therapeutic Application. Neoplasia, 2012, 14, 360-367.	2.3	55
1045	Domain-Based Biosensor Assay to Screen for Epidermal Growth Factor Receptor Modulators in Live Cells. Assay and Drug Development Technologies, 2012, 10, 24-36.	0.6	29
1046	Therapeutic Use of an Anti-ErbB3 Monoclonal Antibody. Hybridoma, 2012, 31, 149-154.	0.5	4
1047	Vandetanib for the treatment of lung cancer. Expert Opinion on Investigational Drugs, 2012, 21, 1211-1221.	1.9	6
1048	Inhibition of proteinâ€“protein interaction of HER2â€“EGFR and HER2â€“HER3 by a rationally designed peptidomimetic. Journal of Biomolecular Structure and Dynamics, 2012, 30, 594-606.	2.0	31
1049	A Water-Based Mechanism of Specificity and Resistance for Lapatinib with ErbB Family Kinases. Biochemistry, 2012, 51, 2390-2406.	1.2	23
1050	Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors. Molecular BioSystems, 2012, 8, 2645.	2.9	11
1051	Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies. Respiratory Medicine, 2012, 106, 173-183.	1.3	67
1052	Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA. Nuclear Medicine and Biology, 2012, 39, 518-529.	0.3	15
1053	An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. Oncogene, 2012, 31, 1275-1286.	2.6	28
1054	Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nature Biotechnology, 2012, 30, 858-867.	9.4	502
1055	Rab5c promotes AMAP1â€“PRKD2 complex formation to enhance Î²1 integrin recycling in EGF-induced cancer invasion. Journal of Cell Biology, 2012, 197, 983-996.	2.3	93
1056	Activation of Janus Kinases During Tumorigenesis. , 2012, , 259-288.		2
1057	Rad18 is a transcriptional target of E2F3. Cell Cycle, 2012, 11, 1131-1141.	1.3	8
1058	Synthesis and Biological Evaluation of Pyrimidine-Based Dual Inhibitors of Human Epidermal Growth Factor Receptor 1 (HER-1) and HER-2 Tyrosine Kinases. Journal of Medicinal Chemistry, 2012, 55, 2846-2857.	2.9	29
1059	Physicalâ€“chemical principles underlying RTK activation, and their implications for human disease. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 995-1005.	1.4	49
1060	Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDACâ€“EGFR dual inhibitors. Bioorganic and Medicinal Chemistry, 2012, 20, 4405-4412.	1.4	39

#	Article	IF	Citations
1061	The Na+/H+ exchanger NHE1, but not the Na+, <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si1.gif" overflow="scroll"><mml:mrow><mml:msubsup><mml:mrow><mml:mtext>HCO</mml:mtext></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math> cotransporter NBCn1, regulates motility of MCF7 breast cancer cells expressing constitutively active ErbB2. Cancer Letters, 2012, 317, 172-183.	3.2	10
1062	Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Letters, 2012, 322, 113-118.	3.2	67
1063	Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers. Biomaterials, 2012, 33, 7519-7529.	5.7	111
1064	Flow cytometric cellâ€based assay to preselect antibody constructs for radionuclide conjugation. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2012, 81A, 865-873.	1.1	8
1065	Nuclear translocation of the cytoplasmic domain of HB-EGF induces gastric cancer invasion. BMC Cancer, 2012, 12, 205.	1.1	15
1066	A new analysis approach of epidermal growth factor receptor pathway activation patterns provides insights into cetuximab resistance mechanisms in head and neck cancer. BMC Medicine, 2012, 10, 43.	2.3	2
1067	Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models. BMC Medicine, 2012, 10, 80.	2.3	78
1068	Girdin locates in centrosome and midbody and plays an important role in cell division. Cancer Science, 2012, 103, 1780-1787.	1.7	17
1069	Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opinion on Therapeutic Targets, 2012, 16, 771-781.	1.5	28
1070	Peptide vaccines and peptidomimetics targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncology, 2012, 8, 961-987.	1.1	44
1071	Targeting Cancer with Small-Molecular-Weight Kinase Inhibitors. Methods in Molecular Biology, 2012, 795, 1-34.	0.4	117
1072	Leptin and HER-2 are associated with gastric cancer progression and prognosis of patients. Biomedicine and Pharmacotherapy, 2012, 66, 419-424.	2.5	24
1073	The interaction of EGFR and repair of DNA damage following chemotherapy and radiation. Drug Discovery Today: Disease Models, 2012, 9, e69-e73.	1.2	1
1074	Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: Dual inhibitors of EGFR and Src protein tyrosine kinases. European Journal of Medicinal Chemistry, 2012, 55, 39-48.	2.6	31
1076	Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells. Lung Cancer, 2012, 75, 30-37.	0.9	61
1077	Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells. Neoplasia, 2012, 14, 463-IN3.	2.3	36
1079	Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790â†' methionine790 mutant. MedChemComm, 2012, 3, 1155.	3.5	16
1081	Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies. BioDrugs, 2012, 26, 83-99.	2.2	33

#	Article	IF	Citations
1082	Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. Journal of Medicinal Chemistry, 2012, 55, 2251-2264.	2.9	53
1083	Kinase Inhibitors. Methods in Molecular Biology, 2012, , .	0.4	2
1084	Genetic Nanomedicine. Methods in Enzymology, 2012, 509, 355-367.	0.4	11
1085	Tyrosine Kinase Inhibitors in Lung Cancer. Hematology/Oncology Clinics of North America, 2012, 26, 589-605.	0.9	32
1086	Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR. Journal of Experimental and Clinical Cancer Research, 2012, 31, 65.	3.5	35
1087	EGF-Induced EMT and Invasiveness in Serous Borderline Ovarian Tumor Cells: A Possible Step in the Transition to Low-Grade Serous Carcinoma Cells?. PLoS ONE, 2012, 7, e34071.	1.1	55
1088	Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer. PLoS ONE, 2012, 7, e39943.	1.1	24
1089	An In Vivo C. elegans Model System for Screening EGFR-Inhibiting Anti-Cancer Drugs. PLoS ONE, 2012, 7, e42441.	1.1	24
1090	Comprehensive Binary Interaction Mapping of SH2 Domains via Fluorescence Polarization Reveals Novel Functional Diversification of ErbB Receptors. PLoS ONE, 2012, 7, e44471.	1.1	60
1091	Effects of Paclitaxel on EGFR Endocytic Trafficking Revealed Using Quantum Dot Tracking in Single Cells. PLoS ONE, 2012, 7, e45465.	1.1	46
1092	Targeted Therapy for Breast Cancer. Hanyang Medical Reviews, 2012, 32, 112.	0.4	2
1093	Regulation of Ubiquitination-Mediated Protein Degradation by Survival Kinases in Cancer. Frontiers in Oncology, 2012, 2, 15.	1.3	49
1094	Signaling of Receptor Tyrosine Kinases in the Nucleus. , 0, , .		3
1095	Epithelial-Mesenchymal Interactions in Oral Cancer Metastasis. , 0, , .		3
1096	A polymorphism withinErbB4is associated with risk for hepatocellular carcinoma in Chinese population. World Journal of Gastroenterology, 2012, 18, 383.	1.4	19
1097	Activating Mutations and Targeted Therapy in Cancer. , 0, , .		3
1098	Investigating the Conformation of HER Membrane Proteins in Cells via Single Molecule and FLIM Microscopy. , 2012, , .		0
1099	Mutual Regulation of Receptor-Mediated Cell Signalling and Endocytosis: EGF Receptor System as an Example. , 0, , .		3

#	Article	IF	Citations
1100	Cooperative Hedgehog-EGFR signaling. Frontiers in Bioscience - Landmark, 2012, 17, 90.	3.0	49
1101	Spatial regulation of receptor tyrosine kinases in development and cancer. Nature Reviews Cancer, 2012, 12, 387-400.	12.8	285
1102	Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligandâ€“dependent terminal keratinocyte differentiation. Journal of Experimental Medicine, 2012, 209, 1105-1119.	4.2	161
1103	Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology, 2012, 25, 347-369.	2.9	215
1104	HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines. Journal of Immunology, 2012, 188, 2136-2145.	0.4	51
1105	EGFR expression in advanced head and neck cutaneous squamous cell carcinoma. Head and Neck, 2012, 34, 681-686.	0.9	32
1106	Antitumor activity of HM781â€36B, a highly effective panâ€HER inhibitor in erlotinibâ€resistant NSCLC and other EGFRâ€dependent cancer models. International Journal of Cancer, 2012, 130, 2445-2454.	2.3	67
1107	Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: Therapeutic implications. International Journal of Cancer, 2012, 131, 244-252.	2.3	42
1108	Effects of epidermal growth factor receptor blockade on ependymoma stem cells in vitro and in orthotopic mouse models. International Journal of Cancer, 2012, 131, E791-803.	2.3	15
1109	Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines. International Journal of Cancer, 2012, 131, 1998-2007.	2.3	25
1110	Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2â€positive cancer cells and cancer stem cells. International Journal of Cancer, 2012, 131, 2808-2819.	2.3	65
1111	ERBB 3 (HER 3) is a key sensor in the regulation of ERBB â€mediated signaling in both low and high ERBB 2 (HER 2) expressing cancer cells. Cancer Medicine, 2012, 1, 28-38.	1.3	38
1112	Development of ¹⁷⁷Luâ€nanobodies for radioimmunotherapy of HER2â€positive breast cancer: evaluation of different bifunctional chelators. Contrast Media and Molecular Imaging, 2012, 7, 254-264.	0.4	70
1113	Gene amplification and protein overexpression of EGFR and ERBB2 in sinonasal squamous cell carcinoma. Cancer, 2012, 118, 1818-1826.	2.0	36
1114	Slow down to stay alive. Cancer, 2012, 118, 5140-5154.	2.0	23
1115	Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis. Cancer, 2012, 118, 5198-5209.	2.0	49
1116	Single Domain Antibodies: A New Concept for Epidermal Growth Factor Receptor and EGFRvIII Targeting. DNA and Cell Biology, 2012, 31, 1015-1026.	0.9	18
1117	Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update. Cancer Investigation, 2012, 30, 433-446.	0.6	58

#	Article	IF	Citations
1118	Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors. Tumor Biology, 2012, 33, 653-659.	0.8	18
1119	A Crossroad of microRNAs and Immediate Early Genes (IEGs) Encoding Oncogenic Transcription Factors in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2012, 17, 3-14.	1.0	6
1120	Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. Journal of Neuro-Oncology, 2012, 108, 395-402.	1.4	51
1121	HER2-specific T lymphocytes kill both trastuzumab-resistant and trastuzumab-sensitive breast cell lines in vitro. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2012, 24, 143-150.	0.7	10
1122	Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis. European Journal of Clinical Pharmacology, 2012, 68, 561-569.	0.8	17
1123	Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunology, Immunotherapy, 2012, 61, 991-1003.	2.0	37
1124	Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemotherapy and Pharmacology, 2012, 69, 891-899.	1.1	77
1125	177Luâ€“DO3Aâ€“HSAâ€“ZEGFR:1907: characterization as a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas. Journal of Biological Inorganic Chemistry, 2012, 17, 709-718.	1.1	8
1126	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Research and Treatment, 2012, 133, 1057-1065.	1.1	183
1127	Structural modelling and dynamics of proteins for insights into drug interactions. Advanced Drug Delivery Reviews, 2012, 64, 323-343.	6.6	32
1128	Identification of New Peptide Ligands for Epidermal Growth Factor Receptor Using Phage Display and Computationally Modeling their Mode of Binding. Chemical Biology and Drug Design, 2012, 79, 246-259.	1.5	29
1129	Rac signaling in breast cancer: A tale of GEFs and GAPs. Cellular Signalling, 2012, 24, 353-362.	1.7	162
1130	EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Cellular Signalling, 2012, 24, 296-301.	1.7	27
1131	IQGAP1 and its binding proteins control diverse biological functions. Cellular Signalling, 2012, 24, 826-834.	1.7	190
1132	Emerging insights into the molecular biology of brain metastases. Biochemical Pharmacology, 2012, 83, 305-314.	2.0	25
1133	Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance. Biochemical Pharmacology, 2012, 84, 260-267.	2.0	65
1134	Clinical and Immunomodulatory Effects of Toceranib Combined with Lowâ€Dose Cyclophosphamide in Dogs with Cancer. Journal of Veterinary Internal Medicine, 2012, 26, 355-362.	0.6	87
1135	Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer, 2012, 118, 1268-1275.	2.0	48

#	Article	IF	Citations
1136	Emerging strategies for the early detection and prevention of head and neck squamous cell cancer. Journal of Cellular Physiology, 2012, 227, 467-473.	2.0	19
1137	Synthesis and in vitro Characterization of Semitelechelic Poly[Nâ€(2â€hydroxypropyl)methacrylamide]â€“Trastuzumab Conjugates Targeted to Breast Cancer. Macromolecular Bioscience, 2012, 12, 55-60.	2.1	4
1138	Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens. Cell Biochemistry and Biophysics, 2012, 62, 221-228.	0.9	89
1139	Treatment of Metastatic Triple-Negative Breast Cancer. Current Breast Cancer Reports, 2012, 4, 10-21.	0.5	0
1140	Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer. Pharmaceutical Research, 2012, 29, 770-781.	1.7	182
1141	In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer. Amino Acids, 2012, 42, 1349-1360.	1.2	23
1142	Fineâ€needle aspiration cytology of tripleâ€negative basalâ€like breast cancer. Diagnostic Cytopathology, 2013, 41, 283-287.	0.5	3
1143	Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Research, 2013, 15, R8.	2.2	61
1144	Identification of a novel antagonist of the ErbB1 receptor capable of inhibiting migration of human glioblastoma cells. Cellular Oncology (Dordrecht), 2013, 36, 201-211.	2.1	2
1145	Preclinical Rationale for PI3K/Akt/mTOR Pathway Inhibitors as Therapy for Epidermal Growth Factor Receptor Inhibitor-Resistant Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2013, 14, 322-332.	1.1	93
1146	Single molecular dissection of the ligand binding property of epidermal growth factor receptor. Analyst, The, 2013, 138, 5325.	1.7	8
1147	Targeting HER2 + breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles. Journal of Controlled Release, 2013, 172, 395-404.	4.8	47
1148	Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5385-5388.	1.0	25
1149	Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity. Bioorganic and Medicinal Chemistry, 2013, 21, 6084-6091.	1.4	18
1150	Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 3090-3104.	1.4	25
1151	CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. Gynecologic Oncology, 2013, 129, 179-187.	0.6	25
1152	Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator. BMC Cancer, 2013, 13, 197.	1.1	72
1153	Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer. BMC Cancer, 2013, 13, 81.	1.1	14

#	Article	IF	Citations
1154	ROR1 is a pseudokinase that is crucial for MET-driven tumorigenesis. BMC Proceedings, 2013, 7, .	1.8	3
1155	Impact of Genetic Targets on Cancer Therapy. Advances in Experimental Medicine and Biology, 2013, 779, v-vi.	0.8	1
1157	Network motifs in the transcriptional regulation network of cervical carcinoma cells respond to EGF. Archives of Gynecology and Obstetrics, 2013, 287, 771-777.	0.8	12
1158	Pertuzumab for the treatment of metastatic breast cancer. Expert Review of Anticancer Therapy, 2013, 13, 907-918.	1.1	7
1159	miRNAâ€214 is related to invasiveness of human nonâ€small cell lung cancer and directly regulates alpha protein kinase 2 expression. Genes Chromosomes and Cancer, 2013, 52, 895-911.	1.5	29
1161	RUNX3 is a prognostic marker and potential therapeutic target in human breast cancer. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1813-1823.	1.2	17
1162	ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. International Journal of Cancer, 2013, 133, 235-246.	2.3	16
1163	FOXM1 (Forkhead box M1) in Tumorigenesis. Advances in Cancer Research, 2013, 119, 191-419.	1.9	146
1164	Computational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs. Journal of Molecular Modeling, 2013, 19, 2797-2810.	0.8	7
1165	Conformational flexibility of the ErbB2 ectodomain and trastuzumab antibody complex as revealed by molecular dynamics and principal component analysis. Journal of Molecular Modeling, 2013, 19, 1227-1236.	0.8	8
1166	Effect of Microformulation on the Bioactivity of an Anthocyanin-rich Bilberry Pomace Extract (Vaccinium myrtillus L.) in Vitro. Journal of Agricultural and Food Chemistry, 2013, 61, 4873-4881.	2.4	19
1167	Bioinformatics analysis reveals potential candidate drugs for cervical cancer. Journal of Obstetrics and Gynaecology Research, 2013, 39, 1052-1058.	0.6	7
1168	Breast Cancer Metastasis. American Journal of Pathology, 2013, 183, 1084-1095.	1.9	67
1169	Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung Cancer, 2013, 80, 120-130.	0.9	43
1170	Recent advances in the epidermal growth factor receptor/ligand system biology on skin homeostasis and keratinocyte stem cell regulation. Journal of Dermatological Science, 2013, 72, 81-86.	1.0	82
1171	Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: A meta-analysis of 22 phase III randomized controlled trials. Respiratory Medicine, 2013, 107, 1280-1283.	1.3	9
1172	Cancer Genome Landscapes. Science, 2013, 339, 1546-1558.	6.0	6,507
1173	Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization. Cancer Research, 2013, 73, 6471-6483.	0.4	49

#	Article	IF	Citations
1174	SMURF1 Plays a Role in EGF-Induced Breast Cancer Cell Migration and Invasion. Molecules and Cells, 2013, 36, 548-555.	1.0	38
1175	Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2013, 56, 8803-8813.	2.9	30
1176	Synthesis and anticancer activities of 5,6,7-trimethoxy-N-phenyl(ethyl)-4-aminoquinazoline derivatives. European Journal of Medicinal Chemistry, 2013, 66, 335-344.	2.6	22
1177	Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. Critical Reviews in Oncology/Hematology, 2013, 88, 477-493.	2.0	71
1178	Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor. Bioorganic and Medicinal Chemistry, 2013, 21, 7988-7998.	1.4	23
1179	Oral Cavity and Oropharyngeal Squamous Cell Carcinoma Genomics. Otolaryngologic Clinics of North America, 2013, 46, 545-566.	0.5	14
1180	Abamectin resistance in Drosophila is related to increased expression of P-glycoprotein via the dEGFR and dAkt pathways. Insect Biochemistry and Molecular Biology, 2013, 43, 627-634.	1.2	48
1181	EGF regulates tyrosine phosphorylation and membrane-translocation of the scaffold protein Tks5. Journal of Molecular Signaling, 2013, 8, 8.	0.5	16
1182	Gene Expression Profiling Reveals Regulation of ERK Phosphorylation by Androgen-Induced Tumor Suppressor U19/EAF2 in the Mouse Prostate. Cancer Microenvironment, 2013, 6, 247-261.	3.1	14
1183	Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 72, 1213-1222.	1.1	15
1184	Molecular predictors of locoregional and distant metastases in oropharyngeal squamous cell carcinoma. Journal of Otolaryngology - Head and Neck Surgery, 2013, 42, 53.	0.9	22
1185	Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline. Clinical Therapeutics, 2013, 35, 1282-1303.	1.1	81
1186	Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 1061-1069.	0.8	87
1187	Molecular Mechanisms of SH2- and PTB-Domain-Containing Proteins in Receptor Tyrosine Kinase Signaling. Cold Spring Harbor Perspectives in Biology, 2013, 5, a008987-a008987.	2.3	130
1188	Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Molecular Systems Biology, 2013, 9, 637.	3.2	267
1189	Interaction of <scp>N</scp>eclâ€4/<scp>CADM</scp>4 with <scp>E</scp>rb<scp>B</scp>3 and integrin Î±₆Î²₄ and inhibition of <scp>E</scp>rb<scp>B</scp>2/<scp>E</scp>rb<scp>B</scp>3 signaling and hemidesmosome disassembly. Genes To Cells, 2013, 18, 519-528.	0.5	24
1190	Acid Active Receptorâ€Specific Peptide Ligand for In Vivo Tumorâ€Targeted Delivery. Small, 2013, 9, 3647-3658.	5.2	30
1191	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitorâ€“Resistant Disease. Journal of Clinical Oncology, 2013, 31, 1070-1080.	0.8	425

#	Article	IF	Citations
1192	Cetuximab Response of Lung Cancerâ€“Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization. Cancer Research, 2013, 73, 6770-6779.	0.4	87
1193	Label-free cell phenotypic assessment of the molecular mechanism of action of epidermal growth factor receptor inhibitors. RSC Advances, 2013, 3, 10370.	1.7	21
1195	The role of afatinib in the management of non-small cell lung carcinoma. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1529-1539.	1.5	4
1196	Reverse Phase Protein Microarray Technology. , 2013, , 349-361.		0
1197	Class I histone deacetylase activity is required for proliferation of renal epithelial cells. American Journal of Physiology - Renal Physiology, 2013, 305, F244-F254.	1.3	18
1198	The Potential Role of Aerobic Exercise to Modulate Cardiotoxicity of Molecularly Targeted Cancer Therapeutics. Oncologist, 2013, 18, 221-231.	1.9	35
1199	Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer. Cellular Signalling, 2013, 25, 26-32.	1.7	24
1200	Cbl and Itch binding sites in ERBB4 CYT-1 and CYT-2 mediate K48- and K63-polyubiquitination, respectively. Cellular Signalling, 2013, 25, 470-478.	1.7	14
1201	Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer. Cancer Discovery, 2013, 3, 224-237.	7.7	697
1202	Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses. Molecular Therapy, 2013, 21, 91-100.	3.7	111
1203	Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors. ACS Medicinal Chemistry Letters, 2013, 4, 201-205.	1.3	117
1204	Oligopeptides derived from autophosphorylation sites of EGF receptor suppress EGF-stimulated responses in human lung carcinoma A549 cells. European Journal of Pharmacology, 2013, 698, 87-94.	1.7	7
1205	Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. Journal of Drug Targeting, 2013, 21, 27-43.	2.1	69
1206	Polydopamine-enabled surface functionalization of gold nanorods for cancer cell-targeted imaging and photothermal therapy. Nanomedicine, 2013, 8, 17-28.	1.7	192
1207	Simulation of homology models for the extracellular domains (ECD) of ErbB3, ErbB4 and the ErbB2â€“ErbB3 complex in their active conformations. Journal of Molecular Modeling, 2013, 19, 931-941.	0.8	8
1208	Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochemical Pharmacology, 2013, 85, 449-465.	2.0	148
1209	Advances in Targeted Therapy for the Prevention of Breast Cancer. Breast Diseases, 2013, 24, 309-314.	0.0	0
1210	EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. Translational Oncology, 2013, 6, 676-IN9.	1.7	26

#	Article	IF	Citations
1211	Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance. Molecular Immunology, 2013, 56, 104-112.	1.0	17
1212	HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells. Biochemical and Biophysical Research Communications, 2013, 434, 81-86.	1.0	21
1213	EGF-like Growth Factors Induce COX-2â€"Derived PGE2 Production Through ERK1/2 in Human Granulosa Cells. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4932-4941.	1.8	54
1214	EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. Pharmacogenomics, 2013, 14, 1765-1777.	0.6	38
1215	RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation. Cancer Research, 2013, 73, 5183-5194.	0.4	96
1216	Somatic cells regulate maternal mRNA translation and developmental competence of mouse oocytes. Nature Cell Biology, 2013, 15, 1415-1423.	4.6	128
1217	Unravelling the molecular complexity of <scp>GPCR</scp>â€mediated <scp>EGFR</scp> transactivation using functional genomics approaches. FEBS Journal, 2013, 280, 5258-5268.	2.2	53
1218	Dithiiranylmethyloxy azaxanthone shows potent anti-tumor activity via suppression of HER2 expression and HER2-mediated signals in HER2-overexpressing breast cancer cells. European Journal of Pharmaceutical Sciences, 2013, 50, 181-190.	1.9	12
1219	Sustained Activation of EGFR Triggers Renal Fibrogenesis after Acute Kidney Injury. American Journal of Pathology, 2013, 183, 160-172.	1.9	99
1220	Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression. Experimental and Molecular Pathology, 2013, 94, 360-365.	0.9	33
1221	Head and neck cancer: from anatomy to biology. International Journal of Cancer, 2013, 133, 2013-2023.	2.3	130
1222	Protein tyrosine phosphatasesÂâ€"Âfrom housekeeping enzymes to master regulators of signal transduction. FEBS Journal, 2013, 280, 346-378.	2.2	370
1223	Regulation of tamoxifen sensitivity by a PAK1â€"EBP1 signalling pathway in breast cancer. British Journal of Cancer, 2013, 108, 557-563.	2.9	18
1224	A combined oncogenic pathway signature ofBRAF,KRASandPI3KCAmutation improves colorectal cancer classification and cetuximab treatment prediction. Gut, 2013, 62, 540-549.	6.1	121
1225	The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. Molecular Oncology, 2013, 7, 392-401.	2.1	80
1226	Beyond antibodies: using biological principles to guide the development of next-generation protein therapeutics. Current Opinion in Biotechnology, 2013, 24, 1072-1077.	3.3	36
1227	Phosphotyrosine Profiling of NSCLC Cells in Response to EGF and HGF Reveals Network Specific Mediators of Invasion. Journal of Proteome Research, 2013, 12, 1856-1867.	1.8	26
1228	Development of cellular signaling pathway inhibitors as new antivirals against influenza. Antiviral Research, 2013, 98, 457-468.	1.9	94

#	Article	IF	Citations
1229	Phase Iâ€“IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. European Journal of Cancer, 2013, 49, 1815-1824.	1.3	18
1230	Application of Aptamers for Targeted Therapeutics. Archivum Immunologiae Et Therapiae Experimentalis, 2013, 61, 255-271.	1.0	28
1231	Genome-wide associations of signaling pathways in glioblastoma multiforme. BMC Medical Genomics, 2013, 6, 11.	0.7	3
1232	Mollugin inhibits proliferation and induces apoptosis by suppressing fatty acid synthase in HER2â€overexpressing cancer cells. Journal of Cellular Physiology, 2013, 228, 1087-1097.	2.0	31
1233	Role of epidermal growth factor receptor in acute and chronic kidney injury. Kidney International, 2013, 83, 804-810.	2.6	122
1234	Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain. European Journal of Medicinal Chemistry, 2013, 65, 60-69.	2.6	22
1235	Monoclonal antibody-based therapies in cancer: Advances and challenges. , 2013, 138, 452-469.		96
1236	Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations. Oncogene, 2013, 32, 2346-2355.	2.6	36
1237	Update on Clinical Trials: Genetic Targets in Breast Cancer. Advances in Experimental Medicine and Biology, 2013, 779, 35-54.	0.8	6
1238	Synthesis, Antitumor Evaluation and Docking Study of Novel 4â€Anilinoquinazoline Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors. ChemMedChem, 2013, 8, 928-933.	1.6	13
1239	Oncogenic ERBB3 Mutations in Human Cancers. Cancer Cell, 2013, 23, 603-617.	7.7	318
1240	Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models. Biochemical and Biophysical Research Communications, 2013, 433, 456-462.	1.0	15
1241	Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer. Journal of Controlled Release, 2013, 169, 185-192.	4.8	141
1242	Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 394-401.	1.0	27
1243	Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: A comparative review. Critical Reviews in Oncology/Hematology, 2013, 88, 293-308.	2.0	35
1244	Selective Induction of Cancer Cell Death by Targeted Granzyme B. Antibodies, 2013, 2, 130-151.	1.2	4
1245	Prognostic Role of Human Epidermal Growth Factor Receptor 2 Status in Premenopausal Early Breast Cancer Treated With Adjuvant Tamoxifen. Clinical Breast Cancer, 2013, 13, 247-253.	1.1	10
1246	EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors. Prostate, 2013, 73, 1453-1461.	1.2	36

#	Article	IF	Citations
1247	Targeting the Epidermal Growth Factor Receptor in Bladder Cancer. Journal of Carcinogenesis & Mutagenesis, 2013, 04, .	0.3	3
1248	Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma. NeuroMolecular Medicine, 2013, 15, 420-434.	1.8	34
1249	Drug delivery systems based on nucleic acid nanostructures. Journal of Controlled Release, 2013, 172, 467-483.	4.8	78
1250	Signal Transduction and Molecular Targets of Selected Flavonoids. Antioxidants and Redox Signaling, 2013, 19, 163-180.	2.5	31
1251	The evolving landscape of protein kinases in breast cancer: Clinical implications. Cancer Treatment Reviews, 2013, 39, 68-76.	3.4	20
1252	Protein tyrosine kinase regulation by ubiquitination: Critical roles of Cbl-family ubiquitin ligases. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 122-139.	1.9	190
1253	Nanotechnology for cancer screening and diagnosis. , 2013, , 137-164.		12
1254	EGF receptor and COX-1/COX-2 enzyme proteins as related to corresponding mRNAs in human per-operative biopsies of colorectal cancer. BMC Cancer, 2013, 13, 511.	1.1	7
1255	Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations. Clinical and Experimental Metastasis, 2013, 30, 309-316.	1.7	20
1256	A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 399-408.	1.2	41
1257	A Peptide Antagonist of ErbB Receptors, Inherbin3, Induces Neurite Outgrowth from Rat Cerebellar Granule Neurons Through ErbB1 Inhibition. Neurochemical Research, 2013, 38, 2550-2558.	1.6	4
1258	Tyrosine Phosphorylation of Mig6 Reduces Its Inhibition of the Epidermal Growth Factor Receptor. ACS Chemical Biology, 2013, 8, 2372-2376.	1.6	27
1259	Expression of epidermal growth factor receptors and epidermal growth factor, amphiregulin and neuregulin in bovine uteroplacental tissues during gestation. Placenta, 2013, 34, 1232-1242.	0.7	12
1260	A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study. Gynecologic Oncology, 2013, 129, 486-494.	0.6	65
1261	Multicomponent phytotherapeutic approach gaining momentum: Is the â€œone drug to fit allâ€•model breaking down?. Phytomedicine, 2013, 21, 1-14.	2.3	75
1262	Antitumor efficacy of piperine in the treatment of human HER2-overexpressing breast cancer cells. Food Chemistry, 2013, 141, 2591-2599.	4.2	125
1263	Autocrine Motility Factor Promotes HER2 Cleavage and Signaling in Breast Cancer Cells. Cancer Research, 2013, 73, 1411-1419.	0.4	32
1264	HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene, 2013, 32, 3846-3856.	2.6	104

#	Article	IF	Citations
1265	Methodologies for the isolation of alternative binders with improved clinical potentiality over conventional antibodies. Critical Reviews in Biotechnology, 2013, 33, 40-48.	5.1	5
1266	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. Current Pharmaceutical Design, 2013, 19, 818-832.	0.9	24
1267	Knockdown of integrin Î±3Î²1 expression induces proliferation and migration of non-small cell lung cancer cells. Oncology Reports, 2013, 29, 662-668.	1.2	19
1268	The in vitro antitumor activity of Siegesbeckia glabrescens against ovarian cancer through suppression of receptor tyrosine kinase expression and the signaling pathways. Oncology Reports, 2013, 30, 221-226.	1.2	26
1269	Oral Administration of a Gemini Vitamin D Analog, a Synthetic Triterpenoid and the Combination Prevents Mammary Tumorigenesis Driven by ErbB2 Overexpression. Cancer Prevention Research, 2013, 6, 959-970.	0.7	20
1270	Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients. Future Oncology, 2013, 9, 327-345.	1.1	8
1271	Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10616-10621.	3.3	143
1272	Targeted Therapy for Breast Cancer Prevention. Frontiers in Oncology, 2013, 3, 250.	1.3	118
1273	A Real-Life Experience Using Panitumumab in Chemo-Refractory Metastatic Colorectal Cancer Patients: A Retrospective Analysis at the Jewish General Hospital, 2009â€“2012. Current Oncology, 2013, 20, 107-112.	0.9	2
1274	Reduction of the ST6 Î²-Galactosamide Î±-2,6-Sialyltransferase 1 (ST6GAL1)-catalyzed Sialylation of Nectin-like Molecule 2/Cell Adhesion Molecule 1 and Enhancement of ErbB2/ErbB3 Signaling by MicroRNA-199a. Journal of Biological Chemistry, 2013, 288, 11845-11853.	1.6	31
1275	Downregulation of HER3 by a Novel Antisense Oligonucleotide, EZN-3920, Improves the Antitumor Activity of EGFR and HER2 Tyrosine Kinase Inhibitors in Animal Models. Molecular Cancer Therapeutics, 2013, 12, 427-437.	1.9	35
1276	PharmGKB summary. Pharmacogenetics and Genomics, 2013, 23, 636-642.	0.7	13
1277	Stromal EGF and IGF-I Together Modulate Plasticity of Disseminated Triple-Negative Breast Tumors. Cancer Discovery, 2013, 3, 922-935.	7.7	39
1278	Prolidase Directly Binds and Activates Epidermal Growth Factor Receptor and Stimulates Downstream Signaling. Journal of Biological Chemistry, 2013, 288, 2365-2375.	1.6	31
1279	Predictors of Biomarkers Guiding Targeted Therapeutic Strategies in Locally Advanced Lung Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 263-271.	1.0	4
1280	Trafficking of the EGFR ligand Spitz regulates its signaling activity in polarized tissues. Journal of Cell Science, 2013, 126, 4469-4478.	1.2	21
1281	Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment. Frontiers in Oncology, 2013, 3, 86.	1.3	64
1282	Induction of apoptosis and the regulation of ErbB signaling by laminarin in HT-29 human colon cancer cells. International Journal of Molecular Medicine, 2013, 32, 291-295.	1.8	78

#	Article	IF	Citations
1283	Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. Future Oncology, 2013, 9, 271-281.	1.1	16
1284	Elevation of Receptor Tyrosine Kinases by Small Molecule AKT Inhibitors in Prostate Cancer Is Mediated by Pim-1. Cancer Research, 2013, 73, 3402-3411.	0.4	58
1285	The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment. BioMed Research International, 2013, 2013, 1-8.	0.9	215
1286	Heparin-Binding Epidermal Growth Factor-like Growth Factor/Diphtheria Toxin Receptor in Normal and Neoplastic Hematopoiesis. Toxins, 2013, 5, 1180-1201.	1.5	32
1287	Pertuzumab: new hope for patients with HER2-positive breast cancer. Annals of Oncology, 2013, 24, 273-282.	0.6	128
1288	pHâ€Controlled Delivery of Nanoparticles into Tumor Cells. Advanced Healthcare Materials, 2013, 2, 1435-1439.	3.9	37
1289	Prognostic role of epidermal growth factor receptor in head and neck cancer: A meta-analysis. Journal of Surgical Oncology, 2013, 108, 387-397.	0.8	44
1290	Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMSâ€690514 in Healthy Participants: Assessing the Mechanism of the Interaction With Physiologicallyâ€Based Pharmacokinetic Simulations. Journal of Clinical Pharmacology, 2013, 53, 217-227.	1.0	11
1291	Acquired Substrate Preference for GAB1 Protein Bestows Transforming Activity to ERBB2 Kinase Lung Cancer Mutants. Journal of Biological Chemistry, 2013, 288, 16895-16904.	1.6	6
1294	HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis. Journal of the National Cancer Institute, 2013, 105, 266-273.	3.0	168
1295	The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. Oncogenesis, 2013, 2, e43-e43.	2.1	27
1296	The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Cell Death and Disease, 2013, 4, e810-e810.	2.7	67
1297	A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Annals of Oncology, 2013, 24, 1392-1400.	0.6	32
1298	Quantitative Proteomics with siRNA Screening Identifies Novel Mechanisms of Trastuzumab Resistance in HER2 Amplified Breast Cancers. Molecular and Cellular Proteomics, 2013, 12, 180-193.	2.5	42
1299	A Receptor Tyrosine Kinase Network Composed of Fibroblast Growth Factor Receptors, Epidermal Growth Factor Receptor, v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 2, and Hepatocyte Growth Factor Receptor Drives Growth and Survival of Head and Neck Squamous Carcinoma Cell Lines. Molecular Pharmacology, 2013, 83, 882-893.	1.0	41
1300	Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index. Science Translational Medicine, 2013, 5, 207ra144.	5.8	211
1303	Anticancer Activity of Pristimerin in Epidermal Growth Factor Receptor 2-Positive SKBR3 Human Breast Cancer Cells. Biological and Pharmaceutical Bulletin, 2013, 36, 316-325.	0.6	41
1304	ErbB3-binding protein EBP1 decreases ErbB2 levels via a transcriptional mechanism. Oncology Reports, 2013, 29, 1161-1166.	1.2	13

#	Article	IF	Citations
1305	Targeted therapy in HER2-positive breast cancer. Biomedical Reports, 2013, 1, 499-505.	0.9	47
1306	Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts. Oncology Reports, 2013, 29, 260-268.	1.2	21
1307	Spheroid Culture of Primary Lung Cancer Cells with Neuregulin 1/HER3 Pathway Activation. Journal of Thoracic Oncology, 2013, 8, 131-139.	0.5	86
1308	Predictive Biomarkers for Epidermal Growth Factor Receptor Agents in Non-Small Cell Lung Cancer. , 2013, , 155-182.		0
1309	Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer. , 2013, , 183-232.		0
1310	Challenges in clinical trial design for recurrent glioblastoma. Clinical Investigation, 2013, 3, 835-848.	0.0	3
1311	Suppression of HER-2 via siRNA interference promotes apoptosis and decreases metastatic potential of SKOV-3 human ovarian carcinoma cells. Oncology Reports, 2013, 29, 1133-1139.	1.2	7
1312	Targeting HER Receptors in Cancer. Current Pharmaceutical Design, 2013, 19, 808-817.	0.9	39
1313	Afatinib after Disease Progression with Gefitinib in Advanced Adenocarcinoma of the Lung. Journal of Pharmacy Practice and Research, 2013, 43, 137-139.	0.5	1
1314	Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family. ELife, 2013, 2, e00708.	2.8	62
1315	Optimization of Substituted 6-Salicyl-4-Anilinoquinazoline Derivatives as Dual EGFR/HER2 Tyrosine Kinase Inhibitors. PLoS ONE, 2013, 8, e69427.	1.1	14
1316	Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells. Oncology Reports, 2013, 29, 1975-1982.	1.2	38
1318	Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 161-169.	2.3	64
1319	The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells. Science Signaling, 2013, 6, ra66.	1.6	236
1320	Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model. Journal of Cancer, 2013, 4, 557-565.	1.2	20
1321	Sex Disparities in the Association of Lung Adenocarcinoma with Colorectal Cancer. Journal of Cancer, 2013, 4, 691-696.	1.2	1
1322	Clinical Relevance of EGFR Mutations in Colorectal Cancer Patients. The Ewha Medical Journal, 2013, 36, 51.	0.1	0
1323	Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond. Lung Cancer: Targets and Therapy, 2013, 4, 43.	1.3	3

#	Article	IF	Citations
1324	Targeting the EGFR family of receptor tyrosine kinases. , 0, , 843-853.		0
1325	NOV-002, A Glutathione Disulfide Mimetic, Suppresses Tumor Cell Invasion and Metastasis. Journal of Carcinogenesis & Mutagenesis, 2013, 2013, .	0.3	9
1326	Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab. PLoS ONE, 2013, 8, e56112.	1.1	32
1327	A Comprehensive, Multi-Scale Dynamical Model of ErbB Receptor Signal Transduction in Human Mammary Epithelial Cells. PLoS ONE, 2013, 8, e61757.	1.1	42
1328	Reconstruction of an Integrated Genome-Scale Co-Expression Network Reveals Key Modules Involved in Lung Adenocarcinoma. PLoS ONE, 2013, 8, e67552.	1.1	99
1329	Magnetic Nanoparticles as Mediators of Ligand-Free Activation of EGFR Signaling. PLoS ONE, 2013, 8, e68879.	1.1	30
1330	Genetic Variants in Epidermal Growth Factor Receptor Pathway Genes and Risk of Esophageal Squamous Cell Carcinoma and Gastric Cancer in a Chinese Population. PLoS ONE, 2013, 8, e68999.	1.1	17
1331	Combination of mTOR and EGFR Kinase Inhibitors Blocks mTORC1 and mTORC2 Kinase Activity and Suppresses the Progression of Colorectal Carcinoma. PLoS ONE, 2013, 8, e73175.	1.1	17
1332	Dmp1Î± Inhibits HER2/neu-Induced Mammary Tumorigenesis. PLoS ONE, 2013, 8, e77870.	1.1	23
1333	Role of PKCÎ± Activation of Src, PI-3K/AKT, and ERK in EGF-Stimulated Proliferation of Rat and Human Conjunctival Goblet Cells. , 2013, 54, 5661.		33
1334	The Tumor Microenvironment Contribution to Development, Growth, Invasion and Metastasis of Head and Neck Squamous Cell Carcinomas. Journal of Cancer, 2013, 4, 66-83.	1.2	262
1335	Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives. Frontiers in Pharmacology, 2013, 4, 15.	1.6	50
1336	Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells. Current Medicinal Chemistry, 2013, 20, 1923-1945.	1.2	86
1337	HER1R497K andHER2I655V Polymorphisms Are Linked to Development of Breast Cancer. Disease Markers, 2013, 34, 407-417.	0.6	13
1338	In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features. Drug Design, Development and Therapy, 2013, 7, 789.	2.0	15
1339	MIG-6 and SPRY2 in the Regulation of Receptor Tyrosine Kinase Signaling: Balancing Act via Negative Feedback Loops. , 0, , .		1
1340	Targeted therapies in breast cancer. , 0, , 598-605.		0
1341	Phosphoproteomics for the Mapping of Altered Cell Signaling Networks in Breast Cancer. , 0, , .		1

#	Article	IF	Citations
1343	SKLB-287, aâ€¯novel oral multikinase inhibitor of EGFR and VEGFR2, exhibits potent antitumor activity in LoVo colorectal tumor model. Neoplasma, 2014, 62, 514-522.	0.7	0
1344	Expression of Signaling Components in Embryonic Eyelid Epithelium. PLoS ONE, 2014, 9, e87038.	1.1	5
1345	Quantification and Kinetic Analysis of Grb2-EGFR Interaction on Micro-Patterned Surfaces for the Characterization of EGFR-Modulating Substances. PLoS ONE, 2014, 9, e92151.	1.1	42
1346	ERBB2 Increases Metastatic Potentials Specifically in Androgen-Insensitive Prostate Cancer Cells. PLoS ONE, 2014, 9, e99525.	1.1	19
1347	EGFR-Targeted TRAIL and a Smac Mimetic Synergize to Overcome Apoptosis Resistance in KRAS Mutant Colorectal Cancer Cells. PLoS ONE, 2014, 9, e107165.	1.1	27
1348	Soluble LRIG2 Ectodomain Is Released from Glioblastoma Cells and Promotes the Proliferation and Inhibits the Apoptosis of Glioblastoma Cells In Vitro and In Vivo in a Similar Manner to the Full-Length LRIG2. PLoS ONE, 2014, 9, e111419.	1.1	23
1349	Amelioration of Hypercholesterolemia by an EGFR Tyrosine Kinase Inhibitor in Mice with Liver-Specific Knockout of Mig-6. PLoS ONE, 2014, 9, e114782.	1.1	17
1350	The Application of the Open Pharmacological Concepts Triple Store (Open PHACTS) to Support Drug Discovery Research. PLoS ONE, 2014, 9, e115460.	1.1	31
1351	ErbB4 as a Potential Molecular Target in the Treatment of Esophageal Squamous Cell Cancers. Scientific World Journal, The, 2014, 2014, 1-9.	0.8	7
1352	Emerging Biological Treatments for Uterine Cervical Carcinoma. Journal of Cancer, 2014, 5, 86-97.	1.2	51
1353	Targeted Radionuclide Therapy with A ¹⁷⁷Lu-labeled Anti-HER2 Nanobody. Theranostics, 2014, 4, 708-720.	4.6	165
1354	Anticancer Effects of Different Seaweeds on Human Colon and Breast Cancers. Marine Drugs, 2014, 12, 4898-4911.	2.2	103
1355	EGF and EGFR genetic polymorphisms predict prognosis in locally advanced pharyngolaryngeal squamous cell carcinoma patients receiving postoperative concurrent chemoradiotherapy. OncoTargets and Therapy, 2014, 7, 2197.	1.0	12
1356	Assessing the role of the EGF receptor in the development and progression of pancreatic cancer. Gastrointestinal Cancer: Targets and Therapy, 2014, , 23.	5.5	3
1357	Regulation of ERBB3/HER3 signaling in cancer. Oncotarget, 2014, 5, 10222-10236.	0.8	90
1358	Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer. Wspolczesna Onkologia, 2014, 2, 95-99.	0.7	2
1359	Potential Roles of mTOR and Protein Degradation Pathways in the Phenotypic Expression of Feed Efficiency in Broilers. Biochemistry & Physiology, 2014, 03, .	0.2	4
1360	Tocotrienols in Pancreatic Cancer Treatment and Prevention. , 2014, , 247-254.		0

#	Article	IF	Citations
1361	Immunohistochemical and Fluorescence In Situ Hybridization Analysis of Angiosarcoma of Soft Tissue and Bone Including those Occurring in Unusual Backgrounds. , 2014, 04, .		0
1362	Crosstalk between Oxidative Stress Signaling and HER2 Pathway in Breast Cancer. American Journal of Immunology, 2014, 10, 176-182.	0.1	3
1363	Understanding nano-bio interactions to improve nanocarriers for drug delivery. MRS Bulletin, 2014, 39, 227-237.	1.7	50
1364	Impact ofERBB2mutations on in vitro sensitivity of bladder cancer to lapatinib. Cancer Biology and Therapy, 2014, 15, 1239-1247.	1.5	30
1365	Different Epidermal Growth Factor (EGF) Receptor Ligands Show Distinct Kinetics and Biased or Partial Agonism for Homodimer and Heterodimer Formation. Journal of Biological Chemistry, 2014, 289, 26178-26188.	1.6	95
1366	Cancer Therapyâ€"Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies. Journal of the American Heart Association, 2014, 3, e000665.	1.6	221
1367	Involvement of de novo synthesized palmitate and mitochondrial EGFR in EGF induced mitochondrial fusion of cancer cells. Cell Cycle, 2014, 13, 2415-2430.	1.3	47
1368	Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC. Diagnostic Pathology, 2014, 9, 165.	0.9	17
1369	Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy. Breast Cancer Research and Treatment, 2014, 148, 563-570.	1.1	14
1370	Role of erbB3 receptors in cancer therapeutic resistance. Acta Biochimica Et Biophysica Sinica, 2014, 46, 190-198.	0.9	37
1371	Identification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growth. Cell Death and Disease, 2014, 5, e1211-e1211.	2.7	22
1372	Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death and Disease, 2014, 5, e1018-e1018.	2.7	160
1373	Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. British Journal of Cancer, 2014, 110, 2716-2727.	2.9	54
1374	Enhanced Prediction of Src Homology 2 (SH2) Domain Binding Potentials Using a Fluorescence Polarization-derived c-Met, c-Kit, ErbB, and Androgen Receptor Interactome. Molecular and Cellular Proteomics, 2014, 13, 1705-1723.	2.5	16
1375	Current Vaccine Trials in Glioblastoma: A Review. Journal of Immunology Research, 2014, 2014, 1-10.	0.9	65
1376	ErbB Receptors as Prognostic and Therapeutic Drug Targets in Bone and Soft Tissue Sarcomas. Cancer Investigation, 2014, 32, 533-542.	0.6	3
1377	Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer. Frontiers in Oncology, 2014, 4, 360.	1.3	70
1378	Trichostatin A Suppresses EGFR Expression through Induction of MicroRNA-7 in an HDAC-Independent Manner in Lapatinib-Treated Cells. BioMed Research International, 2014, 2014, 1-11.	0.9	17

#	Article	IF	Citations
1379	Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies. Colorectal Cancer, 2014, 3, 223-232.	0.8	1
1380	Screening and identification of small molecule inhibitors ofÂErbB2â€induced invasion. Molecular Oncology, 2014, 8, 1703-1718.	2.1	13
1381	Î±-eleostearic acid inhibits growth and induces apoptosis in breast cancer cells via HER2/HER3 signaling. Molecular Medicine Reports, 2014, 9, 993-998.	1.1	15
1382	Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecologic Oncology, 2014, 135, 142-148.	0.6	29
1383	Cetuximab Reduces the Accumulation of Radiolabeled Bevacizumab in Cancer Xenografts without Decreasing VEGF Expression. Molecular Pharmaceutics, 2014, 11, 4249-4257.	2.3	8
1384	Lung Injury and Lung Cancer Caused by Cigarette Smoke-Induced Oxidative Stress: Molecular Mechanisms and Therapeutic Opportunities Involving the Ceramide-Generating Machinery and Epidermal Growth Factor Receptor. Antioxidants and Redox Signaling, 2014, 21, 2149-2174.	2.5	83
1385	Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours. British Journal of Cancer, 2014, 111, 894-902.	2.9	28
1386	A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles. Journal of Medicinal Chemistry, 2014, 57, 9889-9900.	2.9	55
1387	A phase 2 trial of dacomitinib (PFâ€00299804), an oral, irreversible panâ€HER (human epidermal growth) Tj ETQq0 0 0 rgBT /Overlock 1 prior chemotherapy and erlotinib. Cancer, 2014, 120, 1145-1154.	2.0	125
1388	Crucial involvement of the CCL3-CCR5 axis-mediated fibroblast accumulation in colitis-associated carcinogenesis in mice. International Journal of Cancer, 2014, 135, 1297-1306.	2.3	65
1389	In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells. Cell Proliferation, 2014, 47, 435-447.	2.4	22
1390	PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. Molecular Cancer, 2014, 13, 157.	7.9	38
1391	Humanization of the mouse mammary gland by replacement of the luminal layer with genetically-engineered preneoplastic human cells. Breast Cancer Research, 2014, 16, 504.	2.2	13
1392	Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer. Clinical Cancer Research, 2014, 20, 4240-4250.	3.2	102
1393	Integrative analysis of high-throughput RNAi screen data identifies the FER and CRKL tyrosine kinases as new regulators of the mitogenic ERK-dependent pathways in transformed cells. BMC Genomics, 2014, 15, 1169.	1.2	5
1394	CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. Journal of Cell Biology, 2014, 204, 713-727.	2.3	64
1395	Dual Inhibition of Phosphatidylinositol 3â€²-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach for Mucinous Adenocarcinoma of the Ovary. International Journal of Gynecological Cancer, 2014, 24, 444-453.	1.2	19
1396	Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 126-130.	0.6	6

#	Article	IF	Citations
1397	Meta-Analysis of First-Line Therapies in Advanced Nonâ€“Small-Cell Lung Cancer Harboring EGFR-Activating Mutations. Journal of Thoracic Oncology, 2014, 9, 805-811.	0.5	78
1398	FHIT, EGFR, and MSH2. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 275-283.	0.6	4
1399	Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man. Xenobiotica, 2014, 44, 1083-1098.	0.5	4
1400	ErbB2 upregulates the Na⁺,HCO₃^{â€}â€cotransporter NBCn1/SLC4A7in human breast cancer cellsviaAkt, ERK, Src, and KrÃ¼ppelâ€like factor 4. FASEB Journal, 2014, 28, 350-363.	0.2	41
1401	Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RASâ€“ERK Signaling. Cancer Discovery, 2014, 4, 334-347.	7.7	169
1402	EGFR Inhibitors as Therapeutic Agents in Head and Neck Cancer. , 2014, , 55-90.		3
1403	Erlotinib. Recent Results in Cancer Research, 2014, 201, 109-123.	1.8	13
1404	Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers. Cells, 2014, 3, 304-330.	1.8	153
1405	Systems Molecular Imaging: Right Around the Corner. Nano Biomedicine and Engineering, 2014, 6, .	0.3	1
1406	NSCLC and HER2: Between Lights and Shadows. Journal of Thoracic Oncology, 2014, 9, 1750-1762.	0.5	62
1407	Engineering a single ubiquitin ligase for the selective degradation of all activated ErbB receptor tyrosine kinases. Oncogene, 2014, 33, 986-995.	2.6	13
1408	Rapid and sensitive phenotypic marker detection on breast cancer cells using surface-enhanced Raman scattering (SERS) imaging. Biosensors and Bioelectronics, 2014, 51, 238-243.	5.3	179
1409	HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4). Cellular Signalling, 2014, 26, 70-82.	1.7	17
1410	Fabrication of a highly sensitive disposable immunosensor based on indium tin oxide substrates for cancer biomarker detection. Analytical Biochemistry, 2014, 446, 9-18.	1.1	40
1411	Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 1: Erlotinib analogs. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 884-887.	1.0	26
1412	Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited?. Targeted Oncology, 2014, 9, 171-175.	1.7	5
1413	Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene, 2014, 33, 3422-3431.	2.6	94
1414	Prevalence, Clinicopathologic Characteristics, and Molecular Associations of EGFR Exon 20 Insertion Mutations in East Asian Patients with Lung Adenocarcinoma. Annals of Surgical Oncology, 2014, 21, 490-496.	0.7	25

#	Article	IF	Citations
1415	Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. Cancer and Metastasis Reviews, 2014, 33, 295-307.	2.7	5
1416	Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors. Endocrine, 2014, 46, 318-327.	1.1	69
1417	Overexpression of HER-2/neu protein attenuates the oxidative systemic profile in women diagnosed with breast cancer. Tumor Biology, 2014, 35, 3025-3034.	0.8	29
1418	Gelâ€“Liposomeâ€Mediated Coâ€Delivery of Anticancer Membraneâ€Associated Proteins and Smallâ€Molecule Drugs for Enhanced Therapeutic Efficacy. Advanced Functional Materials, 2014, 24, 2295-2304.	7.8	252
1419	Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. Journal of Experimental and Clinical Cancer Research, 2014, 33, 15.	3.5	33
1420	Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. Investigational New Drugs, 2014, 32, 145-153.	1.2	23
1422	Upregulation of miR-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targeting PPP2R2A. Tumor Biology, 2014, 35, 631-640.	0.8	69
1423	Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer. International Journal of Clinical Oncology, 2014, 19, 303-311.	1.0	22
1424	Novel thiazole derivatives: a patent review (2008 â€“ 2012; Part 1). Expert Opinion on Therapeutic Patents, 2014, 24, 201-216.	2.4	42
1425	The role of mitochondria in the oncogenic signal transduction. International Journal of Biochemistry and Cell Biology, 2014, 48, 11-17.	1.2	43
1426	Enhanced PI3K p110Î± Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110Î±-Selective PI3K Inhibitor. Molecular Cancer Therapeutics, 2014, 13, 60-70.	1.9	34
1427	Anthocyanins in Vascular Diseases. , 2014, , 923-941.		5
1428	Molecular Testing in Cancer. , 2014, , .		2
1429	Genomics-Based Cancer Theranostics. , 2014, , 9-20.		1
1430	ErbB2 Activation Upregulates Glutaminase 1 Expression Which Promotes Breast Cancer Cell Proliferation. Journal of Cellular Biochemistry, 2014, 115, 498-509.	1.2	75
1431	Epidermal growth factor receptor inhibitors: a patent review (2010 â€“ present). Expert Opinion on Therapeutic Patents, 2014, 24, 309-321.	2.4	15
1432	Biologically Driven Synthesis of Pyrazolo[3,4-d]pyrimidines As Protein Kinase Inhibitors: An Old Scaffold As a New Tool for Medicinal Chemistry and Chemical Biology Studies. Chemical Reviews, 2014, 114, 7189-7238.	23.0	116
1433	Development of anticancer drugs based on the hallmarks of tumor cells. Tumor Biology, 2014, 35, 3981-3995.	0.8	29

#	Article	IF	Citations
1434	erbB3 Is an Active Tyrosine Kinase Capable of Homo- and Heterointeractions. Molecular and Cellular Biology, 2014, 34, 965-977.	1.1	83
1435	New Treatment Options for Lung Adenocarcinoma - in View of Molecular Background. Pathology and Oncology Research, 2014, 20, 11-25.	0.9	44
1436	Bioengineered Bacterial Outer Membrane Vesicles as Cell-Specific Drug-Delivery Vehicles for Cancer Therapy. ACS Nano, 2014, 8, 1525-1537.	7.3	373
1437	Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer. American Journal of Health-System Pharmacy, 2014, 71, 1933-1938.	0.5	16
1438	Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: Chemoprevention of hepatocellular carcinoma using acyclic retinoid and branchedâ€chain amino acids. Molecular Nutrition and Food Research, 2014, 58, 124-135.	1.5	8
1439	Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis. Cancer Treatment Reviews, 2014, 40, 1221-1229.	3.4	26
1440	Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer. Current Colorectal Cancer Reports, 2014, 10, 279-287.	1.0	0
1441	Upregulation of the PI3K/Akt Pathway in the Tumorigenesis of Canine Thyroid Carcinoma. Journal of Veterinary Internal Medicine, 2014, 28, 1814-1823.	0.6	32
1442	Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3957-65.	3.3	33
1443	Regulation of EGFR nanocluster formation by ionic protein-lipid interaction. Cell Research, 2014, 24, 959-976.	5.7	109
1444	Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis. Cancer Treatment Reviews, 2014, 40, 1048-1055.	3.4	34
1445	Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 353-365.	3.3	30
1446	Pharmacological targeting of the pseudokinase Her3. Nature Chemical Biology, 2014, 10, 1006-1012.	3.9	161
1447	Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling. Journal of Nuclear Medicine, 2014, 55, 650-656.	2.8	77
1448	NF-ÎºB Activation-Induced Anti-apoptosis Renders HER2-Positive Cells Drug Resistant and Accelerates Tumor Growth. Molecular Cancer Research, 2014, 12, 408-420.	1.5	38
1450	Characterization of N- and C-termini of HER2 protein by mass spectrometry-based sequencing: Observation of two types of N-terminal sequence. International Journal of Mass Spectrometry, 2014, 373, 81-87.	0.7	2
1451	Therapeutic potential of siRNA and DNAzymes in cancer. Tumor Biology, 2014, 35, 9505-9521.	0.8	29
1452	Plakophilin-2 Promotes Tumor Development by Enhancing Ligand-Dependent and -Independent Epidermal Growth Factor Receptor Dimerization and Activation. Molecular and Cellular Biology, 2014, 34, 3843-3854.	1.1	34

#	Article	IF	Citations
1453	High-Throughput Screening System To Identify Small Molecules That Induce Internalization and Degradation of HER2. ACS Chemical Biology, 2014, 9, 2237-2241.	1.6	9
1454	Blockade of epidermal growth factor receptor/mammalian target of rapamycin pathway by Icariside II results in reduced cell proliferation of osteosarcoma cells. Food and Chemical Toxicology, 2014, 73, 7-16.	1.8	38
1455	Cellular Uptake and Intracellular Trafficking of Oligonucleotides: Implications for Oligonucleotide Pharmacology. Nucleic Acid Therapeutics, 2014, 24, 101-113.	2.0	99
1456	Crosstalk between Epithelial and Mesenchymal Tissues in Tumorigenesis and Imaginal Disc Development. Current Biology, 2014, 24, 1476-1484.	1.8	44
1457	Somatic alterations as the basis for resistance to targeted therapies. Journal of Pathology, 2014, 232, 244-254.	2.1	31
1458	Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes and Diseases, 2014, 1, 75-86.	1.5	78
1459	Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles. Journal of Controlled Release, 2014, 192, 114-121.	4.8	102
1460	The prognostic value of HER-2/neu overexpression in colorectal cancer: evidence from 16 studies. Tumor Biology, 2014, 35, 10799-10804.	0.8	10
1461	Design and Applications of Bispecific Heterodimers: Molecular Imaging and beyond. Molecular Pharmaceutics, 2014, 11, 1750-1761.	2.3	31
1462	Hypothalamic mTOR: The Rookie Energy Sensor. Current Molecular Medicine, 2014, 14, 3-21.	0.6	82
1463	Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway. Journal of Nutritional Biochemistry, 2014, 25, 1132-1139.	1.9	107
1464	Understanding the Pathobiology of Head and Neck Squamous Cell Carcinoma. Current Oral Health Reports, 2014, 1, 196-203.	0.5	2
1465	Clinicopathological features and EGFR gene mutation status in elderly patients with resected nonâ€“small-cell lung cancer. BMC Cancer, 2014, 14, 610.	1.1	23
1466	Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Molecular Cancer, 2014, 13, 141.	7.9	24
1467	ERÎ² Regulates NSCLC Phenotypes by Controlling Oncogenic RAS Signaling. Molecular Cancer Research, 2014, 12, 843-854.	1.5	14
1468	Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. Journal of Molecular Medicine, 2014, 92, 709-722.	1.7	75
1469	A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer. Journal of Molecular Medicine, 2014, 92, 969-981.	1.7	16
1470	Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 575-581.	1.4	10

#	Article	IF	Citations
1471	Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer. Investigational New Drugs, 2014, 32, 946-954.	1.2	10
1472	International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands. Pharmacological Reviews, 2014, 66, 918-947.	7.1	189
1473	Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. Breast Cancer Research, 2014, 16, R15.	2.2	31
1474	Targeting the Tumor Microenvironment with Interferon-Î² Bridges Innate and Adaptive Immune Responses. Cancer Cell, 2014, 25, 37-48.	7.7	236
1475	Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling. Oncogene, 2014, 33, 4531-4536.	2.6	94
1476	CD74â€“NRG1 Fusions in Lung Adenocarcinoma. Cancer Discovery, 2014, 4, 415-422.	7.7	238
1477	Neuregulin-ErbB4 signaling in the developing lung alveolus: a brief review. Journal of Cell Communication and Signaling, 2014, 8, 105-111.	1.8	9
1478	Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer. Current Breast Cancer Reports, 2014, 6, 96-109.	0.5	36
1479	HER2 expression in primary gastric cancers and paired synchronous lymph node and liver metastases. A possible road to target HER2 with radionuclides. Tumor Biology, 2014, 35, 6319-6326.	0.8	5
1480	Extracellular signal-regulated kinase (ERK) expression and activation in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. Tumor Biology, 2014, 35, 6455-6465.	0.8	15
1481	Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies. Tumor Biology, 2014, 35, 8939-8943.	0.8	14
1482	Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR. BMC Complementary and Alternative Medicine, 2014, 14, 165.	3.7	20
1483	Anticancer activity of cationic porphyrins in melanoma tumour-bearing mice and mechanistic in vitro studies. Molecular Cancer, 2014, 13, 75.	7.9	72
1484	Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation. Cancer Discovery, 2014, 4, 186-199.	7.7	103
1485	n-3 polyunsaturated fatty acids and HER2-positive breast cancer: Interest of the fat-1 transgenic mouse model over conventional dietary supplementation. Biochimie, 2014, 96, 22-27.	1.3	10
1486	Concurrent Expression of Cyclo-oxygenase-2 and Epidermal Growth Factor Receptor in Canine Malignant Mammary Tumours. Journal of Comparative Pathology, 2014, 150, 27-34.	0.1	20
1487	Epigallocatechin 3-O-gallate Induces 67 kDa Laminin Receptor-Mediated Cell Death Accompanied by Downregulation of ErbB Proteins and Altered Lipid Raft Clustering in Mammary and Epidermoid Carcinoma Cells. Journal of Natural Products, 2014, 77, 250-257.	1.5	14
1488	A bispecific transmembrane antibody simultaneously targeting intraâ€•and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth. International Journal of Cancer, 2014, 134, 2547-2559.	2.3	3

#	Article	IF	Citations
1489	Flotillin depletion affects ErbB protein levels in different human breast cancer cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 1987-1996.	1.9	22
1490	Heparin-binding epidermal growth factor-like growth factor (HB-EGF) and proteolytic processing by a disintegrin and metalloproteinases (ADAM): A regulator of several pathways. Seminars in Cell and Developmental Biology, 2014, 28, 22-30.	2.3	61
1491	Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Respiratory Investigation, 2014, 52, 82-91.	0.9	31
1492	EGFR expression in vulvar cancer: clinical implications and tumor heterogeneity. Human Pathology, 2014, 45, 917-925.	1.1	16
1493	Tumor cell membrane-targeting pH-dependent electron donor-acceptor fluorescence systems with low background signals. Biomaterials, 2014, 35, 2952-2960.	5.7	16
1494	Role of Epidermal Growth Factor Receptor Signaling in the Interaction of Neisseria meningitidis with Endothelial Cells. Infection and Immunity, 2014, 82, 1243-1255.	1.0	29
1495	Epidermal Growth Factor Receptor Inhibition Slows Progression of Diabetic Nephropathy in Association With a Decrease in Endoplasmic Reticulum Stress and an Increase in Autophagy. Diabetes, 2014, 63, 2063-2072.	0.3	122
1496	Targeted therapy for gastric cancer: Molecular pathways and ongoing investigations. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 232-237.	3.3	59
1497	Engineered Affibodies in Translational Medicine. , 2014, , 317-342.		0
1498	Short Linear Motifs: Ubiquitous and Functionally Diverse Protein Interaction Modules Directing Cell Regulation. Chemical Reviews, 2014, 114, 6733-6778.	23.0	389
1499	Extracellular Signal-Regulated Kinase 5 and Cyclic AMP Response Element Binding Protein Are Novel Pathways Inhibited by Vandetanib (ZD6474) and Doxorubicin in Mesotheliomas. American Journal of Respiratory Cell and Molecular Biology, 2014, 51, 595-603.	1.4	10
1501	Phage selection of bicyclic peptides binding Her2. Tetrahedron, 2014, 70, 7733-7739.	1.0	27
1502	Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. European Journal of Cancer, 2014, 50, 1855-1863.	1.3	46
1503	Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy. Neoplasia, 2014, 16, 301-318.	2.3	28
1504	Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling. Oncogene, 2014, 33, 225-235.	2.6	81
1505	1,4-Naphthoquinones: From Oxidative Damage to Cellular and Inter-Cellular Signaling. Molecules, 2014, 19, 14902-14918.	1.7	175
1506	Efficacy of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Patients with/without EGFR-Mutation: Evidence Based on Recent Phase III Randomized Trials. Medical Science Monitor, 2014, 20, 2666-2676.	0.5	18
1507	Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer. Molecules, 2014, 19, 15196-15212.	1.7	76

#	Article	IF	Citations
1512	Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review). Molecular and Clinical Oncology, 2014, 2, 647-655.	0.4	26
1513	MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine. Oncology Reports, 2014, 32, 121-130.	1.2	5
1514	Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity. International Journal of Oncology, 2014, 45, 1583-1593.	1.4	12
1515	Transphosphorylation of EGFR at Y845 plays an important role in its autophosphorylation and kinase activity. Oncology Reports, 2014, 31, 2393-2398.	1.2	10
1516	In vitro modeling of HER2-targeting therapy in disseminated prostate cancer. International Journal of Oncology, 2014, 45, 2153-2158.	1.4	8
1517	Inorganic Nanopreparations for Nanomedicine. Frontiers in Nanobiomedical Research, 2014, , 367-401.	0.1	0
1518	Regulation of fibrin-mediated tumor cell adhesion to the endothelium using anti-thrombin aptamer. Experimental Cell Research, 2015, 339, 417-426.	1.2	6
1519	Towards manageable toxicities from targeted lung cancer treatment. Lung Cancer Management, 2015, 4, 279-287.	1.5	0
1520	HCRP-1 regulates cell migration and invasion via EGFR-ERK mediated up-regulation of MMP-2 with prognostic significance in human renal cell carcinoma. Scientific Reports, 2015, 5, 13470.	1.6	23
1521	A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer. International Journal of Oncology, 2015, 46, 497-504.	1.4	29
1522	Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15043.	1.8	19
1523	Co-modulation analysis of gene regulation in breast cancer reveals complex interplay between ESR1 and ERBB2 genes. BMC Genomics, 2015, 16, S19.	1.2	7
1524	Sulforaphane attenuates EGFR signaling in NSCLC cells. Journal of Biomedical Science, 2015, 22, 38.	2.6	31
1525	Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis. Diagnostic Pathology, 2015, 10, 144.	0.9	18
1526	Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies. Journal of Cellular Biochemistry, 2015, 116, 1837-1847.	1.2	22
1527	HER family Receptor Expression and Prognosis in Pancreatic Cancer. International Journal of Biological Markers, 2015, 30, 327-332.	0.7	9
1528	Anterior Gradient 2 is Correlated with EGFR Mutation in Lung Adenocarcinoma Tissues. International Journal of Biological Markers, 2015, 30, 234-242.	0.7	4
1529	Rapid Determination of the Specificity Constant of Irreversible Inhibitors (k_{inact}/K_I) by Means of an Endpoint Competition Assay. Angewandte Chemie - International Edition, 2015, 54, 14099-14102.	7.2	42

#	Article	IF	Citations
1531	Erbin interacts with câ€Cbl and promotes tumourigenesis and tumour growth in colorectal cancer by preventing câ€Cblâ€mediated ubiquitination and downâ€regulation of <scp>EGFR</scp>. Journal of Pathology, 2015, 236, 65-77.	2.1	34
1532	Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization. Clinical and Experimental Ophthalmology, 2015, 43, 449-457.	1.3	12
1533	Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. OncoTargets and Therapy, 2016, 9, 75.	1.0	5
1534	Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2. OncoTargets and Therapy, 2015, 8, 2577.	1.0	3
1535	The distinctive nature of adenocarcinoma of the lung. OncoTargets and Therapy, 2015, 8, 2399.	1.0	16
1536	POTENTIAL COMPOUND DERIVED FROM CATHARANTHUS ROSEUS TO INHIBIT NON SMALL CELL LUNG CANCER (NSCLC). International Journal of Research in Ayurveda and Pharmacy, 2015, 6, 265-271.	0.0	5
1537	Relationship of EGFR DNA methylation with the severity of non-small cell lung cancer. Genetics and Molecular Research, 2015, 14, 11915-11923.	0.3	6
1538	Em08red, a dual functional antiproliferative emodin analogue, is a downregulator of ErbB2 expression and inducer of intracellular oxidative stress. Drug Design, Development and Therapy, 2015, 9, 1499.	2.0	3
1539	Molecular docking analysis of known flavonoids as duel COX-2 inhibitors in the context of cancer. Bioinformation, 2015, 11, 543-549.	0.2	14
1540	Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines, 2015, 3, 519-543.	2.1	15
1541	Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity. Antibodies, 2015, 4, 426-440.	1.2	24
1542	Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. International Journal of Molecular Sciences, 2015, 16, 19447-19457.	1.8	3
1543	Hybrid Dynamic Optimization Methods for Systems Biology with Efficient Sensitivities. Processes, 2015, 3, 701-729.	1.3	9
1544	Epiregulin as a therapeutic target in non-small-cell lung cancer. Lung Cancer: Targets and Therapy, 2015, 6, 91.	1.3	24
1545	The application of click chemistry in the synthesis of agents with anticancer activity. Drug Design, Development and Therapy, 2015, 9, 1585.	2.0	33
1546	Prospects of Molecularly-Targeted Therapies for Cervical Cancer Treatment. Current Drug Targets, 2015, 16, 77-91.	1.0	33
1547	ERBB3 Positively Correlates with Intestinal Stem Cell Markers but Marks a Distinct Non Proliferative Cell Population in Colorectal Cancer. PLoS ONE, 2015, 10, e0138336.	1.1	16
1548	Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical Role. PLoS ONE, 2015, 10, e0143076.	1.1	20

#	Article	IF	Citations
1549	Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors. Drug Discoveries and Therapeutics, 2015, 9, 147-155.	0.6	10
1550	Role of Inflammation Amplifier-Induced Growth Factor Expression in the Development of Inflammatory Diseases. Critical Reviews in Immunology, 2015, 35, 365-378.	1.0	16
1551	Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. Drug Resistance Updates, 2015, 20, 12-28.	6.5	103
1552	Transcriptional changes associated with resistance to inhibitors of epidermal growth factor receptor revealed using metaanalysis. BMC Cancer, 2015, 15, 369.	1.1	4
1553	Docosahexaenoic Acid Downregulates EGF-Induced Urokinase Plasminogen Activator and Matrix Metalloproteinase 9 Expression by Inactivating EGFR/ErbB2 Signaling in SK-BR3 Breast Cancer Cells. Nutrition and Cancer, 2015, 67, 771-782.	0.9	9
1554	Molecular Interaction of a Kinase Inhibitor Midostaurin with Anticancer Drug Targets, S100A8 and EGFR: Transcriptional Profiling and Molecular Docking Study for Kidney Cancer Therapeutics. PLoS ONE, 2015, 10, e0119765.	1.1	20
1555	From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?. Journal of Steroid Biochemistry and Molecular Biology, 2015, 153, 45-53.	1.2	47
1556	The Role of ABC Multidrug Transporters in Resistance to Targeted Anticancer Kinase Inhibitors. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 209-244.	0.1	1
1557	Therapeutic Applications of Spherical Nucleic Acids. Cancer Treatment and Research, 2015, 166, 23-50.	0.2	32
1558	Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. Archives of Toxicology, 2015, 89, 1227-1240.	1.9	42
1559	Simultaneous topographic and recognition imaging of epidermal growth factor receptor (EGFR) on single human breast cancer cells. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 1988-1995.	1.4	15
1560	Genomic Applications in Head and Neck Cancers. , 2015, , 341-358.		0
1561	A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells. Cell Death and Disease, 2015, 6, e1686-e1686.	2.7	59
1562	Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. Clinical Cancer Research, 2015, 21, 3377-3383.	3.2	34
1563	Adverse skin reactions during treatment with cetuximab plus radiotherapy: Multidisciplinary approach to minimize radio-chemotherapy interruption. Journal of Dermatological Treatment, 2015, 26, 183-187.	1.1	4
1564	Epidermal growth factor receptor and <scp>AKT</scp>1 gene copy numbers by multiâ€gene fluorescence inÂsitu hybridization impact on prognosis in breast cancer. Cancer Science, 2015, 106, 642-649.	1.7	17
1565	Synthesis, characterization and biological activity of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as epidermal growth factor receptor inhibitors. Chemical Research in Chinese Universities, 2015, 31, 936-941.	1.3	4
1566	A phase I study of volasertib combined with afatinib, in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2015, 76, 843-851.	1.1	19

#	Article	IF	Citations
1567	Integrin Î±5 Suppresses the Phosphorylation of Epidermal Growth Factor Receptor and Its Cellular Signaling of Cell Proliferation via N-Glycosylation. Journal of Biological Chemistry, 2015, 290, 29345-29360.	1.6	34
1568	Gastric Cancer: New Drugs - New Strategies. Gastrointestinal Tumors, 2015, 1, 180-194.	0.3	15
1569	Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer. Journal of the National Cancer Institute, 2015, 108, djv394.	3.0	50
1570	Regulation mechanism of Fbxw7-related signaling pathways (Review). Oncology Reports, 2015, 34, 2215-2224.	1.2	23
1571	Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway. International Journal of Oncology, 2015, 47, 2165-2172.	1.4	17
1572	Personalized medicine for HER2-positive breast cancer. Breast Cancer Management, 2015, 4, 237-240.	0.2	2
1574	Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2015, 149, 321-330.	1.1	15
1575	The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype. Cancer Letters, 2015, 357, 186-195.	3.2	22
1576	Systemic Delivery of Stable siRNA-Encapsulating Lipid Vesicles: Optimization, Biodistribution, and Tumor Suppression. Molecular Pharmaceutics, 2015, 12, 610-620.	2.3	17
1577	A positive role of DBC1 in PEA3-mediated progression of estrogen receptor-negative breast cancer. Oncogene, 2015, 34, 4500-4508.	2.6	21
1578	Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma. Expert Opinion on Therapeutic Targets, 2015, 19, 795-805.	1.5	82
1579	HER2-directed therapy: current treatment options for HER2-positive breast cancer. Breast Cancer, 2015, 22, 101-116.	1.3	149
1580	Resistance to Targeted ABC Transporters in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , .	0.1	3
1581	Novel membrane-based targets â€“ Therapeutic potential in gynecological cancers. Critical Reviews in Oncology/Hematology, 2015, 93, 293-303.	2.0	0
1582	25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations. Molecular Pharmacology, 2015, 87, 766-775.	1.0	130
1583	Ten things you should know about protein kinases: <scp>IUPHAR R</scp>eview 14. British Journal of Pharmacology, 2015, 172, 2675-2700.	2.7	270
1584	Current and Future Approaches in the Management of Nonâ€“Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs. Clinical Lung Cancer, 2015, 16, 252-261.	1.1	27
1585	Enhancing tumor-specific intracellular delivering efficiency of cell-penetrating peptide by fusion with a peptide targeting to EGFR. Amino Acids, 2015, 47, 997-1006.	1.2	15

#	Article	IF	Citations
1586	BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy. Tumor Biology, 2015, 36, 4243-4252.	0.8	29
1587	Ets1 identified as a novel molecular target of RNA aptamer selected against metastatic cells for targeted delivery of nano-formulation. Oncogene, 2015, 34, 5216-5228.	2.6	33
1588	Addressing the Right Targets in Oncology. Journal of Biomolecular Screening, 2015, 20, 305-317.	2.6	14
1589	Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. Targeted Oncology, 2015, 10, 501-508.	1.7	22
1590	Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells. International Journal of Pharmaceutics, 2015, 479, 364-373.	2.6	53
1591	HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Molecular Oncology, 2015, 9, 586-600.	2.1	31
1592	Conformation-dependent binding and tumor-targeted delivery of siRNA by a designed TRBP2: Affibody fusion protein. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1455-1466.	1.7	16
1593	Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody. Cancer Chemotherapy and Pharmacology, 2015, 75, 837-850.	1.1	17
1594	Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039). Clinical Cancer Research, 2015, 21, 2932-2940.	3.2	27
1595	Textbook of Cell Signalling in Cancer. , 2015, , .		6
1596	Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro. Tumor Biology, 2015, 36, 5505-5513.	0.8	7
1597	The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling. Oncogene, 2015, 34, 1105-1115.	2.6	60
1598	Growth Factors and Tyrosine Kinase Receptors. , 2015, , 1-26.		1
1599	The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors. Cancer Biology and Therapy, 2015, 16, 1535-1547.	1.5	18
1600	Inhibition of the autocrine IL-6â€“JAK2â€“STAT3â€“calprotectin axis as targeted therapy for HR^{â^'}/HER2⁺ breast cancers. Genes and Development, 2015, 29, 1631-1648.	2.7	94
1601	Reconstitution of Functionalized Transmembrane Domains of Receptor Proteins into Biomimetic Membranes. Langmuir, 2015, 31, 9115-9124.	1.6	7
1602	Shp2 signaling suppresses senescence in Py <scp>MT</scp> â€induced mammary gland cancer in mice. EMBO Journal, 2015, 34, 1493-1508.	3.5	31
1603	Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling. Journal of Molecular Graphics and Modelling, 2015, 61, 61-84.	1.3	4

#	Article	IF	Citations
1604	VERO Stable Cell Lines Expressing Full-Length Human Epidermal Growth Factor Receptors 2 and 3: Platforms for Subtractive Phage Display. DNA and Cell Biology, 2015, 34, 573-578.	0.9	3
1605	Cancer Stratification by Molecular Imaging. International Journal of Molecular Sciences, 2015, 16, 4918-4946.	1.8	20
1606	Extracellular Molecules Involved in Cancer Cell Invasion. Cancers, 2015, 7, 238-265.	1.7	40
1607	EGFR negates the proliferative effect of oncogenic HER2 in MDA-MB-231 cells. Archives of Biochemistry and Biophysics, 2015, 575, 69-76.	1.4	7
1608	An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis. Oncogene, 2015, 34, 5971-5982.	2.6	76
1609	Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity. European Journal of Medicinal Chemistry, 2015, 102, 115-131.	2.6	26
1610	Amplified Ras-MAPK signal states correlate with accelerated EGFR internalization, cytostasis and delayed HER2 tumor onset in Fer-deficient model systems. Oncogene, 2015, 34, 4109-4117.	2.6	23
1611	Development of small molecules targeting the pseudokinase Her3. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3382-3389.	1.0	53
1612	PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer: Targets and Therapy, 2015, 7, 111.	1.0	113
1613	Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma. British Journal of Cancer, 2015, 113, 107-118.	2.9	34
1614	Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity. Clinical Cancer Research, 2015, 21, 4110-4122.	3.2	73
1615	Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells. Cancer Biology and Therapy, 2015, 16, 549-557.	1.5	14
1616	Blockade of a Key Region in the Extracellular Domain Inhibits HER2 Dimerization and Signaling. Journal of the National Cancer Institute, 2015, 107, djv090.	3.0	10
1617	A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Human Vaccines and Immunotherapeutics, 2015, 11, 1368-1386.	1.4	16
1618	LRIG3 modulates proliferation, apoptosis and invasion of glioblastoma cells as a potent tumor suppressor. Journal of the Neurological Sciences, 2015, 350, 61-68.	0.3	17
1619	Novel roles of ginsenoside Rg3 in apoptosis through downregulation of epidermal growth factor receptor. Chemico-Biological Interactions, 2015, 233, 25-34.	1.7	46
1620	Elevated Levels of StAR-Related Lipid Transfer Protein 3 Alter Cholesterol Balance and Adhesiveness of Breast Cancer Cells. American Journal of Pathology, 2015, 185, 987-1000.	1.9	68
1621	HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 645-654.	1.4	15

#	Article	IF	Citations
1622	Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab. Journal of Gastroenterology, 2015, 50, 467-479.	2.3	32
1623	Identifying Appropriate Colorectal Cancer-Associated Antigens for the Clinical Trials. Current Colorectal Cancer Reports, 2015, 11, 29-36.	1.0	6
1624	Epidermal Growth Factor Receptor Expression in Spindle Cell Carcinomas of the Head and Neck. Head and Neck Pathology, 2015, 9, 360-368.	1.3	8
1625	Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity. Breast Cancer Research, 2015, 17, 7.	2.2	14
1626	Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinibâ€resistant lung cancer growth. Molecular Carcinogenesis, 2015, 54, 322-331.	1.3	47
1627	Molecular dynamics of the asymmetric dimers of EGFR: Simulations on the active and inactive conformations of the kinase domain. Journal of Molecular Graphics and Modelling, 2015, 58, 16-29.	1.3	11
1628	Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors. Future Oncology, 2015, 11, 1259-1274.	1.1	10
1629	Anti-cancer chalcones: Structural and molecular target perspectives. European Journal of Medicinal Chemistry, 2015, 98, 69-114.	2.6	382
1630	FDA-approved small-molecule kinase inhibitors. Trends in Pharmacological Sciences, 2015, 36, 422-439.	4.0	794
1632	EPMA position paper in cancer: current overview and future perspectives. EPMA Journal, 2015, 6, 9.	3.3	86
1633	Targeting HER2 Positive Breast Cancer with Chemopreventive Agents. Current Pharmacology Reports, 2015, 1, 324-335.	1.5	22
1634	Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib. International Journal of Cancer, 2015, 137, 1446-1456.	2.3	73
1635	Production of Antibodies in Hybridoma and Non-hybridoma Cell Lines. Cell Engineering, 2015, , 65-88.	0.4	1
1636	Puberty in Mice and Rats. , 2015, , 1395-1439.		43
1637	Incidence and risk of xerosis with targeted anticancer therapies. Journal of the American Academy of Dermatology, 2015, 72, 656-667.	0.6	39
1638	EGF-mediated induction of Mcl-1 at the switch to lactation is essential for alveolar cell survival. Nature Cell Biology, 2015, 17, 365-375.	4.6	65
1639	Microscopic Scale of Cancer Systems Biology. SpringerBriefs in Systems Biology, 2015, , .	0.1	0
1640	A Paracrine Mechanism Accelerating Expansion of Human Induced Pluripotent Stem Cell-Derived Hepatic Progenitor-Like Cells. Stem Cells and Development, 2015, 24, 1691-1702.	1.1	11

#	Article	IF	Citations
1641	Screening of epidermal growth factor receptor inhibitors in natural products by capillary electrophoresis combined with high performance liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography A, 2015, 1400, 117-123.	1.8	24
1642	Au@pNIPAM SERRS Tags for Multiplex Immunophenotyping Cellular Receptors and Imaging Tumor Cells. Small, 2015, 11, 4149-4157.	5.2	72
1643	Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 665-672.	0.5	28
1644	Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. Journal of Clinical Pathology, 2015, 68, 374-380.	1.0	26
1645	Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models. Clinical Cancer Research, 2015, 21, 1106-1114.	3.2	42
1646	YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression. Oncogene, 2015, 34, 6040-6054.	2.6	91
1647	Targeting HER (ERBB) signaling in head and neck cancer: An essential update. Molecular Aspects of Medicine, 2015, 45, 74-86.	2.7	22
1648	DNAJB1 negatively regulates MIG6 to promote epidermal growth factor receptor signaling. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 2722-2730.	1.9	33
1650	Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. American Journal of Clinical Pathology, 2015, 144, 713-721.	0.4	34
1651	Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival. Molecular Cancer, 2015, 14, 138.	7.9	24
1652	Pharmacotherapy of head and neck cancer. Expert Opinion on Pharmacotherapy, 2015, 16, 2409-2422.	0.9	11
1653	Meta-analysis reveals no significant correlation between breast cancer survival and ErbB3 expression. Apmis, 2015, 123, 383-393.	0.9	2
1654	Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Failure Reviews, 2015, 20, 621-631.	1.7	40
1655	ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H1271-H1280.	1.5	85
1656	Heregulinâ€“ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells. Molecular Cancer Therapeutics, 2015, 14, 2072-2080.	1.9	7
1657	S-Nitrosylation in Cancer Cells: To Prevent or to Cause?. , 2015, , 97-109.		0
1658	What common biomarkers characterize a triple-negative profile in breast cancer?. Pathologie Et Biologie, 2015, 63, 224-229.	2.2	8
1659	Inflammation-induced desmoglein-2 ectodomain shedding compromises the mucosal barrier. Molecular Biology of the Cell, 2015, 26, 3165-3177.	0.9	45

#	Article	IF	Citations
1660	Assessment of the impact of manufacturing changes on the physicochemical properties and biological activity of Her1-ECD vaccine during product development. Vaccine, 2015, 33, 4292-4299.	1.7	3
1661	Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptorâ€"Positive Breast Cancer Model. Molecular Cancer Therapeutics, 2015, 14, 2642-2652.	1.9	23
1662	Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology. ACS Nano, 2015, 9, 9731-9740.	7.3	220
1663	A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis. Molecular Therapy, 2015, 23, 1722-1733.	3.7	31
1664	Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival. Journal of Biological Chemistry, 2015, 290, 21705-21712.	1.6	18
1665	Cancer targeted therapeutics: From molecules to drug delivery vehicles. Journal of Controlled Release, 2015, 219, 632-643.	4.8	89
1666	Interaction of CDCP1 with HER2 Enhances HER2-Driven Tumorigenesis and Promotes Trastuzumab Resistance in Breast Cancer. Cell Reports, 2015, 11, 564-576.	2.9	52
1667	Distinguishing of tumor cell-targeting peptide ligands through a color-encoding microarray. Lab on A Chip, 2015, 15, 4512-4516.	3.1	6
1668	Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant. EBioMedicine, 2015, 2, 396-405.	2.7	15
1669	Lipid rafts, KCa/ClCa/Ca2+ channel complexes and EGFR signaling: Novel targets to reduce tumor development by lipids?. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2603-2620.	1.4	59
1670	Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2015, 148, 122-131.	1.2	45
1671	Epigenetics in Breast and Prostate Cancer. Methods in Molecular Biology, 2015, 1238, 425-466.	0.4	81
1672	Evaluation of aromatic 6-substituted thienopyrimidines as scaffolds against parasites that cause trypanosomiasis, leishmaniasis, and malaria. MedChemComm, 2015, 6, 339-346.	3.5	32
1673	Nanomaterials for Theranostics: Recent Advances and Future Challenges. Chemical Reviews, 2015, 115, 327-394.	23.0	1,063
1675	Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor. Molecular Therapy, 2015, 23, 330-338.	3.7	274
1676	Synthesis and Evaluation of Salicylanilide Derivatives as Potential Epidermal Growth Factor Receptor Inhibitors. Chemical Biology and Drug Design, 2015, 85, 280-289.	1.5	4
1677	Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia. European Journal of Medicinal Chemistry, 2015, 89, 826-834.	2.6	23
1678	Survival Outcomes of Metaplastic Breast Cancer Patients: Results from a US Population-based Analysis. Annals of Surgical Oncology, 2015, 22, 24-31.	0.7	110

#	Article	IF	Citations
1679	Modulation of RTK by <scp>sE</scp>cad: a putative mechanism for oncogenicity in oropharyngeal SCCs. Oral Diseases, 2015, 21, 185-194.	1.5	0
1680	Genomic Applications in Pathology. , 2015, , .		1
1681	Epidermal growth factor receptor inhibition by anti-CD147 therapy in cutaneous squamous cell carcinoma. Head and Neck, 2016, 38, 247-252.	0.9	7
1682	Quinazoline pharmacophore in therapeutic medicine. Bangladesh Journal of Pharmacology, 2016, 11, 716.	0.1	23
1683	Role of targeted therapy in metastatic colorectal cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 642.	0.8	80
1684	Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review. International Journal of Molecular Sciences, 2016, 17, 1605.	1.8	39
1685	Loquat (Eriobotrya japonica) leaf extract inhibits the growth of MDA-MB-231 tumors in nude mouse xenografts and invasion of MDA-MB-231 cells. Nutrition Research and Practice, 2016, 10, 139.	0.7	12
1686	Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 31-38.	0.7	26
1687	Pertuzumab and trastuzumab: the rationale way to synergy. Anais Da Academia Brasileira De Ciencias, 2016, 88, 565-577.	0.3	47
1688	EGFR and HER2 signaling in breast cancer brain metastasis. Frontiers in Bioscience - Elite, 2016, 8, 245-263.	0.9	51
1689	Molecular mechanisms of peritoneal dissemination in gastric cancer. World Journal of Gastroenterology, 2016, 22, 6829.	1.4	121
1690	Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China. World Journal of Gastroenterology, 2016, 22, 5406.	1.4	21
1691	Genetic variants in ERBB4 is associated with chronic hepatitis B virus infection. Oncotarget, 2016, 7, 4981-4992.	0.8	8
1692	EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma. Journal of Gastrointestinal Oncology, 2016, 7, 838-847.	0.6	6
1693	Feature Classification and Analysis of Lung Cancer Related Genes through Gene Ontology and KEGG Pathways. Current Bioinformatics, 2016, 11, 40-50.	0.7	8
1694	A Holistic <i>In silico</i> Approach to Develop Novel Inhibitors Targeting ErbB1 and ErbB2 Kinases. Tropical Journal of Pharmaceutical Research, 2016, 15, 231.	0.2	8
1695	Lymphangioleiomyomatosis (LAM). , 2016, , 397-415.		0
1696	Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. OncoTargets and Therapy, 2016, 9, 1927.	1.0	43

#	Article	IF	Citations
1698	Septins: Regulators of Protein Stability. Frontiers in Cell and Developmental Biology, 2016, 4, 143.	1.8	6
1699	Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers. Toxins, 2016, 8, 137.	1.5	41
1700	Algorithms for Drug Sensitivity Prediction. Algorithms, 2016, 9, 77.	1.2	41
1701	EGFR Signaling in Liver Diseases. International Journal of Molecular Sciences, 2016, 17, 30.	1.8	161
1702	Induction of Apoptosis by PQ1, a Gap Junction Enhancer that Upregulates Connexin 43 and Activates the MAPK Signaling Pathway in Mammary Carcinoma Cells. International Journal of Molecular Sciences, 2016, 17, 178.	1.8	11
1703	Soluble Epidermal Growth Factor Receptors (sEGFRs) in Cancer: Biological Aspects and Clinical Relevance. International Journal of Molecular Sciences, 2016, 17, 593.	1.8	39
1704	Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer. International Journal of Molecular Sciences, 2016, 17, 1055.	1.8	27
1705	Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy. International Journal of Molecular Sciences, 2016, 17, 2008.	1.8	18
1706	Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells. BMC Veterinary Research, 2016, 12, 82.	0.7	22
1707	Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling. PLoS ONE, 2016, 11, e0146100.	1.1	15
1708	Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model. Frontiers in Pharmacology, 2016, 7, 327.	1.6	11
1709	Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. Therapeutics and Clinical Risk Management, 2016, 12, 807.	0.9	10
1710	Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. OncoTargets and Therapy, 2016, 9, 3711.	1.0	98
1711	EGFR and HER2 signaling in breast cancer brain metastasis. Frontiers in Bioscience - Elite, 2016, 8, 245-263.	0.9	30
1712	Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients. Journal of Cutaneous Pathology, 2016, 43, 211-218.	0.7	8
1713	Helioxanthin suppresses the cross talk of COX-2/PGE2 and EGFR/ERK pathway to inhibit Arecoline-induced Oral Cancer Cell (T28) proliferation and blocks tumor growth in xenografted nude mice. Environmental Toxicology, 2016, 31, 2045-2056.	2.1	10
1714	Design and Synthesis of Novel EGFR Inhibitors with <scp>L</scp>â€Rhamnoseâ€“Benzoxazinone Hybrids. Journal of Heterocyclic Chemistry, 2016, 53, 1563-1569.	1.4	1
1715	Novel Quinazoline Derivatives Bearing Various 4â€Aniline Moieties as Potent <scp>EGFR</scp> Inhibitors with Enhanced Activity Against <scp>NSCLC</scp> Cell Lines. Chemical Biology and Drug Design, 2016, 87, 635-643.	1.5	10

#	Article	IF	Citations
1716	Controllable Selfâ€Assembly of RNA Tetrahedrons with Precise Shape and Size for Cancer Targeting. Advanced Materials, 2016, 28, 7501-7507.	11.1	70
1717	Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles. Archiv Der Pharmazie, 2016, 349, 573-593.	2.1	29
1718	Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer. , 2016, 166, 71-83.		14
1719	Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas. Head and Neck, 2016, 38, E2412-8.	0.9	4
1720	Anthocyanins inhibit trastuzumab-resistant breast cancer in vitro and in vivo. Molecular Medicine Reports, 2016, 13, 4007-4013.	1.1	37
1721	HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib. Oncology Letters, 2016, 12, 5363-5369.	0.8	3
1722	Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells. Scientific Reports, 2016, 6, 37997.	1.6	31
1723	Loss of EGFR-ASAP1 signaling in metastatic and unresectable hepatoblastoma. Scientific Reports, 2016, 6, 38347.	1.6	20
1724	PHLPPing through history: a decade in the life of PHLPP phosphatases. Biochemical Society Transactions, 2016, 44, 1675-1682.	1.6	73
1725	Overexpression of HER-2 in MDA-MB-435/LCC6 Tumours is Associated with Higher Metabolic Activity and Lower Energy Stress. Scientific Reports, 2016, 6, 18537.	1.6	1
1726	Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53 deficient mammary cancers. DMM Disease Models and Mechanisms, 2016, 9, 749-57.	1.2	25
1727	EBP50 interacts with EGFR and regulates EGFR signaling to affect the prognosis of cervical cancer patients. International Journal of Oncology, 2016, 49, 1737-1745.	1.4	15
1728	Integrative regression network for genomic association study. BMC Medical Genomics, 2016, 9, 31.	0.7	8
1729	The Discovery of Dacomitinib, a Potent Irreversible EGFR Inhibitor. ACS Symposium Series, 2016, , 207-233.	0.5	6
1731	miR-148a-3p represses proliferation and EMT by establishing regulatory circuits between ERBB3/AKT2/c-myc and DNMT1 in bladder cancer. Cell Death and Disease, 2016, 7, e2503-e2503.	2.7	93
1732	Loss of CRABP-II Characterizes Human Skin Poorly Differentiated Squamous Cell Carcinomas and Favors DMBA/TPA-Induced Carcinogenesis. Journal of Investigative Dermatology, 2016, 136, 1255-1266.	0.3	11
1733	Hyperglycemic memory in metabolism and cancer. Hormone Molecular Biology and Clinical Investigation, 2016, 26, 77-85.	0.3	25
1734	Targeted agents in GI radiotherapy: Clinical efficacy and side effects. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 537-549.	1.0	5

#	Article	IF	Citations
1735	Human Epidermal Growth Factor Receptor (HER) Family Molecular Structure. , 2016, , 311-322.		0
1736	Molecular Targets in Advanced Therapeutics of Cancers: The Role of Pharmacogenetics. Oncology, 2016, 91, 3-12.	0.9	14
1737	Personalized Treatment of Breast Cancer. , 2016, , .		2
1738	MiR-374a suppresses lung adenocarcinoma cell proliferation and invasion by targetingTGFAgene expression. Carcinogenesis, 2016, 37, 567-575.	1.3	41
1739	Safety of gefitinib in non-small cell lung cancer treatment. Expert Opinion on Drug Safety, 2016, 15, 993-1000.	1.0	14
1740	Synthesis and evaluation of novel non-covalent binding quinazoline glycoside derivatives targeting the L858R and T790M variants of EGFR. RSC Advances, 2016, 6, 36857-36862.	1.7	7
1741	Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model. Clinical Lung Cancer, 2016, 17, 375-383.e2.	1.1	12
1742	Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. Oncogene, 2016, 35, 4914-4926.	2.6	63
1743	Computer-aided design, synthesis, and biological evaluation of new indole-2-carboxamide derivatives as PI3KÎ±/EGFR inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2685-2690.	1.0	27
1744	ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models. Lung Cancer, 2016, 95, 57-64.	0.9	7
1745	The role of Her2 and other oncogenes of the PI3K/AKT pathway in mitochondria. Biological Chemistry, 2016, 397, 607-615.	1.2	26
1746	Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer. Cancer Biology and Therapy, 2016, 17, 751-759.	1.5	14
1747	Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold. European Journal of Medicinal Chemistry, 2016, 120, 26-36.	2.6	36
1748	Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. Physiological Reviews, 2016, 96, 805-829.	13.1	49
1749	Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a Potent Target for Breast Cancer Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2016, 31, 85-90.	0.7	12
1750	PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2. Cell Reports, 2016, 15, 843-856.	2.9	46
1751	Neuregulin/ErbB Signaling in Developmental Myelin Formation and Nerve Repair. Current Topics in Developmental Biology, 2016, 116, 45-64.	1.0	49
1752	Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study. Oral Oncology, 2016, 62, 54-59.	0.8	14

#	Article	IF	Citations
1753	Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies. Laryngoscope, 2016, 126, E387-E395.	1.1	8
1754	Cyclin D1, cancer progression, and opportunities in cancer treatment. Journal of Molecular Medicine, 2016, 94, 1313-1326.	1.7	477
1755	Growth factors: the journey continues. Growth Factors, 2016, 34, 1-4.	0.5	3
1756	Correlation of EGFR Del 19 with Fn14/JAK/STAT signaling molecules in non-small cell lung cancer. Oncology Reports, 2016, 36, 1030-1040.	1.2	23
1757	Differences between integrin Î±5Î²1 and EGRF receptor in signal pathways controlling proliferation and apoptosis of MCF-7/Dox human breast carcinoma cells. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2016, 10, 276-282.	0.2	1
1758	Anti-proliferation effects, efficacy of cyasterone in vitro and in vivo and its mechanism. Biomedicine and Pharmacotherapy, 2016, 84, 330-339.	2.5	9
1759	13-Methyl-palmatrubine induces apoptosis and cell cycle arrest in A549 cells in vitro and in vivo. Oncology Reports, 2016, 36, 2526-2534.	1.2	15
1760	Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3Î²/Foxp3 Axis. Journal of Biological Chemistry, 2016, 291, 21085-21095.	1.6	112
1761	The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity. Current Medical Research and Opinion, 2016, 32, 1839-1848.	0.9	16
1762	Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. Journal of Medicinal Chemistry, 2016, 59, 8103-8124.	2.9	52
1763	Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 2: Gefitinib analogs. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4842-4845.	1.0	14
1764	Bloodâ€based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from <scp>CALGB</scp> 80203 (Alliance). Cancer Medicine, 2016, 5, 2249-2260.	1.3	19
1765	Meta-analysis of the incidence and risk of arterial and venous thromboembolic events associated with anti-EGFR agents in non-small-cell lung cancer patients. Expert Review of Clinical Pharmacology, 2016, 9, 1389-1395.	1.3	0
1766	Cell autonomous or systemic EGFR blockade alters the immuneâ€environment in squamous cell carcinomas. International Journal of Cancer, 2016, 139, 2593-2597.	2.3	36
1767	EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. Journal of Pathology, 2016, 239, 320-334.	2.1	73
1768	Neurological dysfunctions associated with altered <scp>BACE</scp>1â€dependent Neuregulinâ€1 signaling. Journal of Neurochemistry, 2016, 136, 234-249.	2.1	40
1769	Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. Tumor Biology, 2016, 37, 13687-13694.	0.8	37
1770	TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations. Protein Engineering, Design and Selection, 2016, 29, 467-475.	1.0	22

#	Article	IF	Citations
1771	Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis. Future Oncology, 2016, 12, 2741-2753.	1.1	8
1772	Networks and games for precision medicine. BioSystems, 2016, 150, 52-60.	0.9	7
1773	Influence maximization in time bounded network identifies transcription factors regulating perturbed pathways. Bioinformatics, 2016, 32, i128-i136.	1.8	11
1774	Addition of the p110Î± inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer. Tumor Biology, 2016, 37, 14831-14839.	0.8	6
1775	A HER2 selective theranostic agent for surgical resection guidance and photodynamic therapy. Photochemical and Photobiological Sciences, 2016, 15, 1227-1238.	1.6	14
1776	A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer. Molecular Cancer Therapeutics, 2016, 15, 2244-2250.	1.9	25
1777	Conformational Changes in the Epidermal Growth Factor Receptor: Role of the Transmembrane Domain Investigated by Coarse-Grained MetaDynamics Free Energy Calculations. Journal of the American Chemical Society, 2016, 138, 10611-10622.	6.6	103
1778	Recent progress in protein-protein interaction study for EGFR-targeted therapeutics. Expert Review of Proteomics, 2016, 13, 817-832.	1.3	11
1779	EGFR oligomerization organizes kinase-active dimers into competent signalling platforms. Nature Communications, 2016, 7, 13307.	5.8	146
1780	Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance. Scientific Reports, 2016, 6, 25468.	1.6	44
1781	Noscapine targets EGFRp-Tyr1068 to suppress the proliferation and invasion of MG63 cells. Scientific Reports, 2016, 6, 37062.	1.6	20
1782	Catechins and Its Role in Chronic Diseases. Advances in Experimental Medicine and Biology, 2016, 929, 67-90.	0.8	30
1784	Drug Discovery from Mother Nature. Advances in Experimental Medicine and Biology, 2016, , .	0.8	8
1785	CaCO3/Tetraethylenepentamineâ€“Graphene Hollow Microspheres as Biocompatible Bone Drug Carriers for Controlled Release. ACS Applied Materials & Interfaces, 2016, 8, 30027-30036.	4.0	39
1786	PA-MSHA inhibits proliferation and induces apoptosis in human non-small cell lung cancer cell lines with different genotypes. Molecular Medicine Reports, 2016, 14, 5369-5376.	1.1	6
1787	Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation. BMC Cancer, 2016, 16, 567.	1.1	34
1788	uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R. BMC Cancer, 2016, 16, 615.	1.1	26
1789	Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy. Medicine (United States), 2016, 95, e4230.	0.4	17

#	Article	IF	Citations
1790	Molecular Signaling in Benign Odontogenic Neoplasia Pathogenesis. Current Oral Health Reports, 2016, 3, 82-92.	0.5	12
1791	Prognostic value of ERBB4 expression in patients with triple negative breast cancer. BMC Cancer, 2016, 16, 138.	1.1	39
1792	Phorbol myristate acetate suppresses breast cancer cell growth via down-regulation of P-Rex1 expression. Protein and Cell, 2016, 7, 445-449.	4.8	9
1793	A Novel EGFR Extracellular Domain Mutant, EGFRÎ”768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma. Molecular Cancer Research, 2016, 14, 740-752.	1.5	8
1794	Current targeted therapies in the treatment of advanced colorectal cancer: a review. Therapeutic Advances in Medical Oncology, 2016, 8, 276-293.	1.4	72
1795	Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neuâ€“ positive advanced breast cancer: results of the CECOG LaVie trial. BMC Cancer, 2016, 16, 121.	1.1	4
1796	GLI pathogenesis-related 1 functions as a tumor-suppressor in lung cancer. Molecular Cancer, 2016, 15, 25.	7.9	20
1797	The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer. Biomarker Research, 2016, 4, 8.	2.8	6
1798	EGFR gene deregulation mechanisms in lung adenocarcinoma: A molecular review. Pathology Research and Practice, 2016, 212, 672-677.	1.0	26
1799	Epidermal growth factor receptor targeting and challenges in glioblastoma. Neuro-Oncology, 2016, 18, 914-918.	0.6	117
1800	Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR. Expert Opinion on Pharmacotherapy, 2016, 17, 193-203.	0.9	1
1801	Î“-Ionizing radiation-induced activation of the EGFRâ€“p38/ERKâ€“STAT3/CREB-1â€“EMT pathway promotes the migration/invasion of non-small cell lung cancer cells and is inhibited by podophyllotoxin acetate. Tumor Biology, 2016, 37, 7315-7325.	0.8	32
1802	Target Therapy in Lung Cancer. Advances in Experimental Medicine and Biology, 2016, 893, 127-136.	0.8	18
1804	Peptideâ€“Drug Conjugate GnRHâ€“Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth. Cancer Research, 2016, 76, 1181-1192.	0.4	24
1805	Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. Tumor Biology, 2016, 37, 127-140.	0.8	9
1806	Epiregulin Recognition Mechanisms by Anti-epiregulin Antibody 9E5. Journal of Biological Chemistry, 2016, 291, 2319-2330.	1.6	11
1807	ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. Journal of the National Cancer Institute, 2016, 108, .	3.0	282
1808	Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer. , 2016, 161, 97-110.		60

#	Article	IF	Citations
1809	Development of gelatin nanoparticles conjugated with phytohemagglutinin erythroagglutinating loaded with gemcitabine for inducing apoptosis in non-small cell lung cancer cells. Journal of Materials Chemistry B, 2016, 4, 2444-2454.	2.9	18
1810	Genomic Landscape of Esophageal Squamous Cell Carcinoma inÂa Japanese Population. Gastroenterology, 2016, 150, 1171-1182.	0.6	265
1811	Docking and molecular dynamics simulation study of EGFR1 with EGF-like peptides to understand molecular interactions. Molecular BioSystems, 2016, 12, 1987-1995.	2.9	11
1812	Emerging Molecular Targets in the Treatment of Head and Neck Squamous Cell Carcinoma. , 2016, , 163-209.		0
1813	Synthesis of Diagnostic Silicon Nanoparticles for Targeted Delivery of Thiourea to Epidermal Growth Factor Receptor-Expressing Cancer Cells. ACS Applied Materials & Interfaces, 2016, 8, 8908-8917.	4.0	22
1814	A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors. Oncogenesis, 2016, 5, e211-e211.	2.1	10
1815	Expression Profiling of Macrophages Reveals Multiple Populations with Distinct Biological Roles in an Immunocompetent Orthotopic Model of Lung Cancer. Journal of Immunology, 2016, 196, 2847-2859.	0.4	86
1816	Advances of Molecular Targeted Therapy in Gastric Cancer. Journal of Gastrointestinal Cancer, 2016, 47, 125-134.	0.6	15
1817	Preclinical Evaluation of an Epidermal Growth Factor Receptorâ€“Targeted Doxorubicinâ€“Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice. Journal of Pharmaceutical Sciences, 2016, 105, 639-649.	1.6	10
1818	Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 1495-1503.	1.4	25
1819	Targeting Oral Cancer. , 2016, , .		0
1820	Liquid chromatographyâ€“tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquidâ€“liquid extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1012-1013, 118-123.	1.2	18
1821	Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. Breast Cancer Research, 2016, 18, 26.	2.2	25
1822	Cancer Genetics in the Clinic. , 2016, , 305-336.		0
1823	Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model. Journal of Controlled Release, 2016, 231, 2-16.	4.8	45
1824	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2016, 8, 4-31.	1.4	40
1825	Cancer Stem-like Cells Act via Distinct Signaling Pathways in Promoting Late Stages of Malignant Progression. Cancer Research, 2016, 76, 1245-1259.	0.4	21
1826	A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American) Tj ETQq1 1 0.784314 rgBT /Ov	1.0	

#	Article	IF	Citations
1827	Development and evaluation of a single domain antibody against human epidermal growth factor receptor (EGFR). Protein Expression and Purification, 2016, 120, 59-64.	0.6	12
1828	Improving cancer therapies by targeting the physical and chemical hallmarks of the tumor microenvironment. Cancer Letters, 2016, 380, 330-339.	3.2	56
1829	HER2 Expression in Gastric Adenocarcinomaâ€"a Study in a Tertiary Care Centre in South India. Indian Journal of Surgical Oncology, 2016, 7, 18-24.	0.3	4
1830	Activation of the Farnesoid X-receptor in breast cancer cell lines results in cytotoxicity but not increased migration potential. Cancer Letters, 2016, 370, 250-259.	3.2	31
1831	Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR/HER-2 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 677-683.	1.0	54
1832	PI3K-p110Î± mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene, 2016, 35, 3607-3612.	2.6	38
1833	siRNA delivered by EGFR-specific scFv sensitizes EGFR-TKI-resistant human lung cancer cells. Biomaterials, 2016, 76, 196-207.	5.7	26
1834	Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90â€"EGFR association. Oncogene, 2016, 35, 3387-3398.	2.6	42
1836	Galectin-3 modulates the EGFR signalling-mediated regulation of Sox2 expression via c-Myc in lung cancer. Glycobiology, 2016, 26, 155-165.	1.3	45
1837	Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib. Oncogene, 2016, 35, 878-886.	2.6	74
1838	HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models. Clinical Cancer Research, 2017, 23, 677-686.	3.2	58
1839	WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer. Scientific Reports, 2017, 7, 40664.	1.6	36
1840	Antibodies for Treatment of Metastatic Colorectal Cancer. , 2017, , 217-244.		0
1841	Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment. Pharmacological Research, 2017, 117, 406-415.	3.1	55
1842	Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 2017, 60, 2361-2372.	2.9	43
1843	An in-silico approach to find a peptidomimetic targeting extracellular domain of HER3 from a HER3 Nanobody. Computational Biology and Chemistry, 2017, 68, 39-42.	1.1	3
1844	Novel conjugates of endoperoxide and 4-anilinoquinazoline as potential anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1341-1345.	1.0	4
1845	SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors. SAR and QSAR in Environmental Research, 2017, 28, 111-132.	1.0	5

#	Article	IF	Citations
1846	Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line. Pathology and Oncology Research, 2017, 23, 829-835.	0.9	2
1847	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood, 2017, 129, e26-e37.	0.6	195
1848	Gastric cancer: somatic genetics as a guide to therapy. Journal of Medical Genetics, 2017, 54, 305-312.	1.5	105
1849	Long-term treatment with EGFR inhibitor erlotinib attenuates renal inflammatory cytokines but not nephropathy in Alport syndrome mouse model. Clinical and Experimental Nephrology, 2017, 21, 952-960.	0.7	8
1850	Metabolomics analysis reveals aminoquinazolin derivative 9d-induced oxidative stress and cell cycle arrest in A549 cells. RSC Advances, 2017, 7, 13149-13158.	1.7	14
1851	Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution. Oncology Reports, 2017, 37, 1347-1358.	1.2	63
1852	Design, synthesis, SAR discussion, inÂvitro and inÂvivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants. European Journal of Medicinal Chemistry, 2017, 135, 12-23.	2.6	27
1853	Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer. Scientific Reports, 2017, 7, 470.	1.6	55
1854	Synthesis of BODIPY-Peptide Conjugates for Fluorescence Labeling of EGFR Overexpressing Cells. Bioconjugate Chemistry, 2017, 28, 1566-1579.	1.8	46
1855	Integrative meta-modeling identifies endocytic vesicles, late endosome and the nucleus as the cellular compartments primarily directing RTK signaling. Integrative Biology (United Kingdom), 2017, 9, 464-484.	0.6	26
1856	Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters. Molecular Pharmaceutics, 2017, 14, 2147-2157.	2.3	28
1857	Panitumumab interaction with <scp>TAS</scp>â€102 leads to combinational anticancer effects via blocking of <scp>EGFR</scp>â€mediated tumor response to trifluridine. Molecular Oncology, 2017, 11, 1065-1077.	2.1	18
1858	Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab. Oncology, 2017, 93, 51-61.	0.9	18
1859	Application of Nanosecond Laser Photolysis Protein Footprinting to Study EGFR Activation by EGF in Cells. Journal of Proteome Research, 2017, 16, 2282-2293.	1.8	21
1860	Synthesis and anticancer activity of new quinazoline derivatives. Saudi Pharmaceutical Journal, 2017, 25, 1047-1054.	1.2	55
1861	Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. Protein and Cell, 2017, 8, 896-925.	4.8	59
1862	Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer. Journal of Biological Chemistry, 2017, 292, 748-759.	1.6	28
1863	A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties. European Journal of Medicinal Chemistry, 2017, 126, 1107-1117.	2.6	31

#	Article	IF	Citations
1864	EGFR, Growth Factors. , 2017, , 707-717.		0
1865	Protein lysine methyltransferase <scp>SMYD</scp>3 is involved in tumorigenesis through regulation of <scp>HER</scp>2 homodimerization. Cancer Medicine, 2017, 6, 1665-1672.	1.3	25
1866	Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression. Nucleic Acids Research, 2017, 45, 7897-7908.	6.5	87
1867	Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor. Neuro-Oncology, 2017, 19, 1628-1639.	0.6	40
1868	Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody. Molecular Immunology, 2017, 87, 300-307.	1.0	13
1869	System analysis identifies distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer. Molecular BioSystems, 2017, 13, 1481-1494.	2.9	4
1870	Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Nonâ€“Small Cell Lung Cancer. JAMA Dermatology, 2017, 153, 906.	2.0	14
1871	Drug-biomarker co-development in oncology â€“ 20 years and counting. Drug Resistance Updates, 2017, 30, 48-62.	6.5	48
1872	Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies. Drugs, 2017, 77, 843-857.	4.9	40
1873	Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 3148-3157.	1.4	29
1874	PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. Cancer Immunology, Immunotherapy, 2017, 66, 865-876.	2.0	117
1875	Molecular biomarkers for lung adenocarcinoma. European Respiratory Journal, 2017, 49, 1601734.	3.1	110
1876	Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy. Pharmacological Research, 2017, 126, 66-76.	3.1	28
1877	Optical measurement of receptor tyrosine kinase oligomerization on live cells. Biochimica Et Biophysica Acta - Biomembranes, 2017, 1859, 1436-1444.	1.4	13
1878	ERBB signaling attenuates proinflammatory activation of nonclassical monocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 312, H907-H918.	1.5	37
1879	Chimeric antigen receptor T cells: a novel therapy for solid tumors. Journal of Hematology and Oncology, 2017, 10, 78.	6.9	232
1880	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacological Research, 2017, 120, 43-50.	3.1	43
1882	HER3 as a Therapeutic Target in Cancer. BioDrugs, 2017, 31, 63-73.	2.2	29

#	Article	IF	Citations
1883	Genomic sequencing and precision medicine in head and neck cancers. European Journal of Surgical Oncology, 2017, 43, 884-892.	0.5	12
1884	Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1107-1122.	1.2	18
1885	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. Journal of Molecular Diagnostics, 2017, 19, 244-254.	1.2	96
1887	A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors. Journal of Biological Chemistry, 2017, 292, 1288-1301.	1.6	30
1888	Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. Clinical Cancer Research, 2017, 23, 3520-3528.	3.2	19
1890	HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?. Cancer and Metastasis Reviews, 2017, 36, 141-157.	2.7	119
1891	Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant. Bioorganic and Medicinal Chemistry, 2017, 25, 6563-6580.	1.4	24
1892	Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors. European Journal of Medicinal Chemistry, 2017, 141, 84-91.	2.6	34
1893	ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy. Cancer Control, 2017, 24, 89-95.	0.7	14
1894	Regulation of the prometastatic neuregulinâ€“<scp>MMP</scp>13 axis by <scp>SRC</scp> family kinases: therapeutic implications. Molecular Oncology, 2017, 11, 1788-1805.	2.1	7
1896	Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12027-12032.	3.3	78
1897	Polymorphisms in genes related to epithelialâ€“mesenchymal transition and risk of non-small cell lung cancer. Carcinogenesis, 2017, 38, 1029-1035.	1.3	18
1898	FEN1 knockdown improves trastuzumab sensitivity in human epidermal growth factor 2-positive breast cancer cells. Experimental and Therapeutic Medicine, 2017, 14, 3265-3272.	0.8	7
1899	Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 229-238.	0.7	15
1900	Kinase inhibitor screening using artificial neural networks and engineered cardiac biowires. Scientific Reports, 2017, 7, 11807.	1.6	25
1901	Herpesâ€”A Not So Simple(x) History. JAMA Dermatology, 2017, 153, 910.	2.0	2
1902	FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice. Scientific Reports, 2017, 7, 11306.	1.6	14
1903	Proteomic analysis of mitochondria: biological and clinical progresses in cancer. Expert Review of Proteomics, 2017, 14, 891-903.	1.3	10

#	Article	IF	Citations
1905	Internalized CD44s splice isoform attenuates EGFR degradation by targeting Rab7A. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8366-8371.	3.3	36
1906	How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. European Journal of Medicinal Chemistry, 2017, 142, 131-151.	2.6	46
1907	Quantifying the Interaction between EGFR Dimers and Grb2 in Live Cells. Biophysical Journal, 2017, 113, 1353-1364.	0.2	23
1908	Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells. Cell Death and Differentiation, 2017, 24, 1937-1947.	5.0	65
1909	Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients. Cancer Chemotherapy and Pharmacology, 2017, 80, 527-533.	1.1	6
1910	CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer. Cell Systems, 2017, 5, 82-86.e3.	2.9	5
1911	Inhibition of histone deacetylases sensitizes EGF receptorâ€TK inhibitorâ€resistant nonâ€smallâ€cell lung cancer cells to erlotinib <scp>in vitro</scp> and <scp>in vivo</scp>. British Journal of Pharmacology, 2017, 174, 3608-3622.	2.7	34
1912	Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway. Oncogene, 2017, 36, 6691-6700.	2.6	28
1913	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. Expert Opinion on Biological Therapy, 2017, 17, 1297-1308.	1.4	21
1914	A Selfâ€Transformable pHâ€Driven Membraneâ€Anchoring Photosensitizer for Effective Photodynamic Therapy to Inhibit Tumor Growth and Metastasis. Advanced Functional Materials, 2017, 27, 1702122.	7.8	89
1915	ErbB Receptors and Cancer. Methods in Molecular Biology, 2017, 1652, 3-35.	0.4	283
1916	Analysis of Epithelialâ€“Mesenchymal Transition Induced by Overexpression of Twist. Methods in Molecular Biology, 2017, 1652, 259-274.	0.4	7
1917	Isolation of Human Mesenchymal Stem Cells for Studying ErbB Receptor Signaling. Methods in Molecular Biology, 2017, 1652, 295-300.	0.4	0
1918	In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7301-E7310.	3.3	88
1919	Altered expression of cellular proliferation, apoptosis and the cell cycle-related genes in lung cancer cells with acquired resistance to EGFR tyrosine kinase inhibitors. Oncology Letters, 2017, 14, 2191-2197.	0.8	16
1920	ErbB Receptor Signaling. Methods in Molecular Biology, 2017, , .	0.4	10
1921	Single Molecule and Single Cell Analysis of HER2 Receptors in Breast Cancer Cells Using Liquid Phase Scanning Transmission Electron Microscopy. Microscopy and Microanalysis, 2017, 23, 1106-1107.	0.2	0
1922	EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management. Oncology and Therapy, 2017, 5, 135-148.	1.0	29

#	Article	IF	Citations
1923	Efficient Simulation of Reaction Systems on Graphics Processing Units. Fundamenta Informaticae, 2017, 154, 307-321.	0.3	13
1924	Curcumin co-treatment ameliorates resistance to gefitinib in drug-resistant NCI-H1975 lung cancer cells. Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan / Sponsored By All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine, 2017, 37, 355-360.	0.4	12
1925	Bioinformatics analysis of transcription profiling of solid pseudopapillary neoplasm of the pancreas. Molecular Medicine Reports, 2017, 16, 1635-1642.	1.1	9
1926	EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer. Molecular Cancer Research, 2017, 15, 1445-1454.	1.5	40
1927	Identification and characterization of ErbB4 kinase inhibitors for effective breast cancer therapy. Journal of Receptor and Signal Transduction Research, 2017, 37, 470-480.	1.3	13
1928	Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice. Journal of Experimental and Clinical Cancer Research, 2017, 36, 6.	3.5	8
1929	Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines. Lung Cancer, 2017, 109, 109-116.	0.9	25
1930	Osimertinib-related skin and mucosal adverse events. Cancer Treatment and Research Communications, 2017, 12, 53-55.	0.7	1
1931	Exploring Missense Mutations in Tyrosine Kinases Implicated with Neurodegeneration. Molecular Neurobiology, 2017, 54, 5085-5106.	1.9	8
1932	Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy. Bioorganic and Medicinal Chemistry, 2017, 25, 27-37.	1.4	45
1933	Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. Annual Review of Cancer Biology, 2017, 1, 257-274.	2.3	4
1934	Expression of several cytokines in prostate cancer: Correlation with clinical variables of patients. Relationship with biochemical progression of the malignance. Cytokine, 2017, 89, 105-115.	1.4	19
1935	Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma. British Journal of Dermatology, 2017, 176, 1279-1287.	1.4	76
1936	Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e204-e211.	0.7	22
1937	TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation. Oncogene, 2017, 36, 1585-1596.	2.6	58
1938	Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells. European Journal of Medicinal Chemistry, 2017, 125, 914-924.	2.6	14
1939	Blocking SIAH Proteolysis, an Important K-RAS Vulnerability, to Control and Eradicate K-RAS-Driven Metastatic Cancer. , 2017, , 213-232.		4
1940	PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2. Oncogene, 2017, 36, 410-422.	2.6	33

#	Article	IF	Citations
1941	miR-152 is involved in the proliferation and metastasis of ovarian cancer through repression of ERBB3. International Journal of Molecular Medicine, 2018, 41, 1529-1535.	1.8	20
1942	The Dawning of Translational Breast Cancer: From Bench to Bedside. Advances in Experimental Medicine and Biology, 2017, 1026, 1-25.	0.8	0
1943	Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma. Oncotarget, 2017, 8, 2141-2152.	0.8	16
1944	Structural basis of a novel heterodimeric Fc for bispecific antibody production. Oncotarget, 2017, 8, 51037-51049.	0.8	41
1945	Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives. Cureus, 2017, 9, e1258.	0.2	6
1946	Cancer Biology and the Principles of Targeted Cancer Drug Discovery. , 2017, , 1-38.		1
1947	Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells. Oncotarget, 2017, 8, 4277-4288.	0.8	20
1948	Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. International Journal of Molecular Sciences, 2017, 18, 1522.	1.8	23
1949	Gastric Cancer Cell Glycosylation as a Modulator of the ErbB2 Oncogenic Receptor. International Journal of Molecular Sciences, 2017, 18, 2262.	1.8	24
1950	Design, Synthesis, and Antitumor Activity of Novel Quinazoline Derivatives. Molecules, 2017, 22, 1624.	1.7	5
1951	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World Journal of Gastroenterology, 2017, 23, 4675.	1.4	91
1952	Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How It Can Be Overcome. International Journal of Molecular Sciences, 2017, 18, 1854.	1.8	62
1953	EGFR Family Membersâ€™ Regulation of Autophagy Is at a Crossroads of Cell Survival and Death in Cancer. Cancers, 2017, 9, 27.	1.7	73
1954	Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The â€œRotation Modelâ€• Cells, 2017, 6, 13.	1.8	118
1955	Isorhynchophylline, a Potent Plant Alkaloid, Induces Apoptotic and Anti-Metastatic Effects in Human Hepatocellular Carcinoma Cells through the Modulation of Diverse Cell Signaling Cascades. International Journal of Molecular Sciences, 2017, 18, 1095.	1.8	44
1956	Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications. Frontiers in Immunology, 2017, 8, 1850.	2.2	161
1957	ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases. Journal of Oncology, 2017, 2017, 1-20.	0.6	12
1958	Chimeric Antigen Receptor Therapy of Brain Tumors. , 2017, , 337-365.		0

#	Article	IF	Citations
1959	Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Cancer, 2017, 8, 227-239.	1.2	18
1960	Long non-coding RNAs in Colorectal Cancer: Progression and Future Directions. Journal of Cancer, 2017, 8, 3212-3225.	1.2	60
1961	HER2 regulates cancer stem-like cell phenotype in ALK translocated NSCLC. International Journal of Oncology, 2017, 51, 599-606.	1.4	5
1962	A Role for Neuregulin-1 in Promoting Keloid Fibroblast Migration via ErbB2-mediated Signaling. Acta Dermato-Venereologica, 2017, 97, 675-684.	0.6	18
1963	Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. Lung Cancer: Targets and Therapy, 2017, Volume 8, 109-125.	1.3	49
1964	Identification of epidermal growth factor receptor-positive glioblastoma using lipid-encapsulated targeted superparamagnetic iron oxide nanoparticles in vitro. Journal of Nanobiotechnology, 2017, 15, 86.	4.2	17
1965	Lysosome trafficking is necessary for EGF-driven invasion and is regulated by p38 MAPK and Na+/H+ exchangers. BMC Cancer, 2017, 17, 672.	1.1	13
1966	Evaluation of epidermal growth factor receptor signaling effects in gastric cancer cell lines by detailed motility-focused phenotypic characterization linked with molecular analysis. BMC Cancer, 2017, 17, 845.	1.1	16
1967	Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients. BMC Cancer, 2017, 17, 841.	1.1	12
1968	Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer. Frontiers in Bioscience - Elite, 2017, 9, 235-245.	0.9	68
1969	Profiling cancer-related gene mutations in oral squamous cell carcinoma from Japanese patients by targeted amplicon sequencing. Oncotarget, 2017, 8, 59113-59122.	0.8	52
1970	Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer. Oncotarget, 2017, 8, 9885-9898.	0.8	27
1971	Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. Breast Cancer: Targets and Therapy, 2017, Volume 9, 185-198.	1.0	23
1972	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescencein situhybridization (FISH) to select the optimal patients for matched therapy?. Oncotarget, 2017, 8, 100863-100898.	0.8	16
1973	Lead exposure and plasma mRNA expression in ERBB2 gene. Molecular Medicine Reports, 2017, 15, 3361-3365.	1.1	15
1974	A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. International Journal of Molecular Sciences, 2017, 18, 401.	1.8	14
1975	Overexpression of SCAMP3 is an indicator of poor prognosis in hepatocellular carcinoma. Oncotarget, 2017, 8, 109247-109257.	0.8	22
1976	Saikosaponin-d suppresses cell growth in renal cell carcinoma through EGFR/p38 signaling pathway. Neoplasma, 2017, 64, 518-525.	0.7	13

#	Article	IF	Citations
1977	Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. Journal of Gastrointestinal Oncology, 2017, 8, 405-417.	0.6	17
1978	The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a systematic review and meta-analysis. Journal of Thoracic Disease, 2017, 9, 1980-1987.	0.6	7
1979	PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery. BioEssays, 2018, 40, e1700247.	1.2	151
1980	A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations. Medical Oncology, 2018, 35, 34.	1.2	10
1981	Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme. Molecular Neurobiology, 2018, 55, 8236-8242.	1.9	5
1982	<scp>HER</scp>2/<scp>HER</scp>3â€positive metastatic salivary duct carcinoma in the pleural effusion: A case report. Diagnostic Cytopathology, 2018, 46, 429-433.	0.5	2
1984	Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. Journal of Translational Medicine, 2018, 16, 86.	1.8	33
1985	Resistance of Colorectal Tumors to Anti-EGFR Antibodies. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 1-27.	0.1	1
1986	Targeting EGFRâ€mediated autophagy as a potential strategy for cancer therapy. International Journal of Cancer, 2018, 143, 2116-2125.	2.3	61
1987	Cancer drug target identification and node-level analysis of the network of MAPK pathways. Network Modeling Analysis in Health Informatics and Bioinformatics, 2018, 7, 1.	1.2	2
1988	Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Annals of Oncology, 2018, 29, 1108-1119.	0.6	177
1989	The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian Devils. Cancer Cell, 2018, 33, 607-619.e15.	7.7	88
1990	Molecular spherical nucleic acids. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4340-4344.	3.3	130
1991	Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib. Molecular Carcinogenesis, 2018, 57, 1008-1016.	1.3	11
1992	Withanolide A extends the lifespan in human EGFR-driven cancerous Caenorhabditis elegans. Experimental Gerontology, 2018, 104, 113-117.	1.2	11
1993	EGFR expression in circulating tumor cells from high-grade metastatic soft tissue sarcomas. Cancer Biology and Therapy, 2018, 19, 454-460.	1.5	19
1994	Optimal Objective-Based Experimental Design for Uncertain Dynamical Gene Networks with Experimental Error. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2018, 15, 218-230.	1.9	10
1995	L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib. Chemical Science, 2018, 9, 2740-2749.	3.7	66

#	Article	IF	Citations
1996	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open, 2018, 3, e000299.	2.0	29
1997	Targeting EGFR^{L858R/T790M} and EGFR^{L858R/T790M/C797S} resistance mutations in NSCLC: Current developments in medicinal chemistry. Medicinal Research Reviews, 2018, 38, 1550-1581.	5.0	113
1998	Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death. Cell Death and Disease, 2018, 9, 138.	2.7	23
1999	Development and validation of an ELISA to study panitumumab pharmacokinetics. Bioanalysis, 2018, 10, 205-214.	0.6	3
2000	Aberrantly high expression of the CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in mammary epithelium leads to breast tumorigenesis. Journal of Biological Chemistry, 2018, 293, 2850-2864.	1.6	14
2001	Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. British Journal of Cancer, 2018, 118, 344-352.	2.9	7
2002	Design of peptideâ€“dendrimer conjugates with tumor homing and antitumor effects. Research on Chemical Intermediates, 2018, 44, 4685-4695.	1.3	9
2003	Design of cyclic and <scp>d</scp>â€amino acids containing peptidomimetics for inhibition of proteinâ€protein interactions of HER2â€HER3. Journal of Peptide Science, 2018, 24, e3066.	0.8	10
2004	Identification of ARL4C as a Peritoneal Dissemination-Associated Gene and Its Clinical Significance in Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 745-753.	0.7	40
2005	Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. Archivos De Bronconeumologia, 2018, 54, 10-17.	0.4	0
2006	Differential recruitment of CD44 isoforms by ErbB ligands reveals an involvement of CD44 in breast cancer. Oncogene, 2018, 37, 1472-1484.	2.6	33
2007	Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells. Scientific Reports, 2018, 8, 6829.	1.6	18
2008	Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches. Computational Biology and Chemistry, 2018, 74, 327-338.	1.1	34
2009	Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation. European Journal of Medicinal Chemistry, 2018, 152, 298-306.	2.6	8
2010	Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer. Expert Review of Molecular Diagnostics, 2018, 18, 347-356.	1.5	12
2011	Global Variation of Human Papillomavirus Genotypes and Selected Genes Involved in Cervical Malignancies. Annals of Global Health, 2018, 81, 675.	0.8	33
2012	Petri Net Siphon Analysis and Graph Theoretic Measures for Identifying Combination Therapies in Cancer. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2018, 15, 231-243.	1.9	9
2013	Arf6 and its ZEB1-EPB41L5 mesenchymal axis are required for both mesenchymal- and amoeboid-type invasion of cancer cells. Small GTPases, 2018, 9, 420-426.	0.7	9

#	Article	IF	Citations
2014	Membrane protein stoichiometry studied in intact mammalian cells using liquidâ€phase electron microscopy. Journal of Microscopy, 2018, 269, 134-142.	0.8	13
2015	Biomarker-driven and molecular targeted therapies for colorectal cancers. Seminars in Oncology, 2018, 45, 124-132.	0.8	9
2016	Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein and Cell, 2018, 9, 838-847.	4.8	196
2017	Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 133-142.	1.8	48
2018	Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population. Archivos De Bronconeumologia, 2018, 54, 10-17.	0.4	17
2019	Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 67-73.	2.5	28
2020	Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts. European Journal of Medicinal Chemistry, 2018, 143, 449-463.	2.6	46
2021	Epigallocatechin-3-O-gallate alleviates the malignant phenotype in A-431 epidermoid and SK-BR-3 breast cancer cell lines. International Journal of Food Sciences and Nutrition, 2018, 69, 584-597.	1.3	10
2022	Nanoparticle orientation to control RNAÂloading and ligand display on extracellular vesicles for cancer regression. Nature Nanotechnology, 2018, 13, 82-89.	15.6	352
2023	Prognostic and predictive value of EGFR and EGFR-ligands in blood of breast cancer patients: a systematic review. Clinical Chemistry and Laboratory Medicine, 2018, 56, 688-701.	1.4	23
2024	Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment. Journal of Clinical Pathology, 2018, 71, 451-462.	1.0	9
2025	Diversity in peptide recognition by the SH2 domain of SH2B1. Proteins: Structure, Function and Bioinformatics, 2018, 86, 164-176.	1.5	5
2026	Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. Pharmacogenomics Journal, 2018, 18, 460-466.	0.9	16
2027	Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals. European Journal of Dermatology, 2018, 28, 509-518.	0.3	7
2028	Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines. International Journal of Oncology, 2018, 52, 2143-2154.	1.4	6
2030	Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7. Biochemistry and Biophysics Reports, 2018, 16, 103-109.	0.7	3
2031	Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. Cancer Research and Treatment, 2018, 50, 835-842.	1.3	64
2032	Treatment of Patients With Lobular Breast Cancer Harboring Human Epidermal Growth Factor Receptor 2 Mutation With HER2-Directed Therapy. JCO Precision Oncology, 2018, 2, 1-7.	1.5	0

#	Article	IF	Citations
2033	The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC. Bioorganic and Medicinal Chemistry, 2018, 26, 6087-6095.	1.4	9
2034	A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases. Journal of Biomedical Science, 2018, 25, 83.	2.6	9
2035	Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer. Current Breast Cancer Reports, 2018, 10, 262-273.	0.5	1
2036	Ginsenoside Rg3 Decreases NHE1 Expression via Inhibiting EGF-EGFR-ERK1/2-HIF-1Î± Pathway in Hepatocellular Carcinoma: A Novel Antitumor Mechanism. The American Journal of Chinese Medicine, 2018, 46, 1915-1931.	1.5	27
2037	A digital PCR assay development to detect EGFR T790M mutation in NSCLC patients. Frontiers in Laboratory Medicine, 2018, 2, 89-96.	1.7	9
2038	Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All. Advances in Experimental Medicine and Biology, 2018, 1110, 113-131.	0.8	19
2039	Targeted Therapy of Colorectal Cancer Subtypes. Advances in Experimental Medicine and Biology, 2018, , .	0.8	0
2040	HCRP-1 regulates EGFRâ€“AKTâ€“BIM-mediated anoikis resistance and serves as a prognostic marker in human colon cancer. Cell Death and Disease, 2018, 9, 1176.	2.7	24
2041	Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold. Journal of Medicinal Chemistry, 2018, 61, 11372-11383.	2.9	22
2042	Searching for Essential Genes in the Cancer Genome. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2018, 12, 283-296.	0.2	0
2043	Targeting tumor cells with antibodies enhances anti-tumor immunity. Biophysics Reports, 2018, 4, 243-253.	0.2	17
2044	EGFR may participate in immune evasion through regulation of B7â€‘H5 expression in nonâ€‘small cell lung carcinoma. Molecular Medicine Reports, 2018, 18, 3769-3779.	1.1	10
2045	Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer. Cancers, 2018, 10, 342.	1.7	109
2046	Functional Consequences and Clinical Significance of Tyrosine Kinase Inhibitors in Advanced Colorectal Cancer. , 2018, , 115-140.		0
2047	Oncogenic Signaling Induced by HCV Infection. Viruses, 2018, 10, 538.	1.5	19
2048	TRAF4 binds to the juxtamembrane region of EGFR directly and promotes kinase activation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 11531-11536.	3.3	12
2049	Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell, 2018, 34, 792-806.e5.	7.7	102
2050	Association between the overexpression of Her3 and clinical pathology and prognosis of colorectal cancer. Medicine (United States), 2018, 97, e12317.	0.4	9

#	Article	IF	Citations
2051	Rapid screening of drug candidates against EGFR/HER2 signaling pathway using fluorescence assay. Analytical and Bioanalytical Chemistry, 2018, 410, 7827-7835.	1.9	11
2052	The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. PLoS ONE, 2018, 13, e0206007.	1.1	14
2053	EGF Level in Hepatoid Gland Adenomas and Hepatoid Gland Epitheliomas in Dogs After Administering Tamoxifen. In Vivo, 2018, 32, 1175-1181.	0.6	2
2054	Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect. Cancer Letters, 2018, 439, 113-130.	3.2	11
2055	Possible Mechanisms of Green Tea and Its Constituents against Cancer. Molecules, 2018, 23, 2284.	1.7	90
2057	Aptamer as Therapeutics for Cancer with Focus on Retinoblastoma. , 2018, , 147-194.		1
2058	Interaction between Host MicroRNAs and the Gut Microbiota in Colorectal Cancer. MSystems, 2018, 3, .	1.7	97
2059	Targeting an oncogenic kinase/phosphatase signaling network for cancer therapy. Acta Pharmaceutica Sinica B, 2018, 8, 511-517.	5.7	13
2061	The Intestinotrophic Effects of Glucagon-Like Peptide-2 in Relation to Intestinal Neoplasia. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2827-2837.	1.8	9
2063	Combined overexpression of cadherin 6, cadherin 11 and cluster of differentiation 44 is associated with lymph node metastasis and poor prognosis in oral squamous cell carcinoma. Oncology Letters, 2018, 15, 9498-9506.	0.8	9
2064	EGF Regulates the Interaction of Tks4 with Src through Its SH2 and SH3 Domains. Biochemistry, 2018, 57, 4186-4196.	1.2	17
2065	Epidermal growth factor receptor and ligand family expression and activity in glioblastoma. Journal of Neurochemistry, 2018, 147, 99-109.	2.1	20
2066	Inhibition of Epidermal Growth Factor Receptor Activation Is Associated With Improved Diabetic Nephropathy and Insulin Resistance in Type 2 Diabetes. Diabetes, 2018, 67, 1847-1857.	0.3	53
2067	Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells. Drug Design, Development and Therapy, 2018, Volume 12, 2223-2231.	2.0	10
2068	Analysis of MEMO1 Binding Specificity for ErbB2 Using Fluorescence Polarization and Molecular Dynamics Simulations. Biochemistry, 2018, 57, 5169-5181.	1.2	7
2069	Erlotinib. Recent Results in Cancer Research, 2018, 211, 1-17.	1.8	17
2070	Lapatinib. Recent Results in Cancer Research, 2018, 211, 19-44.	1.8	75
2071	An in Vitro Assay of hERG K+ Channel Potency for a New EGFR Inhibitor FHND004. Frontiers in Pharmacology, 2018, 9, 577.	1.6	9

#	Article	IF	Citations
2072	Integrative omics analyses broaden treatment targets in human cancer. Genome Medicine, 2018, 10, 60.	3.6	17
2073	Potential anti-proliferative activity of AgNPs synthesized using M. longifolia in 4T1 cell line through ROS generation and cell membrane damage. Journal of Photochemistry and Photobiology B: Biology, 2018, 186, 160-168.	1.7	23
2074	NRG1 signalling regulates the establishment of Sertoli cell stock in the mouse testis. Molecular and Cellular Endocrinology, 2018, 478, 17-31.	1.6	4
2075	Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3. Oncology Reports, 2018, 40, 867-876.	1.2	42
2076	A New Strategy to Control and Eradicate â€œUndruggableâ€•Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers, 2018, 10, 142.	1.7	17
2077	Entinostat reverses P-glycoprotein activation in snail-overexpressing adenocarcinoma HCC827 cells. PLoS ONE, 2018, 13, e0200015.	1.1	9
2078	VEGF Signaling in Neurological Disorders. International Journal of Molecular Sciences, 2018, 19, 275.	1.8	96
2079	Seaweeds and Cancer Prevention. , 2018, , 269-290.		8
2080	Quantitative Realâ€Time Monitoring of Antibodyâ€Induced Internalization of Epidermal Growth Factor Receptor on Single Living Mammalian Cells Using Scanning Electrochemical Microscopy. ChemElectroChem, 2018, 5, 3096-3101.	1.7	8
2081	EGFR: How Important Is EGFR Mutation Status in the Management of Lung Cancer?. Respiratory Disease Series, 2018, , 275-293.	0.1	0
2082	Binding mechanism of kinase inhibitors to EGFR and T790M, L858R and L858R/T790M mutants through structural and energetic analysis. International Journal of Biological Macromolecules, 2018, 118, 1948-1962.	3.6	24
2083	Bioactivating Silicon (100) Surfaces with Novel UV Grafting of Cyclopropylamine for Promotion of Cell Adhesion. Materials, 2018, 11, 713.	1.3	6
2084	Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors. Medical Oncology, 2018, 35, 87.	1.2	24
2085	The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2. BMC Cancer, 2018, 18, 238.	1.1	33
2086	Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget, 2018, 9, 23878-23889.	0.8	11
2087	Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma. Clinical Cancer Research, 2018, 24, 5815-5819.	3.2	25
2088	Caloric restriction inhibits mammary tumorigenesis in MMTV-ErbB2 transgenic mice through the suppression of ER and ErbB2 pathways and inhibition of epithelial cell stemness in premalignant mammary tissues. Carcinogenesis, 2018, 39, 1264-1273.	1.3	12
2089	HER1-based vaccine: Simultaneous activation of humoral and cellular immune response. Seminars in Oncology, 2018, 45, 75-83.	0.8	6

#	Article	IF	Citations
2090	Radiation Therapy in Rectal Cancer. , 2018, , 1-21.		0
2091	Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors. European Journal of Medicinal Chemistry, 2018, 155, 316-336.	2.6	46
2092	Cell-free synthesis of functional antibody fragments to provide a structural basis for antibodyâ€“antigen interaction. PLoS ONE, 2018, 13, e0193158.	1.1	20
2093	Role of Tocotrienols in Chemosensitization of Cancer. , 2018, , 77-97.		2
2094	Understanding the biology of HER3 receptor as a therapeutic target in human cancer. Acta Pharmaceutica Sinica B, 2018, 8, 503-510.	5.7	80
2095	ANXA2 could act as a moderator of EGFR-directed therapy resistance in triple negative breast cancer. Bioscience, Biotechnology and Biochemistry, 2018, 82, 1733-1741.	0.6	10
2096	PIK3CA mutations in colorectal and breast cancer: impact on oncogenesis and response to nonsteroidal anti-inflammatory drugs. , 2019, , 123-144.		2
2097	Anticancer properties of tocotrienols: A review of cellular mechanisms and molecular targets. Journal of Cellular Physiology, 2019, 234, 1147-1164.	2.0	45
2098	PET imaging of EGFR expression using an 18F-labeled RNA aptamer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 948-956.	3.3	28
2099	Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion. Molecular Cancer Research, 2019, 17, 20-29.	1.5	26
2100	MicroRNAs in cancer drug resistance: Basic evidence and clinical applications. Journal of Cellular Physiology, 2019, 234, 2152-2168.	2.0	54
2101	Pathway Interactions Based on Drug-Induced Datasets. Cancer Informatics, 2019, 18, 117693511985151.	0.9	2
2102	Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). International Journal of Molecular Sciences, 2019, 20, 3821.	1.8	116
2103	MicroRNA-326 Functions as a Tumor Suppressor in Breast Cancer by Targeting ErbB/PI3K Signaling Pathway. Frontiers in Oncology, 2019, 9, 653.	1.3	46
2104	Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines. Cells, 2019, 8, 878.	1.8	17
2105	Immune Resistance and EGFR Antagonists in Colorectal Cancer. Cancers, 2019, 11, 1089.	1.7	37
2106	Cell Biology of Intracellular Adaptation of Mycobacterium leprae in the Peripheral Nervous System. Microbiology Spectrum, 2019, 7, .	1.2	20
2108	The Role of the EGF Receptor in Sex Differences in Kidney Injury. Journal of the American Society of Nephrology: JASN, 2019, 30, 1659-1673.	3.0	25

#	Article	IF	Citations
2109	Siteâ€Specific Encoding of Photoactivity in Antibodies Enables Lightâ€Mediated Antibodyâ€“Antigen Binding on Live Cells. Angewandte Chemie, 2019, 131, 18154-18161.	1.6	10
2110	Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. Critical Reviews in Oncology/Hematology, 2019, 143, 153-163.	2.0	49
2111	Siteâ€Specific Encoding of Photoactivity in Antibodies Enables Lightâ€Mediated Antibodyâ€“Antigen Binding on Live Cells. Angewandte Chemie - International Edition, 2019, 58, 17986-17993.	7.2	38
2112	The Landscape of Atypical and Eukaryotic Protein Kinases. Trends in Pharmacological Sciences, 2019, 40, 818-832.	4.0	87
2113	A Cross-Linking-Aided Immunoprecipitation/Mass Spectrometry Workflow Reveals Extensive Intracellular Trafficking in Time-Resolved, Signal-Dependent Epidermal Growth Factor Receptor Proteome. Journal of Proteome Research, 2019, 18, 3715-3730.	1.8	11
2114	Comprehensive characterization of circular RNAs in ~â€‰1000 human cancer cell lines. Genome Medicine, 2019, 11, 55.	3.6	116
2115	Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors. European Journal of Medicinal Chemistry, 2019, 182, 111648.	2.6	70
2116	Cancer Genetics and Therapeutics. , 2019, , .		6
2117	Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression. Molecular Cancer Research, 2019, 17, 2395-2409.	1.5	36
2118	Distinguishing Stock Indices and Detecting Economic Crises Based on Weighted Symbolic Permutation Entropy. Fluctuation and Noise Letters, 2019, 18, 1950026.	1.0	5
2119	Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells. European Journal of Pharmacology, 2019, 863, 172705.	1.7	15
2121	Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance. DNA and Cell Biology, 2019, 38, 184-192.	0.9	26
2122	Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells. Cancers, 2019, 11, 105.	1.7	26
2123	The onus of cannabinoids in interrupting the molecular odyssey of breast cancer: A critical perspective on UPRER and beyond. Saudi Pharmaceutical Journal, 2019, 27, 437-445.	1.2	9
2124	Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 1274-1290.	2.9	33
2125	Elevated epiregulin expression predicts poor prognosis in gastric cancer. Pathology Research and Practice, 2019, 215, 873-879.	1.0	14
2126	Dysregulated microRNAs in colorectal carcinogenesis: New insight to cell survival and apoptosis regulation. Journal of Cellular Physiology, 2019, 234, 21683-21693.	2.0	26
2127	A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the thirdâ€generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers. Basic and Clinical Pharmacology and Toxicology, 2019, 125, 370-381.	1.2	9

#	Article	IF	Citations
2128	The p53/miR-193a/EGFR feedback loop function as a driving force for non-small cell lung carcinoma tumorigenesis. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985066.	1.4	17
2129	Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase. British Journal of Cancer, 2019, 121, 237-248.	2.9	15
2130	The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	8
2131	Gefitinibâ€'mediated apoptosis is enhanced via inhibition of autophagy by chloroquine diphosphate in cutaneous squamous cell carcinoma cells. Oncology Letters, 2019, 18, 368-374.	0.8	7
2132	Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer. Journal of Translational Medicine, 2019, 17, 201.	1.8	14
2133	Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. Journal of Experimental and Clinical Cancer Research, 2019, 38, 236.	3.5	17
2134	Plakophilin-2 accelerates cell proliferation and migration through activating EGFR signaling in lung adenocarcinoma. Pathology Research and Practice, 2019, 215, 152438.	1.0	21
2135	Phenotypic characterization of the novel, nonâ€'hotspot oncogenic KRAS mutants E31D and E63K. Oncology Letters, 2019, 18, 420-432.	0.8	7
2136	Leo Sachs. 14 October 1924â€"12 December 2013. Biographical Memoirs of Fellows of the Royal Society, 2019, 66, 355-375.	0.1	0
2137	Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts. Cancer Research, 2019, 79, 4539-4550.	0.4	34
2138	LncRNA LOXL1â€AS1/miRâ€letâ€7aâ€5p/EGFRâ€related pathway regulates the doxorubicin resistance of prostate cancer DUâ€145 cells. IUBMB Life, 2019, 71, 1537-1551.	1.5	44
2139	Absence of integrin Î±3Î²1 promotesÂthe progression of HER2-driven breast cancer in vivo. Breast Cancer Research, 2019, 21, 63.	2.2	14
2140	Bisphenol AF promotes estrogen receptor-positive breast cancer cell proliferation through amphiregulin-mediated crosstalk with receptor tyrosine kinase signaling. PLoS ONE, 2019, 14, e0216469.	1.1	7
2141	Functional Characterization of Colon Cancer-Associated Mutations in ADAM17: Modifications in the Pro-Domain Interfere with Trafficking and Maturation. International Journal of Molecular Sciences, 2019, 20, 2198.	1.8	10
2142	Upregulation of HER2 in tubular epithelial cell drives fibroblast activation and renal fibrosis. Kidney International, 2019, 96, 674-688.	2.6	20
2143	Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer. Medical Oncology, 2019, 36, 57.	1.2	18
2144	Deuterated Curcuminoids: Synthesis, Structures, Computational/Docking and Comparative Cell Viability Assays against Colorectal Cancer. ChemMedChem, 2019, 14, 1173-1184.	1.6	8
2145	A compact synthetic pathway rewires cancer signaling to therapeutic effector release. Science, 2019, 364, .	6.0	33

#	Article	IF	Citations
2146	Profiling proteinâ€“protein interactions of single cancer cells with in situ lysis and co-immunoprecipitation. Lab on A Chip, 2019, 19, 1922-1928.	3.1	14
2147	Cytotoxicity of cucurbitacin E from Citrullus colocynthis against multidrug-resistant cancer cells. Phytomedicine, 2019, 62, 152945.	2.3	42
2148	Advances in the strategies for designing receptor-targeted molecular imaging probes for cancer research. Journal of Controlled Release, 2019, 305, 1-17.	4.8	29
2149	Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort. Frontiers in Oncology, 2019, 9, 212.	1.3	20
2150	DNAzyme Catalyzed Tyramide Depositing Reaction for In Situ Imaging of Protein Status on the Cell Surface. Theranostics, 2019, 9, 1993-2002.	4.6	14
2151	Hydroxyl-Rich PGMA-Based Cationic Glycopolymers for Intracellular siRNA Delivery: Biocompatibility and Effect of Sugar Decoration Degree. Biomacromolecules, 2019, 20, 2068-2074.	2.6	24
2152	Expression pattern of microRNAs related with response to trastuzumab in breast cancer. Journal of Cellular Physiology, 2019, 234, 16102-16113.	2.0	8
2153	Dysfunctional ErbB2, an EGF receptor family member, hinders repair of airway epithelial cells from asthmatic patients. Journal of Allergy and Clinical Immunology, 2019, 143, 2075-2085.e10.	1.5	21
2154	Genetic Analyses Confirm SNPs in HSPA8 and ERBB2 are Associated with Milk Protein Concentration in Chinese Holstein Cattle. Genes, 2019, 10, 104.	1.0	3
2155	A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome. BMJ Case Reports, 2019, 12, bcr-2018-227785.	0.2	2
2156	Stem extract of Tabebuia chrysantha induces apoptosis by targeting sEGFR in Ehrlich Ascites Carcinoma. Journal of Ethnopharmacology, 2019, 235, 219-226.	2.0	15
2157	Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations. Current Medicinal Chemistry, 2019, 26, 396-426.	1.2	67
2158	Epidermal growth factor receptor role in pancreatic cancer. , 2019, , 295-324.		3
2159	Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance. Molecular Cancer Therapeutics, 2019, 18, 1909-1915.	1.9	21
2160	Yâ€˜boxâ€˜binding proteinï¿½1 inhibits apoptosis and upregulates EGFR in colon cancer. Oncology Reports, 2019, 41, 2889-2896.	1.2	17
2161	Current Approaches in NSCLC Targeting K-RAS and EGFR. International Journal of Molecular Sciences, 2019, 20, 5701.	1.8	47
2162	The Landscape of Actionable Gene Fusions in Colorectal Cancer. International Journal of Molecular Sciences, 2019, 20, 5319.	1.8	34
2163	The transition model of RTK activation: A quantitative framework for understanding RTK signaling and RTK modulator activity. Cytokine and Growth Factor Reviews, 2019, 49, 23-31.	3.2	31

#	Article	IF	Citations
2164	Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nature Communications, 2019, 10, 5157.	5.8	46
2165	HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer. Bulletin Du Cancer, 2019, 106, 946-958.	0.6	28
2166	The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base. Journal of Thoracic Disease, 2019, 11, 4507-4515.	0.6	27
2167	Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy . Core Evidence, 2019, Volume 14, 51-70.	4.7	50
2168	Epidermal growth factor receptor first generation tyrosine-kinase inhibitors. Translational Lung Cancer Research, 2019, 8, S235-S246.	1.3	8
2169	KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan. PLoS ONE, 2019, 14, e0226473.	1.1	7
2170	Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials. Advanced Materials, 2019, 31, e1802725.	11.1	230
2171	Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. Materials Today, 2019, 25, 66-87.	8.3	22
2172	Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route. Expert Review of Anticancer Therapy, 2019, 19, 105-119.	1.1	107
2173	Inactivation of ADAMTS18 by aberrant promoter hypermethylation contribute to lung cancer progression. Journal of Cellular Physiology, 2019, 234, 6965-6975.	2.0	14
2174	EGFR Mutations. , 2019, , 477-486.		2
2175	Metformin suppresses the esophageal carcinogenesis in rats treated with NMBzA through inhibiting AMPK/mTOR signaling pathway. Carcinogenesis, 2019, 40, 669-679.	1.3	24
2176	ErbB4 acts as a suppressor in colitis and its associated carcinoma by negatively regulating cholesterol metabolism. Carcinogenesis, 2019, 40, 680-686.	1.3	4
2177	Crosstalk between TF/FVIIa and EGFR signaling in colorectal cancer cells. Cancer Biology and Therapy, 2019, 20, 454-460.	1.5	4
2178	Tetraspanin CD151 impairs heterodimerization of ErbB2/ErbB3 in breast cancer cells. Translational Research, 2019, 207, 44-55.	2.2	10
2179	Efficacy and safety of osimertinib in treating EGFRâ€mutated advanced NSCLC: A metaâ€analysis. International Journal of Cancer, 2019, 145, 284-294.	2.3	52
2180	The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease. Cancer Cell, 2019, 35, 125-139.e9.	7.7	43
2181	Targeting Hedgehog signaling pathway: Paving the road for cancer therapy. Pharmacological Research, 2019, 141, 466-480.	3.1	60

#	Article	IF	Citations
2182	A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. Scientific Reports, 2019, 9, 14.	1.6	28
2183	ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer. Biological Research, 2019, 52, 2.	1.5	29
2184	Targeting <scp>HER</scp>2 in patientâ€derived xenograft ovarian cancer models sensitizes tumors to chemotherapy. Molecular Oncology, 2019, 13, 132-152.	2.1	23
2185	Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL858R/T790M inhibitors. European Journal of Medicinal Chemistry, 2019, 163, 367-380.	2.6	28
2186	Colorectal adenocarcinomaâ€derived EGFR mutants are oncogenic and sensitive to EGFRâ€targeted monoclonal antibodies, cetuximab and panitumumab. International Journal of Cancer, 2020, 146, 2194-2200.	2.3	20
2187	Vitamin E and cancer: an update on the emerging role of Î³ and Î´ tocotrienols. European Journal of Nutrition, 2020, 59, 845-857.	1.8	39
2188	Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines. Breast Cancer, 2020, 27, 213-224.	1.3	0
2189	Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. Oncogene, 2020, 39, 50-63.	2.6	43
2190	Molecular biology of oral cavity squamous cell carcinoma. Oral Oncology, 2020, 102, 104552.	0.8	20
2191	10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models. Molecular Cancer Therapeutics, 2020, 19, 490-501.	1.9	9
2192	Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma. Cancers, 2020, 12, 111.	1.7	31
2193	Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118625.	1.9	13
2194	Systematic Comparison of Label-Free, SILAC, and TMT Techniques to Study Early Adaption toward Inhibition of EGFR Signaling in the Colorectal Cancer Cell Line DiFi. Journal of Proteome Research, 2020, 19, 926-937.	1.8	36
2195	CD274 (PD-L1), CDKN2A (p16), TP53, and EGFR immunohistochemical profile in primary, recurrent and metastatic vulvar cancer. Modern Pathology, 2020, 33, 893-904.	2.9	17
2196	Tannic acid and vitamin E loaded PLGA nanoparticles ameliorate hepatic injury in a chronic alcoholic liver damage model via EGFR-AKT-STAT3 pathway. Nanomedicine, 2020, 15, 235-257.	1.7	17
2198	Promising Chimeric Antigen Receptors for Non-B-Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas. , 2020, , 137-163.		2
2199	Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa126.	0.4	27
2200	MEK1/2 Inhibition in Murine Heart and Aorta After Oral Administration of Refametinib Supplemented Drinking Water. Frontiers in Pharmacology, 2020, 11, 1336.	1.6	4

#	Article	IF	Citations
2201	Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial. British Journal of Cancer, 2020, 123, 1616-1624.	2.9	17
2202	Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy. Journal of Controlled Release, 2020, 327, 500-511.	4.8	12
2203	Protein Binding of Lapatinib and Its N- and O-Dealkylated Metabolites Interrogated by Fluorescence, Ultrafast Spectroscopy and Molecular Dynamics Simulations. Frontiers in Pharmacology, 2020, 11, 576495.	1.6	10
2204	Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs. Inorganic Chemistry, 2020, 59, 17794-17810.	1.9	11
2205	EGFR Expression in HER2-Driven Breast Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 9008.	1.8	13
2206	Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors. Cell Communication and Signaling, 2020, 18, 179.	2.7	9
2207	p38Î± MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor. Journal of Biomolecular Structure and Dynamics, 2022, 40, 3046-3059.	2.0	20
2208	In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors. Molecules, 2020, 25, 5190.	1.7	23
2209	Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines. BMC Cancer, 2020, 20, 1039.	1.1	8
2210	The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells. Frontiers in Oncology, 2020, 10, 1249.	1.3	97
2211	Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments. Cells, 2020, 9, 2352.	1.8	31
2212	Tumor Suppressor Role of hsa-miR-193a-3p and -5p in Cutaneous Melanoma. International Journal of Molecular Sciences, 2020, 21, 6183.	1.8	16
2213	Theoretical evaluation of EGFR kinase inhibition and toxicity of di-indol-3-yl disulphides with anti-cancer potency. Journal of Biomolecular Structure and Dynamics, 2022, 40, 622-634.	2.0	4
2214	Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). Bioorganic Chemistry, 2020, 105, 104274.	2.0	14
2215	EGFR and HER2 small molecules inhibitors as potential therapeutics in veterinary oncology. Revista Colombiana De Ciencias QuÃ¡mico FarmacÃ©uticas, 2020, 49, .	0.3	1
2216	Current Understanding of the Emerging Role of Prolidase in Cellular Metabolism. International Journal of Molecular Sciences, 2020, 21, 5906.	1.8	20
2217	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers, 2020, 12, 2392.	1.7	171
2218	Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment. Crystals, 2020, 10, 725.	1.0	4

#	Article	IF	Citations
2219	Role of EGFR in the Nervous System. Cells, 2020, 9, 1887.	1.8	88
2220	EGFRâ€rich extracellular vesicles derived from highly metastatic nasopharyngeal carcinoma cells accelerate tumour metastasis through PI3K/AKT pathwayâ€suppressed ROS. Journal of Extracellular Vesicles, 2020, 10, e12003.	5.5	25
2221	A proximity-exponential hybridization chain reaction (PEHCR) and its application for nondestructive analysis of membrane protein-protein interactions on living cells. Analytica Chimica Acta, 2020, 1125, 8-18.	2.6	2
2222	Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. Cancers, 2020, 12, 1214.	1.7	26
2223	Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. Journal of Medicinal Chemistry, 2020, 63, 10726-10741.	2.9	30
2224	Exosomes Derived from the Human Primary Colorectal Cancer Cell Line SW480 Orchestrate Fibroblastâ€Led Cancer Invasion. Proteomics, 2020, 20, e2000016.	1.3	25
2225	NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma. Cell Death and Disease, 2020, 11, 335.	2.7	35
2226	Tumor Necrosis Factor Î± Blockade: An Opportunity to Tackle Breast Cancer. Frontiers in Oncology, 2020, 10, 584.	1.3	96
2227	EGFRâ€targeted CARâ€T cells are potent and specific in suppressing tripleâ€negative breast cancer both in vitro and in vivo. Clinical and Translational Immunology, 2020, 9, e01135.	1.7	48
2228	EHD1 and RUSC2 Control Basal Epidermal Growth Factor Receptor Cell Surface Expression and Recycling. Molecular and Cellular Biology, 2020, 40, .	1.1	8
2229	Cell Biology of Intracellular Adaptation ofMycobacterium lepraein the Peripheral Nervous System. , 2020, , 227-245.		0
2230	Long noncoding RNA MYLK-AS1 promotes growth and invasion of hepatocellular carcinoma through the EGFR/HER2-ERK1/2 signaling pathway. International Journal of Biological Sciences, 2020, 16, 1989-2000.	2.6	12
2231	Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFRL858R/T790M NSCLCs by the conformation constrained strategy. European Journal of Medicinal Chemistry, 2020, 199, 112388.	2.6	15
2232	Glioblastoma multiforme: novel therapeutic targets. Expert Opinion on Therapeutic Targets, 2020, 24, 605-614.	1.5	36
2233	Recent advances of scanning electrochemical microscopy and scanning ion conductance microscopy for single-cell analysis. Current Opinion in Electrochemistry, 2020, 22, 178-185.	2.5	35
2234	Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. Clinical Colorectal Cancer, 2020, 19, 270-276.	1.0	0
2235	In Utero Exposure to Bisphenol a Promotes Mammary Tumor Risk in MMTV-Erbb2 Transgenic Mice Through the Induction of ER-erbB2 Crosstalk. International Journal of Molecular Sciences, 2020, 21, 3095.	1.8	7
2236	Targeting EGFR Overexpression at the Surface of Colorectal Cancer Cells by Exploiting Amidated BODIPYâ€Peptide Conjugates. Photochemistry and Photobiology, 2020, 96, 581-595.	1.3	5

#	Article	IF	Citations
2237	Theranostic approaches in nuclear medicine: current status and future prospects. Expert Review of Medical Devices, 2020, 17, 331-343.	1.4	63
2238	Microfluidic-Based Holonomic Constraints of siRNA in the Kernel of Lipid/Polymer Hybrid Nanoassemblies for Improving Stable and Safe In Vivo Delivery. ACS Applied Materials & Interfaces, 2020, 12, 14839-14854.	4.0	32
2239	Annotation and cluster analysis of long noncoding RNA linked to male sex and estrogen in cancers. Npj Precision Oncology, 2020, 4, 5.	2.3	14
2240	The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells. Cancers, 2020, 12, 727.	1.7	52
2241	The multifaceted role of kinases in amyotrophic lateral sclerosis: genetic, pathological and therapeutic implications. Brain, 2020, 143, 1651-1673.	3.7	39
2242	In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models. Bioorganic Chemistry, 2020, 99, 103790.	2.0	17
2243	The role of ErbB4 in cancer. Cellular Oncology (Dordrecht), 2020, 43, 335-352.	2.1	66
2244	Epidermal growth factor receptor (EGFR) involvement in epithelialâ€derived cancers and its current antibodyâ€based immunotherapies. Cell Biology International, 2020, 44, 1267-1282.	1.4	47
2245	Modulation of Immune Responses by Platelet-Derived ADAM10. Frontiers in Immunology, 2020, 11, 44.	2.2	26
2246	Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs. Frontiers in Oncology, 2020, 10, 62.	1.3	14
2247	Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial. Clinical Oncology, 2020, 32, 656-664.	0.6	11
2248	Mechanics of actin filaments in cancer onset and progress. International Review of Cell and Molecular Biology, 2020, 355, 205-243.	1.6	8
2249	Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations. European Journal of Medicinal Chemistry, 2020, 203, 112511.	2.6	20
2250	EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells. Advances in Cancer Research, 2020, 147, 161-188.	1.9	77
2251	EPS8 phosphorylation by Src modulates its oncogenic functions. British Journal of Cancer, 2020, 123, 1078-1088.	2.9	2
2252	B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncology, 2020, 16, 1767-1791.	1.1	16
2253	An Automatable Hydrogel Culture Platform for Evaluating Efficacy of Antibodyâ€Based Therapeutics in Overcoming Chemoresistance. Biotechnology Journal, 2020, 15, e1900439.	1.8	16
2254	CAR T cells and checkpoint inhibition for the treatment of glioblastoma. Expert Opinion on Biological Therapy, 2020, 20, 579-591.	1.4	37

#	Article	IF	Citations
2255	Frequent EGFR expression/ EGFR amplification and lack of activating mutation in testicular choriocarcinoma. Pathology International, 2020, 70, 262-269.	0.6	6
2256	Synergistic Anti-Tumour Effect of Syk Inhibitor and Olaparib in Squamous Cell Carcinoma: Roles of Syk in EGFR Signalling and PARP1 Activation. Cancers, 2020, 12, 489.	1.7	10
2257	Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro . International Journal of Nanomedicine, 2020, Volume 15, 991-1003.	3.3	18
2258	Ret Receptor Has Distinct Alterations and Functions in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2020, 25, 13-26.	1.0	12
2259	HUWE1 promotes EGFR ubiquitination and degradation to protect against renal tubulointerstitial fibrosis. FASEB Journal, 2020, 34, 4591-4601.	0.2	17
2260	Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application. Biosensors and Bioelectronics, 2020, 162, 112250.	5.3	27
2261	Nanotechnology for cancer screening and diagnosis: from innovations to clinical applications. , 2020, , 261-289.		3
2262	Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127167.	1.0	34
2263	Dysregulated EGFR pathway in serum in early-stage breast cancer patients: A case control study. Scientific Reports, 2020, 10, 6714.	1.6	7
2264	Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models. Molecular Cancer Therapeutics, 2020, 19, 976-987.	1.9	127
2265	A Feedback Loop Comprising EGF/TGFÎ± Sustains TFCP2-Mediated Breast Cancer Progression. Cancer Research, 2020, 80, 2217-2229.	0.4	18
2266	Notch Mediates Inter-tissue Communication to Promote Tumorigenesis. Current Biology, 2020, 30, 1809-1820.e4.	1.8	25
2267	Nuclear ErbB2 expression in hepatocytes in liver disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 309-318.	1.4	5
2268	Investigation of EGFR/pi3k/Akt signaling pathway in seminomas. Biotechnic and Histochemistry, 2021, 96, 125-137.	0.7	5
2269	Genomeâ€scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinibâ€resistant lung cancer. Molecular Oncology, 2021, 15, 487-502.	2.1	15
2270	Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives. Archiv Der Pharmazie, 2021, 354, e2000351.	2.1	9
2271	Podocyte EGFR Inhibits Autophagy Through Upregulation of Rubicon in Type 2 Diabetic Nephropathy. Diabetes, 2021, 70, 562-576.	0.3	37
2272	Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer. Molecular Cancer Research, 2021, 19, 388-394.	1.5	11

#	Article	IF	Citations
2273	Piptides: New, Easily Accessible Chemotypes For Interactions With Biomolecules. Angewandte Chemie, 2021, 133, 6727-6733.	1.6	0
2274	Experimental HER2- targeted therapies for biliary tract cancer. Expert Opinion on Investigational Drugs, 2021, 30, 389-399.	1.9	9
2275	Piptides: New, Easily Accessible Chemotypes For Interactions With Biomolecules. Angewandte Chemie - International Edition, 2021, 60, 6653-6659.	7.2	4
2276	Cancer cell-targeted cisplatin prodrug delivery in vivo via metabolic labeling and bioorthogonal click reaction. Biomaterials Science, 2021, 9, 1301-1312.	2.6	11
2277	Neuregulin Signaling in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1270, 1-29.	0.8	1
2278	Cancer-driving mutations and variants of components of the membrane trafficking core machinery. Life Sciences, 2021, 264, 118662.	2.0	2
2279	Atomic force microscopy for revealing micro/nanoscale mechanics in tumor metastasis: from single cells to microenvironmental cues. Acta Pharmacologica Sinica, 2021, 42, 323-339.	2.8	43
2280	Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer. , 2021, , 221-270.		0
2281	Advances in Lung Cancer Driver Genes Associated With Brain Metastasis. Frontiers in Oncology, 2020, 10, 606300.	1.3	12
2282	Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 779.	1.8	53
2283	Mechanisms of Cetuximab Resistance and How to Overcome It. , 2021, , 21-51.		1
2284	Oridonin, an AKT1 Inhibitor, Suppresses the Growth of Breast Cancers with Hyperactivation of PI3K/AKT Signaling. E3S Web of Conferences, 2021, 271, 03014.	0.2	0
2285	Changes in Protein Glycosylation in Head and Neck Squamous Cell Carcinoma. Journal of Cancer, 2021, 12, 1455-1466.	1.2	22
2286	Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies. RSC Medicinal Chemistry, 2021, 12, 1650-1671.	1.7	50
2287	Extracellular Prolidase (PEPD) Induces Anabolic Processes through EGFR, Î²1-integrin, and IGF-1R Signaling Pathways in an Experimental Model of Wounded Fibroblasts. International Journal of Molecular Sciences, 2021, 22, 942.	1.8	7
2288	Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. Frontiers in Pharmacology, 2021, 12, 636324.	1.6	2
2289	Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. OncoTargets and Therapy, 2021, Volume 14, 1341-1366.	1.0	12
2290	Mitogenâ€activated protein kinase inhibitionâ€induced modulation of epidermal growth factor receptor signaling in human head and neck squamous cell carcinoma. Head and Neck, 2021, 43, 1721-1729.	0.9	5

#	Article	IF	Citations
2291	Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers. Frontiers in Oncology, 2021, 11, 614332.	1.3	33
2292	The dark-side of the outside: how extracellular heat shock proteins promote cancer. Cellular and Molecular Life Sciences, 2021, 78, 4069-4083.	2.4	39
2293	ERBB1/2/3 Expression, Prognosis, and Immune Infiltration in Cutaneous Melanoma. Frontiers in Genetics, 2021, 12, 602160.	1.1	14
2294	The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis. Molecular Oncology, 2021, 15, 2140-2155.	2.1	3
2295	N â€glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC. Cancer Science, 2021, 112, 1911-1923.	1.7	10
2296	At the Crossroads of Molecular Biology and Immunology: Molecular Pathways for Immunological Targeting of Head and Neck Squamous Cell Carcinoma. Frontiers in Oral Health, 2021, 2, 647980.	1.2	4
2297	Dysregulation of the NRG1/ERBB pathway causes a developmental disorder with gastrointestinal dysmotility in humans. Journal of Clinical Investigation, 2021, 131, .	3.9	24
2298	Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structureâ€“activity relationship and biological activity as potential antitumor and anticonvulsant agents. European Journal of Medicinal Chemistry, 2021, 214, 113222.	2.6	29
2299	Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFRT790M mutant cell lines. European Journal of Medicinal Chemistry, 2021, 213, 113173.	2.6	12
2300	Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake. International Journal of Molecular Sciences, 2021, 22, 2770.	1.8	14
2301	Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts. Oncogene, 2021, 40, 2651-2666.	2.6	13
2302	Optimized Synthesis of New N-Mustards Based on 2-Mercaptobenzoxazole Derivatives with Antitumor Activity. Biomedicines, 2021, 9, 476.	1.4	3
2303	The Combination of Zerumbone and 5-FU: A Significant Therapeutic Strategy in Sensitizing Colorectal Cancer Cells to Treatment. BioMed Research International, 2021, 2021, 1-18.	0.9	5
2304	Synthesis and biological evaluation of new coumarin derivatives as cytotoxic agents. Archiv Der Pharmazie, 2021, 354, e2100029.	2.1	10
2305	Competing Endogenous RNA Networks in Glioma. Frontiers in Genetics, 2021, 12, 675498.	1.1	19
2306	Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review. Molecular Biology Reports, 2021, 48, 3593-3604.	1.0	12
2307	A novel tumor inhibitory hybridoma monoclonal antibody with dual specificity for HER3 and HER2. Current Research in Translational Medicine, 2021, 69, 103277.	1.2	4
2308	Resistance to Intervention: Paclitaxel in Breast Cancer. Mini-Reviews in Medicinal Chemistry, 2021, 21, 1237-1268.	1.1	34

#	Article	IF	Citations
2309	ST6Gal1 targets the ectodomain of ErbB2 in a site-specific manner and regulates gastric cancer cell sensitivity to trastuzumab. Oncogene, 2021, 40, 3719-3733.	2.6	27
2310	Complementarity principle in terms of electron density for the study of EGFR complexes. Future Medicinal Chemistry, 2021, 13, 863-875.	1.1	17
2311	Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice. Cancers, 2021, 13, 2189.	1.7	8
2312	Evaluation of Serum s EGFR in Ovarian Tumors, its Comparison with Serum CA125, HE4 and Correlation with Histopathological Types. Indian Journal of Gynecologic Oncology, 2021, 19, 1.	0.1	3
2313	In vitro and in silico anticancer potential analysis of Streptomyces sp. extract against human lung cancer cell line, A549. 3 Biotech, 2021, 11, 254.	1.1	7
2314	Neuregulin-1-Î²1 and Î³-secretase play a critical role in sphere-formation and cell survival of urothelial carcinoma cancer stem-like cells. Biochemical and Biophysical Research Communications, 2021, 552, 128-135.	1.0	1
2315	Light up multiple protein dimers on cell surface based on proximity-induced fluorescence activation of DNA-templated sliver nanoclusters. Biosensors and Bioelectronics, 2021, 179, 113064.	5.3	16
2316	Growth factorâ€“dependent ErbB vesicular dynamics couple receptor signaling to spatially and functionally distinct Erk pools. Science Signaling, 2021, 14, .	1.6	18
2317	Molecular landscape of head and neck cancer and implications for therapy. Annals of Translational Medicine, 2021, 9, 915-915.	0.7	51
2319	Oxytocin receptor induces mammary tumorigenesis through prolactin/p-STAT5 pathway. Cell Death and Disease, 2021, 12, 588.	2.7	11
2320	The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 639745.	1.3	9
2321	Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2+ Breast Cancer Cells. Journal of Histochemistry and Cytochemistry, 2021, 69, 461-473.	1.3	7
2322	Nextâ€Generation Kinase Inhibitors Targeting Specific Biomarkers in Nonâ€Small Cell Lung Cancer (NSCLC): A Recent Overview. ChemMedChem, 2021, 16, 2459-2479.	1.6	12
2323	Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition. Cell Communication and Signaling, 2021, 19, 67.	2.7	62
2324	Effects of molecular markers on the treatment decision and prognosis of colorectal cancer: a narrative review. Journal of Gastrointestinal Oncology, 2021, 12, 1191-1196.	0.6	8
2326	Mutation status and immunohistochemical correlation of EGFR mutations in gastrointestinal stromal tumors. Balkan Journal of Medical Genetics, 2021, 24, 67-72.	0.5	0
2327	Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors. Bioorganic Chemistry, 2021, 112, 104848.	2.0	6
2328	Oral Cancer Stem Cells: Therapeutic Implications and Challenges. Frontiers in Oral Health, 2021, 2, 685236.	1.2	13

#	Article	IF	Citations
2329	Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 3453.	1.7	6
2330	Amphiregulin stimulates human chorionic gonadotropin expression by inducing ERK1/2-mediated ID3 expression in trophoblast cells. Placenta, 2021, 112, 73-80.	0.7	5
2331	Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature. BMC Cancer, 2021, 21, 850.	1.1	18
2332	Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies. Vaccines, 2021, 9, 724.	2.1	27
2333	The influence of testosterone suppression on HER2 immunoexpression in prostatic neoplastic tissue. Molecular and Clinical Oncology, 2021, 15, 185.	0.4	3
2334	EGFRAP encodes a new negative regulator of the EGFR acting in both normal and oncogenic EGFR/Ras-driven tissue morphogenesis. PLoS Genetics, 2021, 17, e1009738.	1.5	5
2335	Identification of steroidal saponins from Tribulus terrestris and their in silico docking studies. Journal of Cellular Biochemistry, 2021, 122, 1665-1685.	1.2	4
2336	Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry. Biochemical Pharmacology, 2021, 190, 114643.	2.0	11
2337	Altered proTGFÎ±/cleaved TGFÎ± ratios offer new therapeutic strategies in renal carcinoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 256.	3.5	1
2338	Immunohistochemical expression of ErbB/HER family proteins in patients with vulvar cancer. International Journal of Gynecology and Obstetrics, 2021, , .	1.0	3
2339	Prognostic Role of EGFR/p-EGFR in Patients With Nasopharyngeal Carcinoma: A Meta-Analysis. Frontiers in Oncology, 2021, 11, 697369.	1.3	5
2340	Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells. Cellular and Molecular Biology Letters, 2021, 26, 39.	2.7	38
2341	miR-424 induces apoptosis in glioblastoma cells and targets AKT1 and RAF1 oncogenes from the ERBB signaling pathway. European Journal of Pharmacology, 2021, 906, 174273.	1.7	10
2342	MicroRNAs as the critical regulators of protein kinases in prostate and bladder cancers. Egyptian Journal of Medical Human Genetics, 2021, 22, .	0.5	3
2343	Post-transcriptional screen of cancer amplified genes identifies ERBB2/Her2 signaling as AU-rich mRNA stability-promoting pathway. Oncogenesis, 2021, 10, 61.	2.1	1
2344	Peptidomimetic-based antibody surrogate for HER2. Acta Pharmaceutica Sinica B, 2021, 11, 2645-2654.	5.7	8
2345	Stainless steel quantum dots and its resonance fluorescence impact as new therapeutic agents for Laryngeal carcinoma treatment: In vitro study. Optics and Laser Technology, 2021, 142, 107263.	2.2	2
2346	Noncovalent EGFR T790M/L858R inhibitors based on diphenylpyrimidine scaffold: Design, synthesis, and bioactivity evaluation for the treatment of NSCLC. European Journal of Medicinal Chemistry, 2021, 223, 113626.	2.6	8

#	Article	IF	Citations
2347	Developments of CRBN-based PROTACs as potential therapeutic agents. European Journal of Medicinal Chemistry, 2021, 225, 113749.	2.6	64
2348	Molecular Targetable Pathways â€“ EGFR. , 2022, , 844-852.		0
2349	Insight into the impact of EGFR L792Y/F/H mutations on sensitivity to osimertinib: an in silico study. New Journal of Chemistry, 2021, 45, 4756-4765.	1.4	0
2350	Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer. Journal of Immunotherapy, 2021, 44, 49-62.	1.2	7
2351	Photoprocesses of the tyrosine kinase inhibitor gefitinib: from femtoseconds to microseconds and from solution to cells. Chemical Science, 2021, 12, 12027-12035.	3.7	5
2352	Click Conjugation of Boron Dipyrromethene (BODIPY) Fluorophores to EGFR-Targeting Linear and Cyclic Peptides. Molecules, 2021, 26, 593.	1.7	6
2353	Mathematical Modeling of the Dimerization of EGFR and ErbB3 inÂLung Adenocarcinoma. Springer Proceedings in Mathematics and Statistics, 2021, , 195-202.	0.1	0
2355	Intraperitoneal Photodynamic Therapy. , 2007, 134, 493-514.		42
2356	Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a New Target Molecule for Cancer Therapy. , 2008, 622, 281-295.		9
2357	Activated Epidermal Growth Factor Receptor in Ovarian Cancer. Cancer Treatment and Research, 2009, 149, 203-226.	0.2	34
2358	EGFR-Family Expression and Implications for Targeted Radionuclide Therapy. , 2008, , 25-58.		10
2359	Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy. , 2010, , 37-83.		2
2360	Potential Mechanisms Linking Insulin to Cancer. Energy Balance and Cancer, 2011, , 159-180.	0.2	3
2361	Molecular Basis of Lung Carcinogenesis. , 2017, , 447-496.		4
2362	Therapeutic Human Monoclonal Antibodies Against Cancer. Methods in Molecular Biology, 2014, 1060, 61-77.	0.4	20
2363	Beyond Trastuzumab: Second-Generation Targeted Therapies for HER-2-positive Breast Cancer. , 2011, , 91-107.		3
2364	Tyrosine Kinase Inhibitors and Cancer Therapy. , 2007, 172, 25-44.		5
2365	Targeting ERBB Receptors in Cancer. , 2007, 172, 45-57.		8

#	Article	IF	Citations
2366	The Mammalian Target of Rapamycin Kinase and Tumor Growth Inhibition. , 2007, 172, 99-124.		33
2367	An Evolutionary General Purpose WebGIS to Disclose EGFR Mutations in Lung Cancer. Lecture Notes in Computer Science, 2008, , 247-258.	1.0	2
2368	Erlotinib. Recent Results in Cancer Research, 2010, 184, 21-31.	1.8	3
2369	Epidermal Growth Factor (EGF) Receptor Signaling and Cancer. , 2010, , 119-141.		1
2370	Chemoprevention of Hormone Receptor-Negative Breast Cancer: New Approaches Needed. Recent Results in Cancer Research, 2010, 188, 147-162.	1.8	53
2371	Possible Mechanisms of Ï‰-3 PUFA Anti-tumour Action. , 2010, , 3-38.		7
2372	Matrix Metalloproteinases (MMPs) in Cancer Initiation and Progression. , 2017, , 207-236.		1
2373	Neu Oncogene. , 2013, , 30-32.		1
2374	Biology of Head and Neck Cancer. , 2010, , 1015-1029.		5
2380	Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in nonâ€“small cell lung cancer. Cancer Science, 2020, 111, 2736-2746.	1.7	12
2381	Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer. Cancer Science, 2020, 111, 3268-3278.	1.7	15
2382	Combined High Resistin and EGFR Expression Predicts a Poor Prognosis in Breast Cancer. BioMed Research International, 2020, 2020, 1-11.	0.9	8
2383	ErbB2: From an EGFR Relative to a Central Target for Cancer Therapy. Cancer Research, 2016, 76, 3659-3662.	0.4	12
2384	IL-6 involvement in epithelial cancers. Journal of Clinical Investigation, 2007, 117, 3660-3663.	3.9	234
2385	Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. Journal of Clinical Investigation, 2009, 119, 2702-2713.	3.9	80
2386	Î²4 Integrin signaling induces expansion of prostate tumor progenitors. Journal of Clinical Investigation, 2013, 123, 682-99.	3.9	74
2387	Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant. Journal of Clinical Investigation, 2015, 125, 1648-1664.	3.9	110
2388	Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Chemical and Pharmaceutical Bulletin, 2020, 68, 971-980.	0.6	11

#	Article	IF	Citations
2390	Induction of ErbB-3 Expression by Î±6Î²4 Integrin Contributes to Tamoxifen Resistance in ERÎ²1-Negative Breast Carcinomas. PLoS ONE, 2008, 3, e1592.	1.1	47
2391	Structure-Function Analysis of Nucleolin and ErbB Receptors Interactions. PLoS ONE, 2009, 4, e6128.	1.1	29
2392	Coupled Stochastic Spatial and Non-Spatial Simulations of ErbB1 Signaling Pathways Demonstrate the Importance of Spatial Organization in Signal Transduction. PLoS ONE, 2009, 4, e6316.	1.1	26
2393	Profiling the HER3/PI3K Pathway in Breast Tumors Using Proximity-Directed Assays Identifies Correlations between Protein Complexes and Phosphoproteins. PLoS ONE, 2011, 6, e16443.	1.1	20
2394	Comparing the Epidermal Growth Factor Interaction with Four Different Cell Lines: Intriguing Effects Imply Strong Dependency of Cellular Context. PLoS ONE, 2011, 6, e16536.	1.1	46
2395	P130Cas Attenuates Epidermal Growth Factor (EGF) Receptor Internalization by Modulating EGF-Triggered Dynamin Phosphorylation. PLoS ONE, 2011, 6, e20125.	1.1	8
2396	EGF Receptor Exposed to Oxidative Stress Acquires Abnormal Phosphorylation and Aberrant Activated Conformation That Impairs Canonical Dimerization. PLoS ONE, 2011, 6, e23240.	1.1	57
2397	An RNA Interference Phenotypic Screen Identifies a Role for FGF Signals in Colon Cancer Progression. PLoS ONE, 2011, 6, e23381.	1.1	23
2398	A Neutralizing RNA Aptamer against EGFR Causes Selective Apoptotic Cell Death. PLoS ONE, 2011, 6, e24071.	1.1	141
2399	Screening for EGFR and KRAS Mutations in Endobronchial Ultrasound Derived Transbronchial Needle Aspirates in Non-Small Cell Lung Cancer Using COLD-PCR. PLoS ONE, 2011, 6, e25191.	1.1	96
2400	Engagement of Overexpressed Her2 with GEP100 Induces Autonomous Invasive Activities and Provides a Biomarker for Metastases of Lung Adenocarcinoma. PLoS ONE, 2011, 6, e25301.	1.1	40
2401	LIV-1 Promotes Prostate Cancer Epithelial-to-Mesenchymal Transition and Metastasis through HB-EGF Shedding and EGFR-Mediated ERK Signaling. PLoS ONE, 2011, 6, e27720.	1.1	94
2402	BRCA1-IRIS Overexpression Promotes Formation of Aggressive Breast Cancers. PLoS ONE, 2012, 7, e34102.	1.1	27
2403	Modeling of Tumor Progression in NSCLC and Intrinsic Resistance to TKI in Loss of PTEN Expression. PLoS ONE, 2012, 7, e48004.	1.1	42
2404	Systemic Analysis of Gene Expression Profiles Identifies ErbB3 as a Potential Drug Target in Pediatric Alveolar Rhabdomyosarcoma. PLoS ONE, 2012, 7, e50819.	1.1	9
2405	MUC4 Overexpression Augments Cell Migration and Metastasis through EGFR Family Proteins in Triple Negative Breast Cancer Cells. PLoS ONE, 2013, 8, e54455.	1.1	60
2406	Copy Number Variation Analysis in Familial BRCA1/2-Negative Finnish Breast and Ovarian Cancer. PLoS ONE, 2013, 8, e71802.	1.1	26
2407	Microfluidic Generated EGF-Gradients Induce Chemokinesis of Transplantable Retinal Progenitor Cells via the JAK/STAT and PI3Kinase Signaling Pathways. PLoS ONE, 2013, 8, e83906.	1.1	21

#	Article	IF	Citations
2408	Identification of Anti-ErbB2 Dual Variable Domain Immunoglobulin (DVD-Igâ„¢) Proteins with Unique Activities. PLoS ONE, 2014, 9, e97292.	1.1	17
2409	Functional Aspects of the EGF-Induced MAP Kinase Cascade: A Complex Self-Organizing System Approach. PLoS ONE, 2014, 9, e111612.	1.1	1
2410	Identification of Anti-EGFR and Anti-ErbB3 Dual Variable Domains Immunoglobulin (DVD-Ig) Proteins with Unique Activities. PLoS ONE, 2015, 10, e0124135.	1.1	17
2411	Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments. PLoS ONE, 2015, 10, e0128360.	1.1	23
2412	The Epidermal Growth Factor Receptor (EGFR / HER-1) Gatekeeper Mutation T790M Is Present in European Patients with Early Breast Cancer. PLoS ONE, 2015, 10, e0134398.	1.1	15
2413	Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0143132.	1.1	13
2414	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma. PLoS ONE, 2016, 11, e0148101.	1.1	25
2415	Epidermal Growth Factor Receptor in Prostate Cancer Derived Exosomes. PLoS ONE, 2016, 11, e0154967.	1.1	51
2416	HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis. PLoS ONE, 2016, 11, e0161219.	1.1	24
2417	Distinct ErbB2 receptor populations differentially interact with beta1 integrin in breast cancer cell models. PLoS ONE, 2017, 12, e0174230.	1.1	9
2418	Recent developments in receptor tyrosine kinases targeted anticancer therapy. Veterinary World, 2016, 9, 80-90.	0.7	19
2419	Î´-Catenin Increases the Stability of EGFR by Decreasing c-Cbl Interaction and Enhances EGFR/Erk1/2 Signaling in Prostate Cancer. Molecules and Cells, 2018, 41, 320-330.	1.0	10
2420	Emerging Therapeutic Strategies in Breast Cancer. Southern Medical Journal, 2017, 110, 632-637.	0.3	5
2421	High resolution measurement of membrane receptor endocytosis. Journal of Biological Methods, 2018, 5, e105.	1.0	2
2422	Plakophilin-2 induced EGFR phosphorylation: a focus on the intracellular activators of EGFR. Receptors & Clinical Investigation, 2014, 2, e485.	0.9	2
2423	Cancer Stem Cells and Their Mechanism of Chemo-Radiation Resistance. International Journal of Stem Cells, 2009, 2, 109-114.	0.8	76
2424	Aberrant Receptor Signaling and Trafficking as Mechanisms in Oncogenesis. Critical Reviews in Oncogenesis, 2007, 13, 39-74.	0.2	42
2427	A chemoproteomic method for identifying cellular targets of covalent kinase inhibitors. Genes and Cancer, 2016, 7, 148-153.	0.6	10

#	Article	IF	Citations
2428	EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review. Genes and Cancer, 2017, 8, 589-599.	0.6	45
2429	Pathways driving the endocytosis of mutant and wild-type EGFR in cancer. Oncoscience, 2014, 1, 504-512.	0.9	61
2430	Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients. Oncotarget, 2016, 7, 55890-55899.	0.8	34
2431	Characterization of a P-Rex1 gene signature in breast cancer cells. Oncotarget, 2016, 7, 51335-51348.	0.8	12
2432	Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. Oncotarget, 2017, 8, 108463-108479.	0.8	8
2433	Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells. Oncotarget, 2016, 7, 62352-62363.	0.8	22
2434	Role of EGF/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells. Oncotarget, 2016, 7, 65602-65613.	0.8	12
2435	Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials. Oncotarget, 2017, 8, 7014-7024.	0.8	11
2436	Sprouty2 inhibits amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells. Oncotarget, 2016, 7, 81645-81660.	0.8	13
2437	Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma. Oncotarget, 2017, 8, 1555-1568.	0.8	22
2438	Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells. Oncotarget, 2017, 8, 5003-5015.	0.8	16
2439	RHBDD1 upregulates EGFR via the AP-1 pathway in colorectal cancer. Oncotarget, 2017, 8, 25251-25260.	0.8	6
2440	A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer. Oncotarget, 2017, 8, 27286-27299.	0.8	13
2441	Tyrosine kinase inhibitor induced growth factor receptor upregulation enhances the efficacy of near-infrared targeted photodynamic therapy in esophageal adenocarcinoma cell lines. Oncotarget, 2017, 8, 29846-29856.	0.8	12
2442	Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. Oncotarget, 2014, 5, 298-308.	0.8	44
2443	Transcriptional regulation of mixed lineage kinase 3 by estrogen and its implication in ER-positive breast cancer pathogenesis. Oncotarget, 2017, 8, 33172-33184.	0.8	5
2444	siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells. Oncotarget, 2017, 8, 52584-52593.	0.8	8
2445	Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells. Oncotarget, 2017, 8, 60109-60122.	0.8	18

#	Article	IF	Citations
2446	HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma. Oncotarget, 2017, 8, 69559-69576.	0.8	18
2447	Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. Oncotarget, 2017, 8, 67592-67604.	0.8	15
2448	Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells. Oncotarget, 2017, 8, 58847-58864.	0.8	12
2449	Prognostic and predictive value of serum carcinoembryonic antigen levels in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutations and receiving tyrosine kinase inhibitors. Oncotarget, 2017, 8, 70865-70873.	0.8	7
2450	ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells. Oncotarget, 2014, 5, 5138-5152.	0.8	33
2451	Intravesicular epidermal growth factor receptor subject to retrograde trafficking drives epidermal growth factor-dependent migration. Oncotarget, 2018, 9, 6463-6477.	0.8	7
2452	Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer. Oncotarget, 2011, 2, 165-177.	0.8	52
2453	Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib. Oncotarget, 2018, 9, 33382-33395.	0.8	7
2454	Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget, 2015, 6, 6029-6039.	0.8	29
2455	Tyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER). Oncotarget, 2015, 6, 13320-13333.	0.8	27
2456	Frequent amplification of AIB1, a critical oncogene modulating major signaling pathways, is associated with poor survival in gastric cancer. Oncotarget, 2015, 6, 14344-14359.	0.8	24
2457	PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells. Oncotarget, 2011, 2, 1134-1144.	0.8	36
2458	Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. Oncotarget, 2015, 6, 21085-21099.	0.8	31
2459	ROS1 amplification mediates resistance to gefitinib in glioblastoma cells. Oncotarget, 2015, 6, 20388-20395.	0.8	16
2460	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. Oncotarget, 2015, 6, 24780-24796.	0.8	77
2461	Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget, 2015, 6, 30929-30938.	0.8	10
2462	Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer. Oncotarget, 2015, 6, 32027-32038.	0.8	36
2463	Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation. Oncotarget, 2015, 6, 34992-35003.	0.8	51

#	Article	IF	Citations
2464	The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget, 2015, 6, 33602-33611.	0.8	53
2465	Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo. Oncotarget, 2015, 6, 38912-38925.	0.8	34
2466	Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer. Oncotarget, 2016, 7, 610-621.	0.8	37
2467	EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma. Oncotarget, 2016, 7, 9017-9025.	0.8	16
2468	MRTF/SRF dependent transcriptional regulation of TAZ in breast cancer cells. Oncotarget, 2016, 7, 13706-13716.	0.8	27
2469	Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma. Oncotarget, 2016, 7, 13167-13181.	0.8	14
2470	APIP, an ERBB3-binding partner, stimulates erbB2-3 heterodimer formation to promote tumorigenesis. Oncotarget, 2016, 7, 21601-21617.	0.8	9
2471	HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth. Oncotarget, 2016, 7, 23594-23607.	0.8	9
2472	Tumor-suppressive miR-218-5p inhibits cancer cell proliferation and migration via EGFR in non-small cell lung cancer. Oncotarget, 2016, 7, 28075-28085.	0.8	71
2473	Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies. Oncotarget, 2016, 7, 45042-45051.	0.8	21
2474	Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D. Oncotarget, 0, 7, 42340-42352.	0.8	18
2475	PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells. Oncotarget, 2016, 7, 49384-49396.	0.8	12
2476	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. Journal of Cancer Metastasis and Treatment, 2018, 4, 12.	0.5	5
2477	Detection of HER2 polymorphism and expression using circulating DNA and RNA as a tool in lung adenocarcinoma patients: a case control study. Annals of Translational Medicine, 2016, 4, 209-209.	0.7	1
2478	Treatment strategies of epidermal growth factor receptor inhibitor-induced skin toxicities: pre-emptive or reactive?. Annals of Translational Medicine, 2016, 4, 318-318.	0.7	3
2479	MET signaling promotes DNA repair and radiation resistance in glioblastoma stem-like cells. Annals of Translational Medicine, 2017, 5, 61-61.	0.7	8
2480	Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy. Translational Lung Cancer Research, 2020, 9, 2618-2628.	1.3	23
2481	Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer. Current Drug Targets, 2009, 10, 575-576.	1.0	18

#	Article	IF	Citations
2482	Recent Advances in the Development of â€œCurcumin Inspiredâ€•Compounds as New Therapeutic Agents. Mini-Reviews in Medicinal Chemistry, 2020, 20, 1543-1558.	1.1	4
2483	Phytochemicals for Breast Cancer Therapy: Current Status and Future Implications. Current Cancer Drug Targets, 2015, 15, 116-135.	0.8	53
2484	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 2019, 19, 595-630.	0.8	61
2485	Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Current Topics in Medicinal Chemistry, 2020, 20, 815-834.	1.0	229
2486	Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy. Current Cancer Therapy Reviews, 2008, 4, 271-284.	0.2	2
2487	Extraction of Phosphorylated Proteins from Formalin-Fixed Cancer Cells and Tissues. The Open Pathology Journal, 2008, 2, 46-52.	1.0	12
2488	Isoflavone Extracts Enhance the Effect of Epidermal Growth Factor Receptor Inhibitors in NSCLC Cell Lines. Anticancer Research, 2016, 36, 5827-5834.	0.5	6
2489	In Silico Identification of Novel Erlotinib Analogues Against Epidermal Growth Factor Receptor. Anticancer Research, 2016, 36, 6125-6132.	0.5	3
2490	Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis. In Vivo, 2017, 31, 641-648.	0.6	5
2491	EGFR activation monitored by SW-FCCS in live cells. Frontiers in Bioscience - Elite, 2011, E3, 22-32.	0.9	14
2492	Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. Cancer Biology and Medicine, 2016, 13, 87-100.	1.4	21
2493	Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Breast Cancer Cell Lines. Asian Pacific Journal of Cancer Prevention, 2020, 21, 439-447.	0.5	2
2494	Adamantinomatous craniopharyngioma: moving toward targeted therapies. Neurosurgical Focus, 2020, 48, E7.	1.0	26
2495	Computational modeling of drug response with applications to neuroscience. Dialogues in Clinical Neuroscience, 2014, 16, 465-477.	1.8	3
2496	HER1 R497K and HER2 I655V polymorphisms are linked to development of breast cancer. Disease Markers, 2013, 34, 407-17.	0.6	10
2498	Role of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy. World Journal of Gastroenterology, 2006, 12, 3297.	1.4	53
2499	New approaches in angiogenic targeting for colorectal cancer. World Journal of Gastroenterology, 2007, 13, 5857.	1.4	50
2500	Epidermal growth factor receptor inhibitors in colorectal cancer treatment: Whatâ€™s new?. World Journal of Gastroenterology, 2007, 13, 5877.	1.4	35

#	Article	IF	Citations
2501	Association betweenEGF+61A/G polymorphism and gastric cancer in Caucasians. World Journal of Gastroenterology, 2011, 17, 488.	1.4	19
2502	Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. World Journal of Gastroenterology, 2012, 18, 150.	1.4	23
2503	Clinical management of advanced gastric cancer: The role of new molecular drugs. World Journal of Gastroenterology, 2014, 20, 14537.	1.4	41
2504	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World Journal of Gastroenterology, 2016, 22, 6345.	1.4	94
2506	Association of Her-2 Expression and Clinicopathological Parameters in Colorectal Carcinoma in Indian Population. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 6-11.	0.1	5
2507	Receptor tyrosine kinase structure and function in health and disease. AIMS Biophysics, 2015, 2, 476-502.	0.3	12
2508	Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC). Journal of Thoracic Disease, 2011, 3, 57-64.	0.6	16
2509	The significance of genetics for cholangiocarcinoma development. Annals of Translational Medicine, 2013, 1, 28.	0.7	20
2510	Growth factor receptors: promising drug targets in cancer. Journal of Cancer Metastasis and Treatment, 2015, 1, 190.	0.5	35
2511	Clinical profile of cutaneous adverse effects of epidermal growth factor receptor inhibitors: A prospective observational study of 76 cases. Indian Dermatology Online Journal, 2019, 10, 251.	0.2	13
2512	Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells. Cancer Research and Treatment, 2016, 48, 355-364.	1.3	7
2513	Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of Action. Journal of Cancer Science & Therapy, 2013, 05, .	1.7	33
2514	Targeting HER2-Driven Cancers in Non-Breast Cancer Malignancies. Journal of Molecular Biomarkers & Diagnosis, 2012, 02, .	0.4	1
2515	Recent Advances in Molecular Targeted Therapy for advanced Colorectal Cancer and Nonâ€“Small Cell Lung Cancer. , 2012, 02, .		1
2516	Biflorin, A Naphthoquinone, Inhibitsegfr in Breast Cancer Cells. , 2013, 03, .		3
2517	Cancer: Tumor Iron Metabolism, Mitochondrial Dysfunction and Tumor Immunosuppression; â€œA Tight Partnershipâ€”Was Warburg Correct?â€• Journal of Cancer Therapy, 2012, 03, 278-311.	0.1	21
2518	Monoclonal Antibodies: An Emerging Class of Therapeutics in Non Small Cell Lung Cancer. Journal of Cancer Therapy, 2012, 03, 1170-1190.	0.1	4
2519	About the Feasibility of Personalized Medicine in a Low Income Country?. Open Journal of Social Sciences, 2015, 03, 41-45.	0.1	2

#	Article	IF	Citations
2520	HER2-Specific Vaccines for HER2-Positive Breast Cancer Immunotherapy. World Journal of Vaccines, 2015, 05, 106-128.	0.8	4
2521	Current approach in the treatment of hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2010, 2, 348.	0.8	82
2522	Dynamic interplay between adhesion surfaces in carcinomas: Cell-cell and cell-matrix crosstalk. World Journal of Biological Chemistry, 2016, 7, 64.	1.7	9
2523	Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a postâ€“EMA-approval descriptive study with a geriatric oncology focus. Turkish Journal of Gastroenterology, 2020, 31, 695-705.	0.4	1
2524	Targeted immunotherapy for non-small cell lung cancer. World Journal of Clinical Oncology, 2014, 5, 39.	0.9	7
2525	YAC tripeptide of epidermal growth factor promotes the proliferation of HaCaT keratinocytes through activation of EGFR. BMB Reports, 2014, 47, 581-586.	1.1	6
2526	Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective. BMB Reports, 2020, 53, 133-141.	1.1	6
2527	Antineoplastic effects of mammalian target of rapamycine inhibitors. World Journal of Transplantation, 2012, 2, 74.	0.6	12
2528	Triple negative breast cancer - current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2009, 153, 13-17.	0.2	43
2529	LAPATINIB IN BREAST CANCER - THE PREDICTIVE SIGNIFICANCE OF HER1 (EGFR), HER2, PTEN AND PIK3CA GENES AND LAPATINIB PLASMA LEVEL ASSESSMENT. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2010, 154, 281-288.	0.2	20
2530	Quinazoline Derivatives as Anticancer Agents: QSAR, Molecular Docking and in silico Pharmacokinetic Prediction. Indian Journal of Pharmaceutical Education and Research, 2018, 52, S309-S325.	0.3	1
2531	Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chinese Journal of Cancer, 2011, 30, 5-12.	4.9	116
2532	The Role of KRAS Mutation Testing in the Management of Patients With Metastatic Colorectal Cancer. Archives of Pathology and Laboratory Medicine, 2009, 133, 1600-1606.	1.2	98
2533	Second Messenger Systems in Human Gliomas. Archives of Pathology and Laboratory Medicine, 2007, 131, 1585-1590.	1.2	33
2534	Molecular targeted therapy for EGFR and VEGF in head and neck squamous cell carcinomas. Japanese Journal of Head and Neck Cancer, 2010, 36, 436-441.	0.0	3
2535	Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma. Journal of Cancer Research Updates, 2013, 2, 265-282.	0.3	53
2536	EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation. International Journal of Medical Sciences, 2013, 10, 320-330.	1.1	106
2537	Histone Deacetylase Inhibitor Trichostatin A Enhances Antitumor Effects of Docetaxel or Erlotinib in A549 Cell Line. Asian Pacific Journal of Cancer Prevention, 2012, 13, 3471-3476.	0.5	34

#	Article	IF	Citations
2538	Cell Free EGFR mRNA Expression and Implications for Survival and Metastasis in Non-Small Cell Lung Cancer Cases. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6445-6449.	0.5	7
2539	Clinical Implication of EGF A61G Polymorphism in the Risk of Non Small Cell Lung Adenocarcinoma Patients: A Case Control Study. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7529-7534.	0.5	6
2540	Identification of HPV Integration and Genomic Patterns Delineating the Clinical Landscape of Cervical Cancer. Asian Pacific Journal of Cancer Prevention, 2016, 16, 8041-8045.	0.5	3
2541	Pathways of topological rank analysis (PoTRA): a novel method to detect pathways involved in hepatocellular carcinoma. PeerJ, 2018, 6, e4571.	0.9	7
2542	Lipid-induced S-palmitoylation as a Vital Regulator of Cell Signaling and Disease Development. International Journal of Biological Sciences, 2021, 17, 4223-4237.	2.6	26
2543	Design, synthesis, molecular docking and biological evaluation of novel 1,5-diarylpyrazole-N,O-dimethyl hydroxamate derivatives as antiproliferative agents.. Journal of Advanced Biomedical and Pharmaceutical Sciences, 2021, 4, 214-225.	0.3	1
2544	Novel LAMC2 fusion protein has tumorâ€promoting properties in ovarian carcinoma. Cancer Science, 2021, 112, 4957-4967.	1.7	13
2545	Building 2D classification models and 3D CoMSIA models on small-molecule inhibitors of both wild-type and T790M/L858R double-mutant EGFR. Molecular Diversity, 2022, 26, 1715-1730.	2.1	7
2546	Targeted Therapies; Who Detects the Target?. Analytical Cellular Pathology, 2005, 27, 165-167.	0.7	2
2548	ErbB family. British Journal of Pharmacology, 2006, , S128-S128.	2.7	0
2549	Is There a Role for ErbB Dual Kinase Inhibition?. , 2007, , 225-234.		0
2550	Is There a Role for ErbB Dual Kinase Inhibition?. Translational Medicine Series, 2007, , 203-212.	0.0	0
2551	Molecular Biology of Lung Cancer as the Basis for Targeted Therapy. Translational Medicine Series, 2007, , 1-24.	0.0	0
2553	The role of ErbB3 N-glycan in dimer formation: Implications for transforming activity. Trends in Glycoscience and Glycotechnology, 2008, 20, 219-225.	0.0	0
2554	EGFR family heterodimers in cancer pathogenesis and treatment. , 2008, , 14-29.		4
2555	Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer. , 2008, , 103-126.		0
2556	Growth Factor Receptor Signaling and Metastasis of Oral Cancer. , 2009, , 185-196.		0
2557	Drug Combinations as a Therapeutic Approach for mTORC1 Inhibitors in Human Cancer. , 2009, , 149-178.		0

#	Article	IF	Citations
2558	Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. OncoTargets and Therapy, 2009, 2, 251.	1.0	1
2559	EGFR-Directed Monoclonal Antibodies. , 2010, , 407-436.		0
2562	Les facteurs de croissance et les rÃ©cepteurs Ã activitÃ© tyrosine kinase. , 2010, , 21-43.		0
2563	The ERK1/2 MAP Kinase Signaling Pathway in Tumor Progression and Metastasis. Cancer Metastasis - Biology and Treatment, 2010, , 25-40.	0.1	0
2565	Trastuzumab Resistance in Breast Cancer. , 2011, , 51-60.		0
2566	microRNA: A Potential Therapy Able to Target Multiple Cancer Pathways. , 2011, , 155-170.		0
2567	Resistance to Targeted Therapies As a Result of Mutation(s) in the Target. , 2011, , 1-31.		0
2568	Conditions of tumor-associated antigens as a proper target for therapeutic antibodies against solid cancers. Journal of Stem Cells and Regenerative Medicine, 2011, 7, 14-28.	2.2	1
2569	Genotyping non-small cell lung cancer (NSCLC) in Latin America (LATAM).. Journal of Clinical Oncology, 2011, 29, e21155-e21155.	0.8	0
2570	Protein Therapeutics in Oncology. , 2012, , 109-144.		1
2571	Somatic Alterations and Targeted Therapy. , 2012, , 51-101.		0
2573	Overexpression of Her1 (EGFR) in Gastric Cancer: A Saudi Regional Population Based Study. Open Journal of Pathology, 2012, 02, 120-126.	0.0	0
2574	Metastatic Colorectal Cancer: Optimizing Treatment with Anti-EGFR Monoclonal Antibody. Journal of Cancer Therapy, 2012, 03, 902-911.	0.1	0
2575	Growth Factors and the Redox State as New Therapeutic Targets for Colorectal Cancer. , 0, , .		1
2576	HERPESVIRUSES AS ONCOLYTIC AGENTS. , 2012, , 223-250.		0
2577	HGFK1 is Associated with a Better Prognostis and Reverses Inhibition by Gefitinib in NSCLC Cases. Asian Pacific Journal of Cancer Prevention, 2012, 13, 1457-1461.	0.5	0
2579	ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2012, , .	0.1	0
2580	An in vitro multistep carcinogenesis model for both HPV-positive and -negative human oral squamous cell carcinomas. Nihon Koku Geka Gakkai Zasshi, 2013, 59, 159-171.	0.0	1

#	Article	IF	Citations
2581	EGFR, Growth Factors. , 2013, , 1-11.		0
2582	Stress-Driven Endocytosis of Tyrosine-Phosphorylated EGFR Leads to Tumorigenesis: The Critical Role of Oxidative Stress. , 2013, , 303-325.		0
2583	The Clinical Significance of Mutations in Colorectal Cancer. , 2013, , 231-245.		0
2584	Cell Cycle Control and Growth Factor Systems in Metastasis. , 2013, , 57-78.		0
2585	Resistance to HER2-targeted therapy. Research in Molecular Medicine, 2013, 1, 1-9.	0.1	0
2586	Alternative drug therapies are superior to epidermal growth factor receptor -targeted chemotherapeutic drug responses in non-small cell lung cancer. Tang [humanitas Medicine], 2013, 3, 10.1-10.8.	0.2	0
2590	Current Progress and Future Prospects of aptamer-based cancer therapy. Postdoc Journal, 0, , .	0.4	0
2591	Molecular Testing in Pulmonary Tumors. , 2014, , 211-228.		0
2593	Cellular Metabolism of Estradiol in Models for Select Molecular Subtypes of Clinical Breast Cancer. Journal of Steroids & Hormonal Science, 2014, 05, .	0.1	1
2595	Premalignant Lesions. , 2015, , 273-292.		0
2596	Next-Generation Sequencing Applications in Head and Neck Oncology. , 2015, , 401-422.		0
2597	Synthetic Sickness with Molecularly Targeted Agents Against the EGFR Pathway. Cancer Drug Discovery and Development, 2015, , 381-412.	0.2	0
2598	Case Study: Modeling and Comparison of NSCLC and Normal EGFR Signaling. SpringerBriefs in Systems Biology, 2015, , 63-77.	0.1	0
2599	Pharmacology and Clinical Development of New Molecularly Targeted Agents. Current Clinical Pathology, 2015, , 9-29.	0.0	0
2601	HER3 over-expression and overall survival in gastrointestinal cancers. Oncotarget, 2015, 6, 42868-42878.	0.8	6
2602	A Case of KRAS Exon 2 Wild Colorectal Cancer Resistant to the Anti-EGFR Therapy. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2016, 77, 2259-2263.	0.0	0
2603	High-throughput analysis of kinase inhibitor drugs on cardiac function using engineered heart tissue constructs. Frontiers in Bioengineering and Biotechnology, 0, 4, .	2.0	0
2604	INTRAOPERATIVE PHOTODYNAMIC THERAPY FOR METASTATIC PERITONEAL TUMORS. IssledovaniÃ¢ I Praktika V Medicine, 2016, 3, 59-67.	0.1	1

#	Article	IF	Citations
2605	Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through activation of the EGFR/AKT pathway. Nihon Koku Geka Gakkai Zasshi, 2016, 62, 476-486.	0.0	0
2606	Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 27-107.	0.1	0
2608	Molecular docking and admet studies of 3-phenyl coumarin derivatives for their Antiâ€cancer activity. International Journal of Pharma and Bio Sciences, 2016, 7, .	0.1	0
2609	Physiologic and Molecular Basis of PET in Cancer Imaging. , 2017, , 399-427.		2
2611	Role of Bioinformatics in Nanotechnology. Advances in Medical Technologies and Clinical Practice Book Series, 2017, , 293-317.	0.3	0
2612	Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R. , 2017, , 1-31.		0
2613	Molecular Diagnostics in Pathology. , 2017, , 75-102.		0
2614	Targeted Therapies for Lung Cancer. Molecular Pathology Library, 2018, , 239-255.	0.1	0
2616	Molecular Diagnosis of Lung Cancer. Journal of Biomedical and Clinical Research, 2017, 10, 98-103.	0.1	1
2617	Phosphorylated S6 Kinase-1 as Predictive Marker of Lapatinib Efficacy in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. Journal of Breast Disease, 2017, 5, 57-63.	0.2	0
2618	Designing, docking and heterologous expression of an anti-HER2 affibody molecule. Ukrainian Biochemical Journal, 2018, 90, 68-76.	0.1	0
2619	Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer. Anticancer Research, 2018, 38, 2285-2294.	0.5	7
2621	Drugs and Phytochemicals. , 2019, , 83-109.		0
2622	Protein Palmitoylation in Cancer. , 2019, , 51-87.		2
2624	Research Progress on Long Non-Coding RNA and Radiotherapy. Medical Science Monitor, 2019, 25, 5757-5770.	0.5	18
2625	Morphological and pathological features of basal-like breast cancer. Translational Cancer Research, 2019, 8, S503-S509.	0.4	6
2627	The biology of Epidermal Growth Factor Receptor (EGFR) from regulating cell cycle to promoting carcinogenesis: the state of art including treatment options. Annals of Cytology and Pathology, 2020, 5, 048-053.	0.3	3
2628	TNNT2 as a potential biomarker for the progression and prognosis of colorectal cancer. Oncology Reports, 2020, 44, 628-636.	1.2	5

#	Article	IF	Citations
2629	NRG1 and NRG2 fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows. Expert Opinion on Therapeutic Targets, 2021, 25, 865-875.	1.5	4
2630	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 5471.	1.7	18
2631	Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 11833.	1.8	27
2632	Molecular Targeted Therapy for Advanced Oral Cancer. Textbooks in Contemporary Dentistry, 2020, , 359-385.	0.2	0
2633	Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics. PLoS ONE, 2020, 15, e0243901.	1.1	3
2634	An Overview of Promising Biomarkers in Cancer Screening and Detection. Current Cancer Drug Targets, 2020, 20, 831-852.	0.8	1
2635	Signaling pathways in CRC. , 2022, , 519-528.		1
2636	VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. European Journal of Medicinal Chemistry, 2022, 227, 113906.	2.6	27
2637	Gastrointestinal Toxicities of Targeted Therapy. , 2020, , 119-132.		0
2638	Varlitinib Mediates Its Activity Through Down Regulating MAPK/EGFR Pathway in Oral Cancer. Current Proteomics, 2020, 17, 51-58.	0.1	1
2639	Chemical Probes for Kinases. Chemical Biology, 2020, , 182-213.	0.1	0
2640	Role of Bioinformatics in Nanotechnology. , 2020, , 1875-1894.		1
2641	Neurological Toxicities of Immunotherapy. , 2020, , 223-242.		0
2642	Critical Review of EGFR-Mutated NSCLC: What We Do and Do Not Know. Healthbook TIMES Oncology Hematology, 2020, , 20-35.	0.1	3
2645	Discovery of N-(1,3,4-thiadiazol-2-yl)benzamide derivatives containing a 6,7-methoxyquinoline structure as novel EGFR/HER-2 dual-target inhibitors against cancer growth and angiogenesis. Bioorganic Chemistry, 2022, 119, 105469.	2.0	6
2646	Combining Systemic Therapy With Radiation: Head and Neck Cancer Treatments in an Era of Targeted Agents and Immunotherapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 907-913.	2.3	3
2647	An HNSCC syngeneic mouse model for tumor immunology research and preclinical evaluation. International Journal of Molecular Medicine, 2020, 46, 1501-1513.	1.8	5
2648	The Renin-Angiotensin System in the Breast. , 2007, , 135-153.		1

#	Article	IF	Citations
2649	Achievements in targeted therapies. , 0, , 215-233.		0
2650	The Advancement of Epidermal Growth Factor Receptor Inhibitors in Cancer Therapy. , 2007, , 335-357.		0
2651	Intercellular Targets of Prostate Cancer. , 2007, , 475-486.		0
2653	Conserved roles for receptor tyrosine kinase extracellular regions in regulating receptor and pathway activity. Biochemical Journal, 2020, 477, 4207-4220.	1.7	3
2654	Evaluation of methylation profiles of an epidermal growth factor receptor gene in a head and neck squamous cell carcinoma patient group. Balkan Journal of Medical Genetics, 2021, 23, 65-72.	0.5	0
2655	EGFR Immunoexpression in Malignant Serous and Mucinous Ovarian Tumors. Current Health Sciences Journal, 2018, 44, 129-134.	0.2	4
2656	Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck. Therapeutics and Clinical Risk Management, 2007, 3, 871-6.	0.9	21
2657	Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer. Biologics: Targets and Therapy, 2007, 1, 229-39.	3.0	5
2658	A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. International Journal of Oncology, 2010, 36, 19-27.	3.9	4
2659	Mammalian target of rapamycin: a central node of complex signaling cascades. International Journal of Clinical and Experimental Pathology, 2011, 4, 476-95.	0.5	68
2660	N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells. American Journal of Cancer Research, 2011, 1, 823-33.	1.4	19
2661	An in vitro multistep carcinogenesis model for both HPV-positive and -negative human oral squamous cell carcinomas. American Journal of Cancer Research, 2011, 1, 869-81.	1.4	5
2663	Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. Molecular Imaging, 2010, 9, 192-200.	0.7	22
2665	The Role of EGFR and HER2- Activating Mutations in Maxillary Sinus Cancer. MÃ¦dica, 2012, 7, 70-4.	0.4	1
2666	HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. Anticancer Research, 2006, 26, 4235-43.	0.5	51
2668	Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing. International Journal of Clinical and Experimental Pathology, 2013, 6, 1880-9.	0.5	24
2669	Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of Action. Journal of Cancer Science & Therapy, 2013, 5, 334-342.	1.7	41
2671	Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer. Journal of Surgery and Science, 2013, 1, 3-7.	0.0	14

#	Article	IF	Citations
2672	EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. American Journal of Cancer Research, 2014, 4, 411-35.	1.4	102
2673	Inhibition of LN-308 glioma cell proliferation and migration by retinoic acid amide through activation of Akt pathway. International Journal of Clinical and Experimental Pathology, 2015, 8, 13921-7.	0.5	0
2675	Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience. Cancer Biology and Medicine, 2016, 13, 136-41.	1.4	2
2676	Targeted-TERS detection of integrin receptors on human cancer cells. Journal of Plant Sciences (Science Publishing Group), 2016, 3, .	0.1	2
2677	Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma. American Journal of Cancer Research, 2017, 7, 203-217.	1.4	4
2678	The addition of calcitriol or its synthetic analog EB1089 to lapatinib and neratinib treatment inhibits cell growth and promotes apoptosis in breast cancer cells. American Journal of Cancer Research, 2017, 7, 1486-1500.	1.4	11
2680	EGFRwt/vIII-PKM2-Î²-catenin cascade affects proliferation and chemo-sensitivity in head and neck squamous cell carcinoma. American Journal of Cancer Research, 2017, 7, 2491-2502.	1.4	2
2681	Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC). American Journal of Cancer Research, 2018, 8, 879-891.	1.4	7
2683	An essential role of PRMT1-mediated EGFR methylation in EGFR activation by ribonuclease 5. American Journal of Cancer Research, 2019, 9, 180-185.	1.4	4
2684	Value of CagA, HER2, ALDH1, and KiSS-1 in predicting metastasis and prognosis for gastric adenocarcinoma. International Journal of Clinical and Experimental Pathology, 2018, 11, 3628-3637.	0.5	1
2685	Differential Expression and Prognostic Significance of STARD3 Gene in Breast Carcinoma. International Journal of Molecular and Cellular Medicine, 2021, 10, 34-41.	1.1	1
2686	Tumor treating fields can effectively overcome trastuzumab resistant breast cancer multiplication. American Journal of Cancer Research, 2021, 11, 3935-3945.	1.4	0
2687	Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. Advanced Drug Delivery Reviews, 2022, 181, 114033.	6.6	5
2688	Network medicine for disease module identification and drug repurposing with the NeDRex platform. Nature Communications, 2021, 12, 6848.	5.8	39
2689	Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma. Molecules, 2021, 26, 7069.	1.7	4
2690	Glycosylation promotes the cancer regulator EGFR-ErbB2 heterodimer formation â€" molecular dynamics study. Journal of Molecular Modeling, 2021, 27, 361.	0.8	6
2691	Insights Into the Regulation of Gynecological Inflammation-Mediated Malignancy by Metalloproteinases. Frontiers in Cell and Developmental Biology, 2021, 9, 780510.	1.8	2
2692	Noscapine, an Emerging Medication for Different Diseases: A Mechanistic Review. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-16.	0.5	23

#	Article	IF	Citations
2693	Integrated approach to functional analysis of an ERBB2 variant of unknown significance detected by a cancer gene panel test. Cellular Oncology (Dordrecht), 2022, 45, 121.	2.1	1
2694	Potential applications of clickable probes in EGFR activity visualization and prediction of EGFR-TKI therapy response for NSCLC patients. European Journal of Medicinal Chemistry, 2022, 230, 114100.	2.6	3
2695	Studies on ligand-based pharmacophore modeling approach in identifying potent future EGFR inhibitors. Journal of Molecular Graphics and Modelling, 2022, 112, 108114.	1.3	7
2696	Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma. Medicine (United States), 2022, 101, e28507.	0.4	4
2697	The biomarkers of key miRNAs and gene targets associated with extranodal NK/T-cell lymphoma. Open Medicine (Poland), 2022, 17, 124-134.	0.6	0
2698	Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR^{T790M/C797S} Mutants. ACS Medicinal Chemistry Letters, 2022, 13, 196-202.	1.3	8
2699	EGFR-Targeted Photodynamic Therapy. Pharmaceutics, 2022, 14, 241.	2.0	35
2700	Poly-Lysine Dendritic Nanocarrier to Target Epidermal Growth Factor Receptor Overexpressed Breast Cancer for Methotrexate Delivery. Materials, 2022, 15, 800.	1.3	8
2701	The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein. Pharmacological Reviews, 2022, 74, 18-47.	7.1	31
2702	In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell line. Bulletin of the National Research Centre, 2022, 46, .	0.7	18
2703	Designing of kinase hinge binders: A medicinal chemistry perspective. Chemical Biology and Drug Design, 2022, 100, 968-980.	1.5	11
2704	Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer. Molecular Pharmacology, 2022, 101, 191-200.	1.0	5
2705	Exploring the role of extracellular vesicles and their protein cargo in lung cancer metastasis: A review. Critical Reviews in Oncology/Hematology, 2022, 171, 103603.	2.0	5
2706	Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data. Breast, 2022, 62, 1-9.	0.9	6
2707	One-step synthesis of picolinohydrazides from fusaric acid: DFT, structural characterization and molecular inhibitory studies on metastatic tumor-derived exosomal and non-exosomal proteins. Journal of Molecular Structure, 2022, 1255, 132442.	1.8	9
2708	Molecular Approaches to Protein Dimerization: Opportunities for Supramolecular Chemistry. Frontiers in Chemistry, 2022, 10, 829312.	1.8	7
2709	Pharmacophore modeling, Virtual screening, Molecular docking and dynamics studies for the discovery of HER2-tyrosine kinase inhibitors: An in-silico approach. Journal of Molecular Structure, 2022, , 132531.	1.8	8
2710	Deciphering the Mechanism of Binding Selectivity of Chlorofluoroacetamide-Based Covalent Inhibitors toward L858R/T790M Resistance Mutation. Journal of Chemical Information and Modeling, 2022, , .	2.5	3

#	Article	IF	Citations
2711	Construction and Verification of a Combined Hypoxia and Immune Index for Clear Cell Renal Cell Carcinoma. Frontiers in Genetics, 2022, 13, 711142.	1.1	0
2712	Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. Clinical and Translational Oncology, 2009, 11, 737-47.	1.2	3
2714	CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers. Acta Pharmacologica Sinica, 2022, , .	2.8	0
2715	NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells. Cancers, 2022, 14, 1603.	1.7	6
2716	Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer. JAMA Oncology, 2022, 8, 760.	3.4	35
2717	Advances in Organ Preservation for Laryngeal Cancer. Current Treatment Options in Oncology, 2022, 23, 594-608.	1.3	5
2718	Insights on ErbB glycosylation â€“ contributions to precision oncology. Trends in Cancer, 2022, 8, 448-455.	3.8	9
2719	The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy. Frontiers in Molecular Biosciences, 2022, 9, 870395.	1.6	6
2720	Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment. BMC Cancer, 2022, 22, 355.	1.1	2
2721	HER2 targeted therapy in colorectal cancer: New horizons. Cancer Treatment Reviews, 2022, 105, 102363.	3.4	12
2722	The EGFR Signaling Modulates in Mesenchymal Stem Cells the Expression of miRNAs Involved in the Interaction with Breast Cancer Cells. Cancers, 2022, 14, 1851.	1.7	4
2723	Computational Pathways Analysis and Personalized Medicine in HER2- Positive Breast Cancer. Current Pharmacogenomics and Personalized Medicine, 2022, 19, .	0.2	0
2724	Optimal solutions in the third line therapy for refractory metastatic colorectal cancer. CORRECTness and CONCURency. Meditsinskiy Sovet, 2021, , 47-52.	0.1	0
2725	The Important Role of Ion Transport System in Cervical Cancer. International Journal of Molecular Sciences, 2022, 23, 333.	1.8	2
2726	Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. Cancers, 2022, 14, 154.	1.7	30
2727	Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer. ACS Applied Materials & Interfaces, 2022, 14, 452-463.	4.0	22
2729	Evolution of the ErbB gene family and analysis of regulators of Egfr expression during development of the rat spinal cord. Neural Regeneration Research, 2022, 17, 2484.	1.6	1
2730	Translational Strategies to Target Metastatic Bone Disease. Cells, 2022, 11, 1309.	1.8	4

#	Article	IF	Citations
2731	Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Frontiers in Cardiovascular Medicine, 2022, 9, 847012.	1.1	36
2752	Low expression of miR-27b in serum exosomes of non-small cell lung cancer facilitates its progression by affecting EGFR. Open Medicine (Poland), 2022, 17, 816-825.	0.6	4
2753	An Update on the Effect of Natural Products on Oncogenic Transcription Factors in Triple Negative Breast Cancer. Advances in Medical Diagnosis, Treatment, and Care, 2022, , 1-26.	0.1	0
2754	Prognostic Significance of HER3 Expression in Patients with Cervical Cancer. Cancers, 2022, 14, 2139.	1.7	3
2755	Thietanes and derivatives thereof in medicinal chemistry.. Current Topics in Medicinal Chemistry, 2022, 22, .	1.0	1
2756	Epiregulin increases stemness-associated genes expression and promotes chemoresistance of non-small cell lung cancer via ERK signaling. Stem Cell Research and Therapy, 2022, 13, 197.	2.4	8
2757	Disentangling ERBB Signaling in Breast Cancer Subtypesâ€"A Model-Based Analysis. Cancers, 2022, 14, 2379.	1.7	4
2758	Transmembrane stem cell factor protein therapeutics enhance revascularization in ischemia without mast cell activation. Nature Communications, 2022, 13, 2497.	5.8	8
2759	The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine. Biomedicine and Pharmacotherapy, 2022, 150, 113064.	2.5	14
2760	CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer. Life Sciences, 2022, 301, 120600.	2.0	5
2761	Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustainÂcarcinoma cell cycle progression. Journal of Biological Chemistry, 2022, 298, 102029.	1.6	4
2762	HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 219-232.	1.8	21
2763	Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1437-1453.	2.5	13
2764	EGFRC797S mutation and fourth-generation EGFR tyrosine kinase inhibitors. , 2022, , 689-709.		1
2765	Targeting the altered tyrosine kinases in colorectal cancer: From inhibitors to drugs. , 2022, , 361-391.		3
2766	Kinase inhibitors: An overview. , 2022, , 1-22.		2
2767	Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer. Cancers, 2022, 14, 2613.	1.7	8
2768	Combinatorial Therapy of Cancer: Possible Advantages of Involving Modulators of Ionic Mechanisms. Cancers, 2022, 14, 2703.	1.7	11

#	Article	IF	Citations
2769	Defining the versican interactome in lung health and disease. American Journal of Physiology - Cell Physiology, 2022, 323, C249-C276.	2.1	6
2770	HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function. Scientific Reports, 2022, 12, .	1.6	3
2771	Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma. Oral Oncology, 2022, 131, 105939.	0.8	5
2772	Long-term complications of chemotherapy. , 2023, , 234-240.		0
2773	Expanded Application of a Photoaffinity Probe to Study Epidermal Growth Factor Receptor Tyrosine Kinase with Functional Activity. Analytical Chemistry, 2022, 94, 10118-10126.	3.2	2
2774	YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4. Cell Reports, 2022, 39, 110970.	2.9	18
2775	Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1667-1693.	2.5	6
2776	Mind the target: human epidermal growth factor receptor 2 in colorectal cancer. Current Opinion in Oncology, 0, Publish Ahead of Print, .	1.1	2
2777	New phthalimide-based derivatives as EGFR-TK inhibitors: Synthesis, biological evaluation, and molecular modeling study. Bioorganic Chemistry, 2022, 127, 105966.	2.0	5
2778	Molecular dynamic simulation, free binding energy calculation of Thiazolo-[2,3-b]quinazolinone derivatives against EGFR-TKD and their anticancer activity. Results in Chemistry, 2022, 4, 100418.	0.9	10
2779	Discovery and evaluation of cytisine N-isoflavones as novel EGFR/HER2 dual inhibitors. Bioorganic Chemistry, 2022, 127, 105868.	2.0	10
2780	Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer. Medicinal Chemistry Research, 2022, 31, 1401-1413.	1.1	1
2781	Long-term follow-up of early stage HER2-positive breast cancer patients treated with trastuzumab: A population-based real world multicenter cohort study. Frontiers in Oncology, 0, 12, .	1.3	4
2782	Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffoldâ€”A Short Review of Most Recent Studies 2013â€“2022. International Journal of Molecular Sciences, 2022, 23, 8874.	1.8	5
2783	Mammaglobin 1 mediates progression of trastuzumabâ€resistant breast cancer cells through regulation of cyclins and <scp>NFâ€ºB</scp>. FEBS Open Bio, 2022, 12, 1797-1813.	1.0	3
2785	Osteoclast-derived extracellular vesicles are implicated in sensory neurons sprouting through the activation of epidermal growth factor signaling. Cell and Bioscience, 2022, 12, .	2.1	5
2786	Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer. Cancer Journal (Sudbury, Mass) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.0	67
2787	Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer. Drug Science, Policy and Law, 2022, 8, 205032452211143.	0.6	0

#	Article	IF	Citations
2788	Study of the correlation between the expression of nuclear factor kappa B and proliferation regulatory proteins and chronic superficial gastritis. Vojnosanitetski Pregled, 2022, 79, 548-555.	0.1	0
2789	Luminescence chemosensors, biological probes, and imaging reagents. , 2022, , .		0
2790	The Anti-inflammatory Mechanism of Tauroursodeoxycholic Acid based on Network Pharmacology and Molecular Docking. Letters in Drug Design and Discovery, 2023, 20, 1360-1371.	0.4	0
2791	Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3â€“ABCB1 Signaling in Hepatocellular Carcinoma. Cancer Research, 2022, 82, 3845-3857.	0.4	26
2792	Evolutionary Trajectories of Primary and Metastatic Pancreatic Neuroendocrine Tumors Based on Genomic Variations. Genes, 2022, 13, 1588.	1.0	2
2793	SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition. BioMed Research International, 2022, 2022, 1-14.	0.9	2
2794	EGFR, the Lazarus target for precision oncology in glioblastoma. Neuro-Oncology, 2022, 24, 2035-2062.	0.6	16
2795	The anti-tumor and renoprotection study of E-[c(RGDfK)2]/folic acid co-modified nanostructured lipid carrier loaded with doxorubicin hydrochloride/salvianolic acid A. Journal of Nanobiotechnology, 2022, 20, .	4.2	6
2796	In-silico molecular modelling and docking studies on kinase inhibitors as potential anti-cancer target in HER2 associated breast cancer. Letters in Organic Chemistry, 2022, 19, .	0.2	0
2797	Magneto-Mechanical Approach in Biomedicine: Benefits, Challenges, and Future Perspectives. International Journal of Molecular Sciences, 2022, 23, 11134.	1.8	10
2798	Rezeptoren und ihre Signaltransduktion. , 2022, , 533-571.		0
2799	Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies. Cancers, 2022, 14, 5160.	1.7	7
2800	EphA1 receptor tyrosine kinase is localized to the nucleus in rhabdomyosarcoma from multiple species. Biology Open, 2022, 11, .	0.6	0
2801	Discoidin domain receptor 1 regulates ErbB2/ErbB3 signaling in mammary epithelial cells. FEBS Letters, 2022, 596, 2795-2807.	1.3	1
2802	ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma. Onco, 2022, 2, 282-304.	0.2	4
2803	Crosstalk between CXCR4/ACKR3 and EGFR Signaling in Breast Cancer Cells. International Journal of Molecular Sciences, 2022, 23, 11887.	1.8	1
2804	PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer. British Journal of Cancer, 2023, 128, 121-129.	2.9	8
2805	Design, synthesis, and biological evaluation of 2-arylamino-4-(piperidin-4-yloxy)pyrimidines as potent EGFRT790M/L858R inhibitors to treat non-small cell lung cancer. Bioorganic and Medicinal Chemistry, 2022, 74, 117052.	1.4	2

#	Article	IF	Citations
2806	Strategic design of photofunctional transition metal complexes for cancer diagnosis and therapy. Advances in Inorganic Chemistry, 2022, , .	0.4	0
2807	Structure-based modification of ortho-amidophenylaminopyrimidines as a novel mutant EGFR inhibitor against resistant non-small cell lung cancer. Journal of Molecular Structure, 2023, 1274, 134499.	1.8	3
2808	Relationship between 18F-fluorodeoxyglucose PET/computed tomography metabolic parameters and clinicopathology in endometrial cancer. Nuclear Medicine Communications, 2022, 43, 1233-1238.	0.5	0
2809	LINC01608 activated by YY1 facilitate hepatocellular carcinoma progression by modulating the EGFR/ERK axis. Liver International, 2023, 43, 471-489.	1.9	0
2810	Generation and Integrated Analysis of Advanced Patientâ€Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer. Advanced Science, 0, , 2204211.	5.6	4
2812	Current concepts of anti-EGFR targeting in metastatic colorectal cancer. Frontiers in Oncology, 0, 12, .	1.3	3
2813	Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents. , 2022, , 153-172.		1
2814	ErbB4-encoded novel miRNAs act as tumor suppressors by regulating ErbB/PI3K signaling. Tumor Biology, 2022, 44, 215-230.	0.8	2
2815	Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer. Cancers, 2022, 14, 5678.	1.7	1
2816	Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma. Frontiers in Immunology, 0, 13, .	2.2	4
2817	A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells. Cells, 2022, 11, 4093.	1.8	3
2818	A systematic review of epidermal growth factor receptor tyrosine kinase inhibitor-induced heart failure and its management. The Egyptian Journal of Internal Medicine, 2022, 34, .	0.3	1
2819	Network-based approach for targeting human kinases commonly associated with amyotrophic lateral sclerosis and cancer. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	0
2820	A chiral fluorescent Ir(<scp>iii</scp>) complex that targets the GPX4 and ErbB pathways to induce cellular ferroptosis. Chemical Science, 2023, 14, 1114-1122.	3.7	16
2821	A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma. Frontiers of Medicine, 0, , .	1.5	0
2822	Identification of Genes Involved in EGF-induced Apoptosis Using CRISPR/Cas9 Knockout Screening: Implications for Novel Therapeutic Targets in EGFR-Overexpressing Cancers. Cancer Research and Treatment, 2023, 55, 737-745.	1.3	1
2823	Absence of Scaffold Protein Tks4 Disrupts Several Signaling Pathways in Colon Cancer Cells. International Journal of Molecular Sciences, 2023, 24, 1310.	1.8	0
2824	Antimicrobial Peptide Pt5â€1c Promotes Keratinocyte Migration and Proliferation via EGFRâ€mediated Akt/MAPK/STAT3 pathways. ChemistrySelect, 2023, 8, .	0.7	0

#	Article	IF	Citations
2825	Recombinant Human Prolidase (rhPEPD) Induces Wound Healing in Experimental Model of Inflammation through Activation of EGFR Signalling in Fibroblasts. Molecules, 2023, 28, 851.	1.7	3
2826	Efficacy and safety of HER2-targeted therapy in patients with colorectal cancer: What should we expect from a meta-analysis?. Clinics and Research in Hepatology and Gastroenterology, 2023, 47, 102078.	0.7	1
2827	The clinicopathological and prognostic significance of mTOR and p-mTOR expression in patients with non-small cell lung cancer: A meta-analysis. Medicine (United States), 2022, 101, e32340.	0.4	0
2829	Pan-HER, an antibody mixture, simultaneously targeting EGFR, HER2, and HER3 effectively overcomes resistance to anti-EGFR antibodies. , 2023, , 47-54.		0
2830	Irreversible tyrosine kinase inhibitors induce the endocytosis and downregulation of ErbB2. Biochemistry and Biophysics Reports, 2023, 34, 101436.	0.7	1
2831	Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications. Biomedicine and Pharmacotherapy, 2023, 162, 114676.	2.5	2
2832	A herbal product inhibits carbon tetrachloride-induced liver fibrosis by suppressing the epidermal growth factor receptor signaling pathway. Journal of Ethnopharmacology, 2023, 311, 116419.	2.0	1
2833	miRNAs role in bladder cancer pathogenesis and targeted therapy: Signaling pathways interplay â€“ A review. Pathology Research and Practice, 2023, 242, 154316.	1.0	52
2834	Treatment Considerations for Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin. Current Treatment Options in Oncology, 2023, 24, 147-161.	1.3	1
2835	Control of EGFR signaling by endocytosis and endosomal trafficking. , 2023, , 89-104.		0
2836	Mechanistic Modeling of Lys745 Sulfonylation in EGFR C797S Reveals Chemical Determinants for Inhibitor Activity and Discriminates Reversible from Irreversible Agents. Journal of Chemical Information and Modeling, 2023, 63, 1301-1312.	2.5	3
2837	Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report. World Journal of Clinical Cases, 0, 11, 1165-1174.	0.3	1
2838	New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization. Molecular Diversity, 0, , .	2.1	1
2839	Regulation of ErbB Receptors by the Ca2+ Sensor Protein Calmodulin in Cancer. Biomedicines, 2023, 11, 661.	1.4	2
2840	Pharmacogenetic Biomarkers of Protein Therapeutics. , 2023, , 233-249.		1
2842	Emerging Targeted Therapies for HER2-Positive Breast Cancer. Cancers, 2023, 15, 1987.	1.7	18
2845	A NIR-II fluorescent probe for high contrast non-invasive imaging of tumors with a high EGFR-expression. New Journal of Chemistry, 2023, 47, 9635-9642.	1.4	1
2846	Antitumor effects of NK cells expanded by activation preâ€‘processing of autologous feeder cells before irradiation in colorectal cancer. Oncology Letters, 2023, 25, .	0.8	0

#	Article	IF	Citations
2847	Generation of Rat Monoclonal Antibodies Against Human Epidermal Growth Factor Receptor 2. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 0, , .	0.8	0
2850	Radiomics and Radiogenomics in Glioma. , 2023, , 1313-1321.		0
2856	Common hotspots of cancer chemotherapy. Genome Instability & Disease, 0, , .	0.5	0
2882	Signal Transduction Inhibitors. , 2023, , 89-110.		2
2885	Systemic Treatment for Cholangiocarcinoma. Recent Results in Cancer Research, 2023, , 223-244.	1.8	1
2922	Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer. British Journal of Cancer, 2024, 130, 1239-1248.	2.9	0